

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	CA/CAPLUS records now contain indexing from 1907 to the present
NEWS	4	DEC 08	INPADOC: Legal Status data reloaded
NEWS	5	SEP 29	DISSABS now available on STN
NEWS	6	OCT 10	PCTFULL: Two new display fields added
NEWS	7	OCT 21	BIOSIS file reloaded and enhanced
NEWS	8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS	9	NOV 24	MSDS-CCOHS file reloaded
NEWS	10	DEC 08	CABA reloaded with left truncation
NEWS	11	DEC 08	IMS file names changed
NEWS	12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS	13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAPLUS
NEWS	14	DEC 17	DGENE: Two new display fields added
NEWS	15	DEC 18	BIOTECHNO no longer updated
NEWS	16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS	17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS	18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS	19	DEC 22	ABI-INFORM now available on STN
NEWS EXPRESS			DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:22:40 ON 16 JAN 2004

=> file medline, uspatful, biosis, fsta, wpids, japio, jicst, embase, dgene, biobusiness

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 12:23:20 ON 16 JAN 2004

FILE 'USPATFULL' ENTERED AT 12:23:20 ON 16 JAN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'FSTA' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'WPIDS' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'JAPIO' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 Japanese Patent Office (JPO)- JAPIO

FILE 'JICST-EPLUS' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'EMBASE' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'DGENE' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'BIOBUSINESS' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 Biological Abstracts, Inc. (BIOSIS)

=> s albumin fusion protein
L1 2849 ALBUMIN FUSION PROTEIN

=> s BMP-1 and albumin
9 FILES SEARCHED...
L2 193 BMP-1 AND ALBUMIN

=> s l2 and l1
L3 0 L2 AND L1

=> d l2 ti abs ibib 1-10

L2 ANSWER 1 OF 193 USPATFULL on STN
TI Novel proteins and nucleic acids encoding same
AB Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

ACCESSION NUMBER: 2004:13595 USPATFULL
TITLE: Novel proteins and nucleic acids encoding same
INVENTOR(S): Zerhusen, Bryan D., Branford, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Spytek, Kimberly, New Haven, CT, UNITED STATES
Spaderna, Steven, Berlin, CT, UNITED STATES
Gangolli, Esha A., Branford, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES

Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Majumder, Kumud, Stamford, CT, UNITED STATES
Shimkets, Richard, West Haven, CT, UNITED STATES
Mishra, Vishnu, Branford, CT, UNITED STATES
Vernet, Corine, North Branford, CT, UNITED STATES
Szekeres, Edward S., Branford, CT, UNITED STATES
Grosse, William M., Branford, CT, UNITED STATES
Alsobrook, John P., II, Madison, CT, UNITED STATES
Liu, Xiaohong, Branford, CT, UNITED STATES
Gerlach, Valerie L., Branford, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Smithson, Glennda, Branford, CT, UNITED STATES
Peyman, John, New Haven, CT, UNITED STATES
Stone, David, Guilford, CT, UNITED STATES
MacDougall, John, Hamden, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010118	A1	20040115
APPLICATION INFO.:	US 2001-930512	A1	20010815 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-225692P	20000816 (60)
	US 2000-225693P	20000816 (60)
	US 2000-225837P	20000816 (60)
	US 2000-226236P	20000818 (60)
	US 2000-226353P	20000818 (60)
	US 2000-227085P	20000822 (60)
	US 2000-227395P	20000823 (60)
	US 2000-227492P	20000824 (60)
	US 2000-227600P	20000824 (60)
	US 2001-275952P	20010314 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C.,
ONE FINANCIAL CENTER, BOSTON, MA, 02111
NUMBER OF CLAIMS: 49
EXEMPLARY CLAIM: 1
LINE COUNT: 9358

L2 ANSWER 2 OF 193 USPATFULL on STN
TI Methods of treatment of periodontal disease
AB Purified BMP-2 and BMP-4 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.

ACCESSION NUMBER: 2004:13394 USPATFULL
TITLE: Methods of treatment of periodontal disease
INVENTOR(S): Wang, Elizabeth, Carlisle, MA, UNITED STATES
Wozney, John M., Hudson, MA, UNITED STATES
Rosen, Vicki A., Brookline, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009916	A1	20040115
APPLICATION INFO.:	US 2003-397214	A1	20030327 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-804625, filed on 9 Mar 2001, PENDING Continuation of Ser. No. US 1997-925779, filed on 9 Sep 1997, GRANTED, Pat. No. US 6245889 Continuation of Ser. No. US 1991-721847, filed on 14 Jun 1991, GRANTED, Pat. No. US 6150328 Continuation-in-part of Ser. No. US 1990-493272, filed on 14 Mar 1990, ABANDONED Continuation-in-part of Ser.		

No. US 1989-406217, filed on 12 Sep 1989, ABANDONED
Continuation-in-part of Ser. No. US 1989-378537, filed
on 11 Jul 1989, GRANTED, Pat. No. US 5166058

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow,, Garrett & Dunner,
L.L.P., 1300 I Street, N.W., Washington, DC, 20005-3315
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 1876

L2 ANSWER 3 OF 193 USPATFULL on STN

TI Chondrogenic and osteogenic inducing molecule

AB The present invention is directed to methods of using and compositions
comprising amelogenin peptides capable of inducing chondrogenesis and
osteogenesis when implanted in vivo, a chondrogenesis in cultures in
vitro. Compositions and methods of enhancing bone and cartilage growth
using these peptides are described.

ACCESSION NUMBER: 2004:9593 USPATFULL
TITLE: Chondrogenic and osteogenic inducing molecule
INVENTOR(S): Veis, Arthur, Skokie, IL, United States
Nebgen, Denise R., Houston, TX, United States
PATENT ASSIGNEE(S): Northwestern University, Evanston, IL, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6677306	B1	20040113
	WO 2000006734		20000210
APPLICATION INFO.:	US 2001-744128		20010516 (9)
	WO 1999-US17342		19990729

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-94489P	19980729 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Mertz, Prema	
LEGAL REPRESENTATIVE:	Marshall, Gerstein & Borun LLP	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	16 Drawing Figure(s); 16 Drawing Page(s)	
LINE COUNT:	1877	

L2 ANSWER 4 OF 193 USPATFULL on STN

TI Treatment of inflammatory bowel disease using growth factors

AB The present invention is based upon methods of treating inflammatory
conditions in the intestinal tract of mammals using growth factor
related polypeptides. The invention includes methods of reducing the
mortality rate or delaying mortality in a subject suffering from an
inflammatory pathology. Methods of using fibroblast growth factor-CX
(FGF-CX) polynucleotides sequences and the FGF-CX polypeptides encoded
by such nucleic acid sequence, or variants, fragments and homologs
thereof, are claimed in the invention. Similarly, methods of using FCTR
polynucleotide sequences and the FCTR polypeptides encoded by such
nucleic acid sequences, or variants, fragments and homologs thereof,
alone or in combination, are also claimed in the invention. FCTR
collectively refers to any of six variant FCTR sequences, variously
designated FCTR1, FCTR2, FCTR3, FCTR4, FCTR5 and FCTR6.

ACCESSION NUMBER: 2004:7775 USPATFULL
TITLE: Treatment of inflammatory bowel disease using growth

INVENTOR(S) : factors
 Boldog, Ferenc L., North Haven, CT, UNITED STATES
 Burgess, Catherine E., Wethersfield, CT, UNITED STATES
 Fernandes, Elma R., Branford, CT, UNITED STATES
 Jeffers, Michael E., Branford, CT, UNITED STATES
 LaRochelle, William J., Madison, CT, UNITED STATES
 Lichenstein, Henri S., Guilford, CT, UNITED STATES
 Peterson, Jeffrey, Brookfield, CT, UNITED STATES
 Prayaga, Sudhirdas K., O'Fallon, MO, UNITED STATES
 Rittman, Beth, Colchester, CT, UNITED STATES
 Shimkets, Juliette B., Guilford, CT, UNITED STATES
 Shimkets, Richard A., Guilford, CT, UNITED STATES
 Yang, Meijia, East Lyme, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004006015	A1	20040108
APPLICATION INFO.:	US 2002-321962	A1	20021216 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-11364, filed on 16 Nov 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-386545P	20020606 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C., ONE FINANCIAL CENTER, BOSTON, MA, 02111	
NUMBER OF CLAIMS:	67	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	73 Drawing Page(s)	
LINE COUNT:	7115	

L2 ANSWER 5 OF 193 USPATFULL on STN
 TI Proteins and nucleic acids encoding same
 AB Disclosed are polypeptides and nucleic acids encoding same. Also disclosed are vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using same.

ACCESSION NUMBER: 2004:7342 USPATFULL
 TITLE: Proteins and nucleic acids encoding same
 INVENTOR(S) : Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES
 Li, Li, Branford, CT, UNITED STATES
 Patturajan, Meera, Branford, CT, UNITED STATES
 Shimkets, Richard A., Guilford, CT, UNITED STATES
 Casman, Stacie J., North Haven, CT, UNITED STATES
 Malyankar, Uriel M., Branford, CT, UNITED STATES
 Tchernev, Velizar T., Branford, CT, UNITED STATES
 Vernet, Corine A., North Branford, CT, UNITED STATES
 Spytek, Kimberly A., New Haven, CT, UNITED STATES
 Shenoy, Suresh G., Branford, CT, UNITED STATES
 Alsobrook, John P., II, Madison, CT, UNITED STATES
 Edinger, Schlomit, New Haven, CT, UNITED STATES
 Peyman, John A., New Haven, CT, UNITED STATES
 Stone, David J., Guilford, CT, UNITED STATES
 Ellerman, Karen, Branford, CT, UNITED STATES
 Gangolli, Esha A., Madison, CT, UNITED STATES
 Boldog, Ferenc L., North Haven, CT, UNITED STATES
 Colman, Steven D., Guilford, CT, UNITED STATES
 Eisen, Andrew, Rockville, MD, UNITED STATES
 Liu, Xiaohong, Lexington, MA, UNITED STATES
 Padigaru, Muralidhara, Branford, CT, UNITED STATES
 Spaderna, Steven K., Berlin, CT, UNITED STATES

Zerhusen, Bryan D., Branford, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005576	A1	20040108
APPLICATION INFO.:	US 2002-231913	A1	20020830 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-10680, filed on 6 Dec 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-251660P	20001206 (60)
	US 2001-260326P	20010108 (60)
	US 2001-318712P	20010912 (60)
	US 2000-255029P	20001212 (60)
	US 2001-263800P	20010124 (60)
	US 2001-286183P	20010424 (60)
	US 2001-269942P	20010220 (60)
	US 2001-313627P	20010820 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C., ONE FINANCIAL CENTER, BOSTON, MA, 02111	
NUMBER OF CLAIMS:	41	
EXEMPLARY CLAIM:	1	
LINE COUNT:	17887	

L2 ANSWER 6 OF 193 USPATFULL on STN
TI Growth factor homolog ZVEGF4
AB Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 70% identical to residues 52-179 of SEQ ID NO:2 or residues 258-370 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents.

ACCESSION NUMBER: 2004:2119 USPATFULL
TITLE: Growth factor homolog ZVEGF4
INVENTOR(S): Gilbert, Teresa, Seattle, WA, UNITED STATES
Hart, Charles E., Woodinville, WA, UNITED STATES
Sheppard, Paul O., Granite Falls, WA, UNITED STATES
Gilbertson, Debra G., Seattle, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002140	A1	20040101
APPLICATION INFO.:	US 2001-876813	A1	20010606 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-564595, filed on 3 May 2000, GRANTED, Pat. No. US 6495668		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-132250P	19990503 (60)
	US 1999-164463P	19991110 (60)
	US 2000-180169P	20000204 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Gary E. Parker, ZymoGenetics, Inc., Patent Department, 1201 Eastlake Avenue East, Seattle, WA, 98102	
NUMBER OF CLAIMS:	54	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	

LINE COUNT: 5092

L2 ANSWER 7 OF 193 USPATFULL on STN

TI Bone morphogenic protein polynucleotides, polypeptides, and antibodies
AB The present invention relates to novel human BMP polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human BMP polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human BMP polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:318756 USPATFULL

TITLE: Bone morphogenic protein polynucleotides, polypeptides, and antibodies

INVENTOR(S): Young, Paul E., Gaithersburg, MD, UNITED STATES
Ruben, Steven M., Brookeville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003224501	A1	20031204
APPLICATION INFO.:	US 2003-366345	A1	20030214 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-345236, filed on 16 Jan 2003, PENDING Continuation-in-part of Ser. No. US 2001-809269, filed on 16 Mar 2001, ABANDONED Continuation-in-part of Ser. No. WO 2001-US9229, filed on 23 Mar 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-356749P	20020215 (60)
	US 2000-190067P	20000317 (60)
	US 2002-348621P	20020117 (60)
	US 2002-349356P	20020122 (60)
	US 2002-351520P	20020128 (60)
	US 2002-354265P	20020206 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 42

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 23 Drawing Page(s)

LINE COUNT: 16963

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 8 OF 193 USPATFULL on STN

TI Sulfonamide compounds

AB This invention relates to certain sulfonamide derivatives that are inhibitors of procollagen C-proteinase, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:306969 USPATFULL

TITLE: Sulfonamide compounds

INVENTOR(S): Billlèdeau, Roland Joseph, Santa Clara, CA, UNITED STATES

Broka, Chris Allen, Foster City, CA, UNITED STATES

Campbell, Jeffrey Allen, Middletown, CT, UNITED STATES

Chen, Jian Jeffrey, Santa Clara, CA, UNITED STATES

Dankwardt, Sharon Marie, Foster City, CA, UNITED STATES

Delaet, Nancy, San Diego, CA, UNITED STATES

Robinson, Leslie Ann, San Diego, CA, UNITED STATES
Walker, Keith Adrian Murray, Los Altos, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003216405	A1	20031120
APPLICATION INFO.:	US 2002-267727	A1	20021009 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-469660, filed on 22 Dec 1999, GRANTED, Pat. No. US 6492394		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-113311P	19981222 (60)
	US 1999-147053P	19990803 (60)
	US 1999-164138P	19991108 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ROCHE PALO ALTO LLC, 3431 HILLVIEW AVENUE, PATENT DEPT., M/S A2-250, PALO ALTO, CA, 94304	
NUMBER OF CLAIMS:	52	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3904	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 9 OF 193 USPATFULL on STN
TI Composition and method for modulating vasculogenesis or angiogenesis
AB A method for modulating vasculogenesis or angiogenesis using the core domain protein of PDGF-C, a new member of the PDGF/VEGF family of growth factors, or a homodimer or a heterodimer comprising the core domain. Also disclosed are pharmaceutical compositions comprising the core protein, nucleotide sequences encoding the protein, and uses thereof in medical and diagnostic applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:300768 USPATFULL
TITLE: Composition and method for modulating vasculogenesis or angiogenesis
INVENTOR(S): Li, Xuri, Stockholm, SWEDEN
Eriksson, Ulf, Stockholm, SWEDEN
Carmeliet, Peter, Leuven, BELGIUM
Collen, Desire, Leuven, BELGIUM
PATENT ASSIGNEE(S): Ludwig Institute for Cancer Research (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003211994	A1	20031113
APPLICATION INFO.:	US 2002-303997	A1	20021126 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-410349, filed on 30 Sep 1999, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-102461P	19980930 (60)
	US 1998-108109P	19981112 (60)
	US 1998-110749P	19981203 (60)
	US 1998-113002P	19981218 (60)
	US 1999-135426P	19990521 (60)
	US 1999-144022P	19990715 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	CROWELL & MORING LLP, INTELLECTUAL PROPERTY GROUP, P.O. BOX 14300, WASHINGTON, DC, 20044-4300	

NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 42 Drawing Page(s)
LINE COUNT: 2790
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 10 OF 193 USPATFULL on STN

TI OSTEOPROTEGERIN

AB The present invention discloses a novel secreted polypeptide, termed osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind OPG, and pharmaceutical compositions. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:294810 USPATFULL

TITLE: OSTEOPROTEGERIN

INVENTOR(S): BOYLE, WILLIAM J., MOORPARK, CA, UNITED STATES
LACEY, DAVID L., THOUSAND OAKS, CA, UNITED STATES
CALZONE, FRANK J., WEST LAKE VILLAGE, CA, UNITED STATES
CHANG, MING-SHI, NEWBURY PARK, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003207827	A1	20031106
APPLICATION INFO.:	US 1999-405032	A1	19990924 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-132985, filed on 12 Aug 1998, PENDING Continuation of Ser. No. US 1996-771777, filed on 20 Dec 1996, ABANDONED Continuation-in-part of Ser. No. US 1996-706945, filed on 3 Sep 1996, GRANTED, Pat. No. US 6369027 Continuation-in-part of Ser. No. US 1995-577788, filed on 22 Dec 1995, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	AMGEN INCORPORATED, MAIL STOP 27-4-A, ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320-1799		
NUMBER OF CLAIMS:	60		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	46 Drawing Page(s)		
LINE COUNT:	5457		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:22:40 ON 16 JAN 2004)

FILE 'MEDLINE, USPATFULL, BIOSIS, FSTA, WPIDS, JAPIO, JICST-EPLUS, EMBASE, DGENE, BIOBUSINESS' ENTERED AT 12:23:20 ON 16 JAN 2004

L1 2849 S ALBUMIN FUSION PROTEIN
L2 193 S BMP-1 AND ALBUMIN
L3 0 S L2 AND L1

=> s l1 and FGF-16

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	CA/CAPLUS records now contain indexing from 1907 to the present
NEWS	4	DEC 08	INPADOC: Legal Status data reloaded
NEWS	5	SEP 29	DISSABS now available on STN
NEWS	6	OCT 10	PCTFULL: Two new display fields added
NEWS	7	OCT 21	BIOSIS file reloaded and enhanced
NEWS	8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS	9	NOV 24	MSDS-CCOHS file reloaded
NEWS	10	DEC 08	CABA reloaded with left truncation
NEWS	11	DEC 08	IMS file names changed
NEWS	12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS	13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAPLUS
NEWS	14	DEC 17	DGENE: Two new display fields added
NEWS	15	DEC 18	BIOTECHNO no longer updated
NEWS	16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS	17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS	18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS	19	DEC 22	ABI-INFORM now available on STN
NEWS EXPRESS			DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS			STN Operating Hours.Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:38:37 ON 16 JAN 2004

=> file medline, uspatful, dgene, embase, wpids, fsta, jicst, biosis	
COST IN U.S. DOLLARS	SINCE FILE TOTAL

FULL ESTIMATED COST

	ENTRY	SESSION
	0.21	0.21

FILE 'MEDLINE' ENTERED AT 12:39:04 ON 16 JAN 2004

FILE 'USPATFULL' ENTERED AT 12:39:04 ON 16 JAN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'JICST-EPLUS' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'BIOSIS' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

=> s Rantes
L1 13014 RANTES

=> s albumin fusion protein
L2 2849 ALBUMIN FUSION PROTEIN

=> s l1 and l2
L3 8 L1 AND L2

=> d l3 ti abs ibib tot

L3 ANSWER 1 OF 8 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

ACCESSION NUMBER: 2004:13611 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)

US 2000-229358P 20000412 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 25066

L3 ANSWER 2 OF 8 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:312278 USPATFULL

TITLE: Albumin fusion proteins

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219875	A1	20031127
APPLICATION INFO.:	US 2001-833118	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 15415

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 3 OF 8 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:282700 USPATFULL

TITLE: Albumin fusion proteins
INVENTOR(S): Ballance, David J., Berwyn, PA, UNITED STATES
Sleep, Darrell, West Bridgford, UNITED KINGDOM
Prior, Christopher P., Rosemont, PA, UNITED STATES
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199043	A1	20031023
APPLICATION INFO.:	US 2001-832501	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 14339
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 8 USPATFULL on STN

TI Neutrokin-alpha and neutrokin-alpha splice variant

AB The present invention relates to nucleic acid molecules encoding Neutrokin-alpha and/or Neutrokin-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokin-alpha and/or Neutrokin-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokin-alpha and/or Neutrokin-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:250423 USPATFULL
TITLE: Neutrokin-alpha and neutrokin-alpha splice variant
INVENTOR(S): Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ullrich, Stephen, Rockville, MD, UNITED STATES
Laird, Michael, Germantown, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003175208	A1	20030918
APPLICATION INFO.:	US 2002-270487	A1	20021016 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-929493, filed on 15 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2000-588947, filed on 8 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-589285, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589286, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589287, filed		

on 8 Jun 2000, GRANTED, Pat. No. US 6403770
 Continuation-in-part of Ser. No. US 2000-589288, filed
 on 8 Jun 2000, PENDING Continuation-in-part of Ser. No.
 US 2000-507968, filed on 22 Feb 2000, PENDING
 Continuation-in-part of Ser. No. US 1999-255794, filed
 on 23 Feb 1999, PENDING Continuation-in-part of Ser.
 No. US 2000-588947, filed on 8 Jun 2000, ABANDONED
 Continuation-in-part of Ser. No. US 2000-589285, filed
 on 8 Jun 2000, PENDING Continuation-in-part of Ser. No.
 US 2000-589286, filed on 8 Jun 2000, PENDING
 Continuation-in-part of Ser. No. US 2000-589288, filed
 on 8 Jun 2000, PENDING Continuation-in-part of Ser. No.
 US 2000-507968, filed on 22 Feb 2000, PENDING
 Continuation-in-part of Ser. No. US 1999-255794, filed
 on 23 Feb 1999, PENDING Continuation-in-part of Ser.
 No. US 1998-5874, filed on 12 Jan 1998, PENDING
 Continuation-in-part of Ser. No. WO 1996-US17957, filed
 on 25 Oct 1996, PENDING Continuation-in-part of Ser.
 No. US 1999-255794, filed on 23 Feb 1999, PENDING
 Continuation-in-part of Ser. No. US 1998-5874, filed on
 12 Jan 1998, PENDING

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2001-329508P	20011017 (60)
	US 2001-329747P	20011018 (60)
	US 2001-330835P	20011031 (60)
	US 2001-331478P	20011116 (60)
	US 2001-336726P	20011207 (60)
	US 2002-368548P	20020401 (60)
	US 2000-225628P	20000815 (60)
	US 2000-227008P	20000823 (60)
	US 2000-234338P	20000922 (60)
	US 2000-240806P	20001017 (60)
	US 2000-250020P	20001130 (60)
	US 2001-276248P	20010316 (60)
	US 2001-293499P	20010525 (60)
	US 2001-296122P	20010607 (60)
	US 2001-304809P	20010713 (60)
	US 1999-122388P	19990302 (60)
	US 1999-124097P	19990312 (60)
	US 1999-126599P	19990326 (60)
	US 1999-127598P	19990402 (60)
	US 1999-130412P	19990416 (60)
	US 1999-130696P	19990423 (60)
	US 1999-131278P	19990427 (60)
	US 1999-131673P	19990429 (60)
	US 1999-136784P	19990528 (60)
	US 1999-142659P	19990706 (60)
	US 1999-145824P	19990727 (60)
	US 1999-167239P	19991124 (60)
	US 1999-168624P	19991203 (60)
	US 1999-171108P	19991216 (60)
	US 1999-171626P	19991223 (60)
	US 2000-176015P	20000114 (60)
	US 1999-122388P	19990302 (60)
	US 1999-124097P	19990312 (60)
	US 1999-126599P	19990326 (60)
	US 1999-127598P	19990402 (60)
	US 1999-130412P	19990416 (60)
	US 1999-130696P	19990423 (60)
	US 1999-131278P	19990427 (60)
	US 1999-131673P	19990429 (60)
	US 1999-136784P	19990528 (60)

US 1999-142659P 19990706 (60)
US 1999-145824P 19990727 (60)
US 1999-167239P 19991124 (60)
US 1999-168624P 19991203 (60)
US 1999-171108P 19991216 (60)
US 1999-171626P 19991223 (60)
US 2000-176015P 20000114 (60)
US 1997-36100P 19970114 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 27 Drawing Page(s)
LINE COUNT: 18884
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 8 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:244853 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
Prior, Christopher P., Rosemont, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003171267	A1	20030911
APPLICATION INFO.:	US 2001-833117	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 59
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 13208
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 8 USPATFULL on STN

TI Chemokine beta-1 fusion proteins

AB The present invention relates to novel chemokine polypeptides and encoding nucleic acids. More specifically, therapeutic compositions and methods are provided using isolated nucleic acid molecules encoding a

human chemokine beta-1 (Ck.beta.-1 or Ckb1) polypeptide (previously termed monocyte-colony inhibitory factor (M-CIF), MIP1-.gamma., and Hemofiltrate CC chemokine-1 (HCC-1)), and Ckb1 polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same. Also provided are methods of treating, preventing, ameliorating diseases using such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:206834 USPATFULL
TITLE: Chemokine beta-1 fusion proteins
INVENTOR(S): Bell, Adam, Germantown, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003143191	A1	20030731
APPLICATION INFO.:	US 2002-153604	A1	20020524 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-293212P	20010525 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	21 Drawing Page(s)	
LINE COUNT:	15446	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 8 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:181414 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003125247	A1	20030703
APPLICATION INFO.:	US 2001-833041	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	

NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 15235
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 8 USPATFULL on STN

TI Binding polypeptides and methods based thereon

AB Binding polypeptides that specifically bind BLyS protein or BLyS-like polypeptides can be used in methods of the invention for detecting, diagnosing, or prognosing a disease or disorder associated with aberrant BLyS or BLyS receptor expression or inappropriate function of BLyS or BLyS receptor, comprising BLyS binding polypeptides or fragments or variants thereof, that specifically bind to BLyS. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant BLyS or BLyS receptor expression or inappropriate BLyS function or BLyS receptor function, comprising administering to an animal, preferably a human, an effective amount of one or more BLyS binding polypeptides or fragments or variants thereof, that specifically bind to BLyS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:133480 USPATFULL

TITLE: Binding polypeptides and methods based thereon

INVENTOR(S): Beltzer, James P., Carlisle, MA, UNITED STATES

Potter, M. Daniel, UNITED STATES

Potter, Marilou, Acton, MA, UNITED STATES LR

Fleming, Tony J., Waltham, MA, UNITED STATES

Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003091565	A1	20030515
APPLICATION INFO.:	US 2001-932613	A1	20010817 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-226700P	20000818 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Leon R. Yankwich, Esq., Yankwich & Associates, 130 Bishop Allen Drive, Cambridge, MA, 02139	
NUMBER OF CLAIMS:	71	
EXEMPLARY CLAIM:	1	
LINE COUNT:	11834	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:38:37 ON 16 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS, BIOSIS' ENTERED AT 12:39:04 ON 16 JAN 2004

L1 13014 S RANTES

L2 2849 S ALBUMIN FUSION PROTEIN

L3 8 S L1 AND L2

=> s FGF-8

L4 1364 FGF-8

=> s l4 and albumin

L5 509 L4 AND ALBUMIN

=> s 15 and fusion
L6 491 L5 AND FUSION

=> d 16 and l1
L1 IS NOT VALID HERE
For an explanation, enter "HELP DISPLAY".

=> s 16 and l1
L7 207 L6 AND L1

=> s 17 and stabilizer
L8 0 L7 AND STABILIZER

=> d 17 ti abs ibib 1-10

L7 ANSWER 1 OF 207 USPATFULL on STN
TI **Albumin fusion** proteins
AB The present invention encompasses **albumin fusion** proteins. Nucleic acid molecules encoding the **albumin fusion** proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin fusion** proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin fusion** proteins of the invention.

ACCESSION NUMBER: 2004:13611 USPATFULL
TITLE: **Albumin fusion** proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 25066

L7 ANSWER 2 OF 207 USPATFULL on STN
TI 53 human secreted proteins
AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

ACCESSION NUMBER: 2004:13609 USPATFULL

TITLE: 53 human secreted proteins
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Brewer, Laurie A., St. Paul, MN, UNITED STATES
 Duan, Roxanne D., Bethesda, MD, UNITED STATES
 Ruben, Steven M., Olney, MD, UNITED STATES
 Florence, Kimberly A., Rockville, MD, UNITED STATES
 Greene, John M., Gaithersburg, MD, UNITED STATES
 Young, Paul E., Gaithersburg, MD, UNITED STATES
 Ferrie, Ann M., Painted Post, NY, UNITED STATES
 Yu, Guo-Liang, Berkeley, CA, UNITED STATES
 Florence, Charles, Rockville, MD, UNITED STATES
 Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
 Olsen, Henrik, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010132	A1	20040115
APPLICATION INFO.:	US 2001-984429	A1	20011030 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-288143, filed on 8 Apr 1999, GRANTED, Pat. No. US 6433139		
	Continuation-in-part of Ser. No. WO 1998-US21142, filed on 8 Oct 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-244591P	20001101 (60)
	US 1997-61463P	19971009 (60)
	US 1997-61529P	19971009 (60)
	US 1997-71498P	19971009 (60)
	US 1997-61527P	19971009 (60)
	US 1997-61536P	19971009 (60)
	US 1997-61532P	19971009 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
 NUMBER OF CLAIMS: 24
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 4 Drawing Page(s)
 LINE COUNT: 27480

L7 ANSWER 3 OF 207 USPATFULL on STN

TI 7 Human ovarian and ovarian cancer associated proteins
 AB This invention relates to newly identified ovarian or ovarian cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "ovarian cancer antigens", and the use of such ovarian antigens for detecting disorders of the reproductive system, particularly the presence of ovarian cancer and ovarian cancer metastases. This invention relates to ovarian cancer antigens as well as vectors, host cells, antibodies directed to ovarian cancer antigens and the recombinant methods and synthetic methods for producing the same. Also provided are diagnostic methods for detecting, treating, preventing and/or prognosing disorders related to the ovary, including ovarian cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of ovarian cancer antigens of the invention. The present invention further relates to inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:13598 USPATFULL
 TITLE: 7 Human ovarian and ovarian cancer associated proteins
 INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
 Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010121	A1	20040115
APPLICATION INFO.:	US 2003-333900	A1	20030124 (10)
	WO 2001-US8585		20010316
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
LINE COUNT:	16023		

L7 ANSWER 4 OF 207 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel polynucleotides associated with the plasma membrane, the polypeptides encoded by these polynucleotides herein collectively referred to as "plasma membrane associated antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such plasma membrane associated polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders related to these novel polypeptides. More specifically, isolated nucleic acid molecules are provided encoding novel plasma membrane associated polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing these plasma membrane associated polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the novel polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:12971 USPATFULL
 TITLE: Nucleic acids, proteins, and antibodies
 INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
 Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009491	A1	20040115
APPLICATION INFO.:	US 2002-264237	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US16450, filed on 18 May 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	18144	

L7 ANSWER 5 OF 207 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel musculoskeletal system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "musculoskeletal system antigens," and the

use of such musculoskeletal system antigens for detecting disorders of the musculoskeletal system, particularly the presence of cancer and cancer metastases. More specifically, isolated musculoskeletal system associated nucleic acid molecules are provided encoding novel musculoskeletal system associated polypeptides. Novel musculoskeletal system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human musculoskeletal system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the musculoskeletal system, including cancer of musculoskeletal tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:12968 USPATFULL
 TITLE: Nucleic acids, proteins, and antibodies
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Ruben, Steven M., Olney, MD, UNITED STATES
 Barash, Steven C., Rockville, MD, UNITED STATES
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009488	A1	20040115
APPLICATION INFO.:	US 2002-242515	A1	20020913 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764877, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)

US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)

US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 32038

L7 ANSWER 6 OF 207 USPATFULL on STN

TI Apoptosis inducing molecule II and methods of use

AB The present invention relates to a novel member of the TNF-Ligand superfamily. More specifically, isolated nucleic acid molecules are provided encoding a human Apoptosis Inducing Molecule II (AIM II). AIM II polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of AIM II activity. Also provided are therapeutic methods for treating lymphadenopathy, aberrant bone development, autoimmune and other immune system diseases, graft versus host disease, rheumatoid arthritis, osteoarthritis and to inhibit neoplasia, such as tumor cell growth.

ACCESSION NUMBER: 2004:12629 USPATFULL
 TITLE: Apoptosis inducing molecule II and methods of use
 INVENTOR(S): Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
 Yu, Guo-Liang, Berkeley, CA, UNITED STATES
 Ruben, Steven M., Brookeville, MD, UNITED STATES
 Zhai, Yifan, Rockville, MD, UNITED STATES
 Ullrich, Stephen, Rockville, MD, UNITED STATES
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009147	A1	20040115
APPLICATION INFO.:	US 2003-375680	A1	20030228 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-523323, filed on 10 Mar 2000, GRANTED, Pat. No. US 6635743		
	Continuation-in-part of Ser. No. US 1999-252656, filed on 19 Feb 1999, GRANTED, Pat. No. US 6495520		
	Continuation-in-part of Ser. No. US 1998-27287, filed on 20 Feb 1998, GRANTED, Pat. No. US 6479254		
	Continuation-in-part of Ser. No. US 1998-3886, filed on 7 Jan 1998, ABANDONED		
	Continuation-in-part of Ser. No. US 1997-822953, filed on 21 Mar 1997, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-360234P	20020301 (60)
	US 1999-168380P	19991202 (60)
	US 1999-148326P	19990811 (60)
	US 1999-142657P	19990706 (60)
	US 1999-137457P	19990604 (60)
	US 1999-124041P	19990311 (60)
	US 1998-75409P	19980220 (60)
	US 1996-13923P	19960322 (60)
	US 1996-30157P	19961031 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W., WASHINGTON, DC, 20005
 NUMBER OF CLAIMS: 45
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 48 Drawing Page(s)
 LINE COUNT: 13322

L7 ANSWER 7 OF 207 USPATFULL on STN
 TI Nucleic acids, proteins, and antibodies
 AB The present invention relates to novel ovarian related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "ovarian antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such ovarian polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the reproductive system, particularly disorders of the ovaries and/or breast, including, but not limited to, the presence of ovarian and/or breast cancer and ovarian and/or breast cancer metastases. More specifically, isolated ovarian nucleic acid molecules are provided encoding novel ovarian polypeptides. Novel ovarian polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human ovarian polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the ovaries and/or breast, including ovarian and/or breast cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of

polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:7345 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005579	A1	20040108
APPLICATION INFO.:	US 2002-264049	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US18569, filed on 7 Jun 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-209467P	20000607 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	18130	

L7 ANSWER 8 OF 207 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:7343 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005577	A1	20040108
APPLICATION INFO.:	US 2002-242747	A1	20020913 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764881, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)

US 2000-225758P	20000814 (60)
US 2000-220963P	20000726 (60)
US 2000-217496P	20000711 (60)
US 2000-225447P	20000814 (60)
US 2000-218290P	20000714 (60)
US 2000-225757P	20000814 (60)
US 2000-226868P	20000822 (60)
US 2000-216647P	20000707 (60)
US 2000-225267P	20000814 (60)
US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)

US 2000-249212P	20001117	(60)
US 2000-249207P	20001117	(60)
US 2000-249245P	20001117	(60)
US 2000-249244P	20001117	(60)
US 2000-249217P	20001117	(60)
US 2000-249211P	20001117	(60)
US 2000-249215P	20001117	(60)
US 2000-249264P	20001117	(60)
US 2000-249214P	20001117	(60)
US 2000-249297P	20001117	(60)
US 2000-232400P	20000914	(60)
US 2000-231242P	20000908	(60)
US 2000-232081P	20000908	(60)
US 2000-232080P	20000908	(60)
US 2000-231414P	20000908	(60)
US 2000-231244P	20000908	(60)
US 2000-233064P	20000914	(60)
US 2000-233063P	20000914	(60)
US 2000-232397P	20000914	(60)
US 2000-232399P	20000914	(60)
US 2000-232401P	20000914	(60)
US 2000-241808P	20001020	(60)
US 2000-241826P	20001020	(60)
US 2000-241786P	20001020	(60)
US 2000-241221P	20001020	(60)
US 2000-246475P	20001108	(60)
US 2000-231243P	20000908	(60)
US 2000-233065P	20000914	(60)
US 2000-232398P	20000914	(60)
US 2000-234998P	20000925	(60)
US 2000-246477P	20001108	(60)
US 2000-246528P	20001108	(60)
US 2000-246525P	20001108	(60)
US 2000-246476P	20001108	(60)
US 2000-246526P	20001108	(60)
US 2000-249209P	20001117	(60)
US 2000-246527P	20001108	(60)
US 2000-246523P	20001108	(60)
US 2000-246524P	20001108	(60)
US 2000-246478P	20001108	(60)
US 2000-246609P	20001108	(60)
US 2000-246613P	20001108	(60)
US 2000-249300P	20001117	(60)
US 2000-249265P	20001117	(60)
US 2000-246610P	20001108	(60)
US 2000-246611P	20001108	(60)
US 2000-230437P	20000906	(60)
US 2000-251990P	20001208	(60)
US 2000-251988P	20001205	(60)
US 2000-251030P	20001205	(60)
US 2000-251479P	20001206	(60)
US 2000-256719P	20001205	(60)
US 2000-250160P	20001201	(60)
US 2000-251989P	20001208	(60)
US 2000-250391P	20001201	(60)
US 2000-254097P	20001211	(60)
US 2000-231968P	20000912	(60)
US 2000-226279P	20000818	(60)
US 2000-186350P	20000302	(60)
US 2000-184664P	20000224	(60)
US 2000-189874P	20000316	(60)
US 2000-198123P	20000418	(60)
US 2000-227009P	20000823	(60)
US 2000-235484P	20000926	(60)

US 2000-190076P 20000317 (60)
US 2000-209467P 20000607 (60)
US 2000-205515P 20000519 (60)
US 2001-259678P 20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 27694

L7 ANSWER 9 OF 207 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel cardiovascular system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cardiovascular system antigens," and the use of such cardiovascular system antigens for detecting disorders of the cardiovascular system, particularly the presence of cancer of cardiovascular system tissues and cancer metastases. More specifically, isolated cardiovascular system associated nucleic acid molecules are provided encoding novel cardiovascular system associated polypeptides. Novel cardiovascular system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human cardiovascular system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the cardiovascular system, including cancer of cardiovascular system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:7341 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005575	A1	20040108
APPLICATION INFO.:	US 2002-227577	A1	20020826 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-91504, filed on 7 Mar 2002, PENDING Continuation of Ser. No. US 2001-764869, filed on 17 Jan 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)

US 2000-226868P	20000822 (60)
US 2000-216647P	20000707 (60)
US 2000-225267P	20000814 (60)
US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)

US 2000-249215P	20001117	(60)
US 2000-249264P	20001117	(60)
US 2000-249214P	20001117	(60)
US 2000-249297P	20001117	(60)
US 2000-232400P	20000914	(60)
US 2000-231242P	20000908	(60)
US 2000-232081P	20000908	(60)
US 2000-232080P	20000908	(60)
US 2000-231414P	20000908	(60)
US 2000-231244P	20000908	(60)
US 2000-233064P	20000914	(60)
US 2000-233063P	20000914	(60)
US 2000-232397P	20000914	(60)
US 2000-232399P	20000914	(60)
US 2000-232401P	20000914	(60)
US 2000-241808P	20001020	(60)
US 2000-241826P	20001020	(60)
US 2000-241786P	20001020	(60)
US 2000-241221P	20001020	(60)
US 2000-246475P	20001108	(60)
US 2000-231243P	20000908	(60)
US 2000-233065P	20000914	(60)
US 2000-232398P	20000914	(60)
US 2000-234998P	20000925	(60)
US 2000-246477P	20001108	(60)
US 2000-246528P	20001108	(60)
US 2000-246525P	20001108	(60)
US 2000-246476P	20001108	(60)
US 2000-246526P	20001108	(60)
US 2000-249209P	20001117	(60)
US 2000-246527P	20001108	(60)
US 2000-246523P	20001108	(60)
US 2000-246524P	20001108	(60)
US 2000-246478P	20001108	(60)
US 2000-246609P	20001108	(60)
US 2000-246613P	20001108	(60)
US 2000-249300P	20001117	(60)
US 2000-249265P	20001117	(60)
US 2000-246610P	20001108	(60)
US 2000-246611P	20001108	(60)
US 2000-230437P	20000906	(60)
US 2000-251990P	20001208	(60)
US 2000-251988P	20001205	(60)
US 2000-251030P	20001205	(60)
US 2000-251479P	20001206	(60)
US 2000-256719P	20001205	(60)
US 2000-250160P	20001201	(60)
US 2000-251989P	20001208	(60)
US 2000-250391P	20001201	(60)
US 2000-254097P	20001211	(60)
US 2000-231968P	20000912	(60)
US 2000-226279P	20000818	(60)
US 2000-186350P	20000302	(60)
US 2000-184664P	20000224	(60)
US 2000-189874P	20000316	(60)
US 2000-198123P	20000418	(60)
US 2000-227009P	20000823	(60)
US 2000-235484P	20000926	(60)
US 2000-190076P	20000317	(60)
US 2000-209467P	20000607	(60)
US 2000-205515P	20000519	(60)
US 2001-259678P	20010105	(60)

DOCUMENT TYPE:
FILE SEGMENT:

Utility
APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 28742

L7 ANSWER 10 OF 207 USPATFULL on STN

TI 50 human secreted proteins

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:2568 USPATFULL

TITLE: 50 human secreted proteins

INVENTOR(S): Moore, Paul A., Germantown, MD, UNITED STATES

Ruben, Steven M., Olney, MD, UNITED STATES

LaFleur, David W., Washington, DC, UNITED STATES

Shi, Yanggu, Gaithersburg, MD, UNITED STATES

Rosen, Craig A., Laytonsville, MD, UNITED STATES

Olsen, Henrik S., Gaithersburg, MD, UNITED STATES

Ebner, Reinhard, Gaithersburg, MD, UNITED STATES

Brewer, Laurie A., St. Paul, MN, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002591	A1	20040101
APPLICATION INFO.:	US 2002-47021	A1	20020117 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-722329, filed on 28 Nov 2000, PENDING Continuation of Ser. No. US 1999-262109, filed on 4 Mar 1999, ABANDONED Continuation-in-part of Ser. No. WO 1998-US18360, filed on 3 Sep 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-262066P	20010118 (60)
	US 1997-57626P	19970905 (60)
	US 1997-57663P	19970905 (60)
	US 1997-57669P	19970905 (60)
	US 1997-58666P	19970912 (60)
	US 1997-58667P	19970912 (60)
	US 1997-58973P	19970912 (60)
	US 1997-58974P	19970912 (60)
	US 1998-90112P	19980622 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 23

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 2 Drawing Page(s)

LINE COUNT: 33379

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:38:37 ON 16 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS, BIOSIS' ENTERED AT 12:39:04 ON 16 JAN 2004

L1 13014 S RANTES
L2 2849 S ALBUMIN FUSION PROTEIN
L3 8 S L1 AND L2
L4 1364 S FGF-8
L5 509 S L4 AND ALBUMIN
L6 491 S L5 AND FUSION
L7 207 S L6 AND L1
L8 0 S L7 AND STABILIZER

=> s fusion partner

L9 6424 FUSION PARTNER

=> s l9 and albumin

L10 2467 L9 AND ALBUMIN

=> s l9 and BMP

L11 176 L9 AND BMP

=> s l11 and l10

L12 141 L11 AND L10

=> s l12 and l1

L13 101 L12 AND L1

=> d l13 ti abs ibib 1-10

L13 ANSWER 1 OF 101 USPATFULL on STN

TI **Albumin** fusion proteins

AB The present invention encompasses **albumin** fusion proteins. Nucleic acid molecules encoding the **albumin** fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin** fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin** fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin** fusion proteins of the invention.

ACCESSION NUMBER: 2004:13611 USPATFULL

TITLE: **Albumin** fusion proteins

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 29

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 25066

L13 ANSWER 2 OF 101 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel polynucleotides associated with the plasma membrane, the polypeptides encoded by these polynucleotides herein collectively referred to as "plasma membrane associated antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such plasma membrane associated polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders related to these novel polypeptides. More specifically, isolated nucleic acid molecules are provided encoding novel plasma membrane associated polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing these plasma membrane associated polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the novel polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:12971 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES

Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009491	A1	20040115
APPLICATION INFO.:	US 2002-264237	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US16450, filed on 18 May 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	18144	

L13 ANSWER 3 OF 101 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel musculoskeletal system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "musculoskeletal system antigens," and the use of such musculoskeletal system antigens for detecting disorders of the musculoskeletal system, particularly the presence of cancer and cancer metastases. More specifically, isolated musculoskeletal system associated nucleic acid molecules are provided encoding novel musculoskeletal system associated polypeptides. Novel musculoskeletal system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human musculoskeletal system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating,

preventing and/or prognosing disorders related to the musculoskeletal system, including cancer of musculoskeletal tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:12968 USPATFULL
 TITLE: Nucleic acids, proteins, and antibodies
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Ruben, Steven M., Olney, MD, UNITED STATES
 Barash, Steven C., Rockville, MD, UNITED STATES
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009488	A1	20040115
APPLICATION INFO.:	US 2002-242515	A1	20020913 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764877, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-229345P	20000901 (60)
	US 2000-229287P	20000901 (60)
	US 2000-229513P	20000905 (60)

US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)

US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 32038

L13 ANSWER 4 OF 101 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel ovarian related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "ovarian antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such ovarian polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the reproductive system, particularly disorders of the ovaries and/or breast, including, but not limited to, the presence of ovarian and/or breast cancer and ovarian and/or breast cancer metastases. More specifically, isolated ovarian nucleic acid molecules are provided encoding novel ovarian polypeptides. Novel ovarian polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human ovarian polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the ovaries and/or breast, including ovarian and/or breast cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the

production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:7345 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005579	A1	20040108
APPLICATION INFO.:	US 2002-264049	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US18569, filed on 7 Jun 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-209467P	20000607 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	18130	

L13 ANSWER 5 OF 101 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:7343 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005577	A1	20040108
APPLICATION INFO.:	US 2002-242747	A1	20020913 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764881, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)

US 2000-217496P	20000711	(60)
US 2000-225447P	20000814	(60)
US 2000-218290P	20000714	(60)
US 2000-225757P	20000814	(60)
US 2000-226868P	20000822	(60)
US 2000-216647P	20000707	(60)
US 2000-225267P	20000814	(60)
US 2000-216880P	20000707	(60)
US 2000-225270P	20000814	(60)
US 2000-251869P	20001208	(60)
US 2000-235834P	20000927	(60)
US 2000-234274P	20000921	(60)
US 2000-234223P	20000921	(60)
US 2000-228924P	20000830	(60)
US 2000-224518P	20000814	(60)
US 2000-236369P	20000929	(60)
US 2000-224519P	20000814	(60)
US 2000-220964P	20000726	(60)
US 2000-241809P	20001020	(60)
US 2000-249299P	20001117	(60)
US 2000-236327P	20000929	(60)
US 2000-241785P	20001020	(60)
US 2000-244617P	20001101	(60)
US 2000-225268P	20000814	(60)
US 2000-236368P	20000929	(60)
US 2000-251856P	20001208	(60)
US 2000-251868P	20001208	(60)
US 2000-229344P	20000901	(60)
US 2000-234997P	20000925	(60)
US 2000-229343P	20000901	(60)
US 2000-229345P	20000901	(60)
US 2000-229287P	20000901	(60)
US 2000-229513P	20000905	(60)
US 2000-231413P	20000908	(60)
US 2000-229509P	20000905	(60)
US 2000-236367P	20000929	(60)
US 2000-237039P	20001002	(60)
US 2000-237038P	20001002	(60)
US 2000-236370P	20000929	(60)
US 2000-236802P	20001002	(60)
US 2000-237037P	20001002	(60)
US 2000-237040P	20001002	(60)
US 2000-240960P	20001020	(60)
US 2000-239935P	20001013	(60)
US 2000-239937P	20001013	(60)
US 2000-241787P	20001020	(60)
US 2000-246474P	20001108	(60)
US 2000-246532P	20001108	(60)
US 2000-249216P	20001117	(60)
US 2000-249210P	20001117	(60)
US 2000-226681P	20000822	(60)
US 2000-225759P	20000814	(60)
US 2000-225213P	20000814	(60)
US 2000-227182P	20000822	(60)
US 2000-225214P	20000814	(60)
US 2000-235836P	20000927	(60)
US 2000-230438P	20000906	(60)
US 2000-215135P	20000630	(60)
US 2000-225266P	20000814	(60)
US 2000-249218P	20001117	(60)
US 2000-249208P	20001117	(60)
US 2000-249213P	20001117	(60)
US 2000-249212P	20001117	(60)
US 2000-249207P	20001117	(60)

US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)

US 2000-205515P 20000519 (60)
 US 2001-259678P 20010105 (60)
 DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
 ROCKVILLE, MD, 20850
 NUMBER OF CLAIMS: 24
 EXEMPLARY CLAIM: 1
 LINE COUNT: 27694

L13 ANSWER 6 OF 101 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel cardiovascular system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cardiovascular system antigens," and the use of such cardiovascular system antigens for detecting disorders of the cardiovascular system, particularly the presence of cancer of cardiovascular system tissues and cancer metastases. More specifically, isolated cardiovascular system associated nucleic acid molecules are provided encoding novel cardiovascular system associated polypeptides. Novel cardiovascular system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human cardiovascular system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the cardiovascular system, including cancer of cardiovascular system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:7341 USPATFULL
 TITLE: Nucleic acids, proteins, and antibodies
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Ruben, Steven M., Olney, MD, UNITED STATES
 Barash, Steven C., Rockville, MD, UNITED STATES
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005575	A1	20040108
APPLICATION INFO.:	US 2002-227577	A1	20020826 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-91504, filed on 7 Mar 2002, PENDING Continuation of Ser. No. US 2001-764869, filed on 17 Jan 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)

US 2000-225267P	20000814 (60)
US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)

US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE:

FILE SEGMENT:

LEGAL REPRESENTATIVE:

Utility

APPLICATION

HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 28742

L13 ANSWER 7 OF 101 USPATFULL on STN

TI 50 human secreted proteins

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:2568 USPATFULL

TITLE: 50 human secreted proteins

INVENTOR(S): Moore, Paul A., Germantown, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
LaFleur, David W., Washington, DC, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002591	A1	20040101
APPLICATION INFO.:	US 2002-47021	A1	20020117 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-722329, filed on 28 Nov 2000, PENDING Continuation of Ser. No. US 1999-262109, filed on 4 Mar 1999, ABANDONED Continuation-in-part of Ser. No. WO 1998-US18360, filed on 3 Sep 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-262066P	20010118 (60)
	US 1997-57626P	19970905 (60)
	US 1997-57663P	19970905 (60)
	US 1997-57669P	19970905 (60)
	US 1997-58666P	19970912 (60)
	US 1997-58667P	19970912 (60)
	US 1997-58973P	19970912 (60)
	US 1997-58974P	19970912 (60)
	US 1998-90112P	19980622 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 23

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 2 Drawing Page(s)

LINE COUNT: 33379

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 8 OF 101 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel excretory system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "excretory system antigens," and the use of

such excretory system antigens for detecting disorders of the excretory system, particularly the presence of cancer of excretory system tissues and cancer metastases. More specifically, isolated excretory system associated nucleic acid molecules are provided encoding novel excretory system associated polypeptides. Novel excretory system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human excretory system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the excretory system, including cancer of excretory system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:334955 USPATFULL
 TITLE: Nucleic acids, proteins, and antibodies
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Ruben, Steven M., Olney, MD, UNITED STATES
 Barash, Steven C., Rockville, MD, UNITED STATES
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235831	A1	20031225
APPLICATION INFO.:	US 2002-242355	A1	20020913 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764897, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)

US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)

US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 22457
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 9 OF 101 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for

identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:334953 USPATFULL
 TITLE: Nucleic acids, proteins, and antibodies
 INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES
 Barash, Steven C., Rockville, MD, UNITED STATES
 Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Birse, Charles E., North Potomac, MD, UNITED STATES
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235829	A1	20031225
APPLICATION INFO.:	US 2002-227646	A1	20020826 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-860670, filed on 21 May 2001, PENDING Continuation-in-part of Ser. No. WO 2001-US1346, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)
	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-216880P	20000707 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-236367P	20000929 (60)
	US 2000-239937P	20001013 (60)
	US 2000-249210P	20001117 (60)
	US 2000-249211P	20001117 (60)
	US 2000-249214P	20001117 (60)
	US 2000-231243P	20000908 (60)
	US 2000-246477P	20001108 (60)
	US 2000-246528P	20001108 (60)
	US 2000-246525P	20001108 (60)
	US 2000-246476P	20001108 (60)
	US 2000-246526P	20001108 (60)
	US 2000-249265P	20001117 (60)
	US 2000-230437P	20000906 (60)
	US 2000-251990P	20001208 (60)
	US 2000-251988P	20001205 (60)
	US 2000-251030P	20001205 (60)
	US 2000-251479P	20001206 (60)
	US 2000-256719P	20001205 (60)
	US 2000-250160P	20001201 (60)
	US 2000-251989P	20001208 (60)
	US 2000-250391P	20001201 (60)
	US 2000-254097P	20001211 (60)
	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)

US 2000-225757P	20000814 (60)
US 2000-226868P	20000822 (60)
US 2000-216647P	20000707 (60)
US 2000-225267P	20000814 (60)
US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)

US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)
US 2000-179065P	20000131 (60)

US 2000-180628P	20000204 (60)
US 2000-214886P	20000628 (60)
US 2000-217487P	20000711 (60)
US 2000-225758P	20000814 (60)
US 2000-220963P	20000726 (60)
US 2000-217496P	20000711 (60)
US 2000-225447P	20000814 (60)
US 2000-218290P	20000714 (60)
US 2000-225757P	20000814 (60)
US 2000-226868P	20000822 (60)
US 2000-216647P	20000707 (60)
US 2000-225267P	20000814 (60)
US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)

US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)

US 2000-198123P 20000418 (60)
US 2000-227009P 20000823 (60)
US 2000-235484P 20000926 (60)
US 2000-190076P 20000317 (60)
US 2000-209467P 20000607 (60)
US 2000-205515P 20000519 (60)
US 2001-259678P 20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 20415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 10 OF 101 USPATFULL on STN

TI Novel methods of diagnosis of metastatic colorectal cancer, compositions
and methods of screening for modulators of metastatic colorectal cancer
AB Described herein are methods and compositions that can be used for
diagnosis and treatment of metastatic colorectal cancer. Also described
herein are methods that can be used to identify modulators of metastatic
colorectal cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:334944 USPATFULL
TITLE: Novel methods of diagnosis of metastatic colorectal
cancer, compositions and methods of screening for
modulators of metastatic colorectal cancer
INVENTOR(S): Mack, David H., Menlo Park, CA, UNITED STATES
Markowitz, Sanford David, Pepper Pike, OH, UNITED
STATES
PATENT ASSIGNEE(S): Eos Biotechnology, Inc., South San Francisco, CA (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235820	A1	20031225
APPLICATION INFO.:	US 2002-87080	A1	20020227 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-284555P	20010417 (60)
	US 2001-281149P	20010402 (60)
	US 2001-272206P	20010227 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO
CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 22670
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:38:37 ON 16 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS,
BIOSIS' ENTERED AT 12:39:04 ON 16 JAN 2004

L1 13014 S RANTES
L2 2849 S ALBUMIN FUSION PROTEIN
L3 8 S L1 AND L2

L4 1364 S FGF-8
 L5 509 S L4 AND ALBUMIN
 L6 491 S L5 AND FUSION
 L7 207 S L6 AND L1
 L8 0 S L7 AND STABILIZER
 L9 6424 S FUSION PARTNER
 L10 2467 S L9 AND ALBUMIN
 L11 176 S L9 AND BMP
 L12 141 S L11 AND L10
 L13 101 S L12 AND L1

=> s albumin () fusion proteain

L14 2849 ALBUMIN (W) FUSION PROTEIN

=> s albumin () BMP

L15 0 ALBUMIN (W) BMP

=> s albumin () FGF

L16 35 ALBUMIN (W) FGF

=> d l16 ti abs ibib tot

L16 ANSWER 1 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 TI Fibroblast growth factor family polypeptide which stimulates
 proliferation and growth of hepatocytes is useful for treating hepatic
 disorders -
 AN AAY58432 Protein DGENE
 AB This sequence represents a truncated rat fibroblast growth factor-16
 (FGF-16) des-N-9, where residues 1-9 of the full-length rat FGF-16
 (AAY58428) have been removed by proteolytic cleavage. FGF-16 has
 hepatocyte proliferation and growth activity, and increases hepatic
 production of triglycerides and serum proteins (e.g., **albumin**).
FGF-16 nucleic acids and/or proteins may be used for stimulating
 the proliferation and development of hepatocytes both in vitro and in
 vivo. The isolated nucleic acid molecules may be used directly in cell or
 gene therapy applications to treat or prevent liver disorders, including
 hepatic cirrhosis, fulminant liver failure, damage caused by acute viral
 hepatitis and toxic insults to the liver.
 ACCESSION NUMBER: AAY58432 Protein DGENE
 TITLE: Fibroblast growth factor family polypeptide which stimulates
 proliferation and growth of hepatocytes is useful for
 treating hepatic disorders -
 INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
 PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
 PATENT INFO: US 5998170 A 19991207 33p
 APPLICATION INFO: US 1997-943915 19971003
 PRIORITY INFO: US 1997-943915 19971003
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 OTHER SOURCE: 2000-085497 [07]
 DESCRIPTION: Rat truncated fibroblast growth factor FGF-16, des-N-9.

L16 ANSWER 2 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 TI Fibroblast growth factor family polypeptide which stimulates
 proliferation and growth of hepatocytes is useful for treating hepatic
 disorders -
 AN AAY58431 Protein DGENE
 AB This sequence represents a truncated rat fibroblast growth factor-16
 (FGF-16) des-N-34, where residues 1-34 of the full-length rat FGF-16
 (AAY58428) have been removed by proteolytic cleavage. FGF-16 has
 hepatocyte proliferation and growth activity, and increases hepatic
 production of triglycerides and serum proteins (e.g., **albumin**).
FGF-16 nucleic acids and/or proteins may be used for stimulating
 the proliferation and development of hepatocytes both in vitro and in

vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.

ACCESSION NUMBER: AAY58431 Protein DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat truncated fibroblast growth factor FGF-16, des-N-34.

L16 ANSWER 3 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAY58430 peptide DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. This sequence represents an E tag, DNA encoding which was fused to the 3' end of the rat FGF-16 coding region, along with DNA encoding a hexahistidine tag. The tagged rat FGF-16 cDNA was cloned into a baculovirus expression system in an exemplification of the present invention.

ACCESSION NUMBER: AAY58430 peptide DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: E tag peptide, SEQ ID NO:6.

L16 ANSWER 4 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAY58429 Protein DGENE
AB This sequence represents human fibroblast growth factor-16 (FGF-16). FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent

liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.

ACCESSION NUMBER: AAY58429 Protein DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
CROSS REFERENCES: N-PSDB: AAZ55791
DESCRIPTION: Human fibroblast growth factor FGF-16.

L16 ANSWER 5 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAY58428 Protein DGENE
AB This sequence represents rat fibroblast growth factor-16 (FGF-16). FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.

ACCESSION NUMBER: AAY58428 Protein DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
CROSS REFERENCES: N-PSDB: AAZ55790
DESCRIPTION: Rat fibroblast growth factor FGF-16.

L16 ANSWER 6 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55819 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55818-Z55819 represent oligonucleotides used in the preparation of the construct pAMG21-delta-N34-rFGF-16, comprising a fragment of the rat FGF-16 cDNA sequence, in an exemplification of the

present invention.

ACCESSION NUMBER: AAZ55819 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Oligonucleotide SEQ ID NO:32, used to construct pAMG21-delta-N34-rFGF-16.

L16 ANSWER 7 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55818 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF-16** nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55818-Z55819 represent oligonucleotides used in the preparation of the construct pAMG21-delta-N34-rFGF-16, comprising a fragment of the rat FGF-16 cDNA sequence, in an exemplification of the present invention.

ACCESSION NUMBER: AAZ55818 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Oligonucleotide SEQ ID NO:31, used to construct pAMG21-delta-N34-rFGF-16.

L16 ANSWER 8 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55817 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF-16** nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure,

vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.

ACCESSION NUMBER: AAY58431 Protein DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat truncated fibroblast growth factor FGF-16, des-N-34.

L16 ANSWER 3 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAY58430 peptide DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. This sequence represents an E tag, DNA encoding which was fused to the 3' end of the rat FGF-16 coding region, along with DNA encoding a hexahistidine tag. The tagged rat FGF-16 cDNA was cloned into a baculovirus expression system in an exemplification of the present invention.

ACCESSION NUMBER: AAY58430 peptide DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: E tag peptide, SEQ ID NO:6.

L16 ANSWER 4 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAY58429 Protein DGENE
AB This sequence represents human fibroblast growth factor-16 (FGF-16). FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent

liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.

ACCESSION NUMBER: AAY58429 Protein DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
CROSS REFERENCES: N-PSDB: AAZ55791
DESCRIPTION: Human fibroblast growth factor FGF-16.

L16 ANSWER 5 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAY58428 Protein DGENE
AB This sequence represents rat fibroblast growth factor-16 (FGF-16). FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.

ACCESSION NUMBER: AAY58428 Protein DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
CROSS REFERENCES: N-PSDB: AAZ55790
DESCRIPTION: Rat fibroblast growth factor FGF-16.

L16 ANSWER 6 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55819 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55818-Z55819 represent oligonucleotides used in the preparation of the construct pAMG21-delta-N34-rFGF-16, comprising a fragment of the rat FGF-16 cDNA sequence, in an exemplification of the

present invention.

ACCESSION NUMBER: AAZ55819 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Oligonucleotide SEQ ID NO:32, used to construct pAMG21-delta-N34-rFGF-16.

L16 ANSWER 7 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55818 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55818-Z55819 represent oligonucleotides used in the preparation of the construct pAMG21-delta-N34-rFGF-16, comprising a fragment of the rat FGF-16 cDNA sequence, in an exemplification of the present invention.

ACCESSION NUMBER: AAZ55818 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Oligonucleotide SEQ ID NO:31, used to construct pAMG21-delta-N34-rFGF-16.

L16 ANSWER 8 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55817 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure,

damage caused by acute viral hepatitis and toxic insults to the liver.
This sequence represents a pAMG21 vector PCR primer used to ascertain
that a pAMG21/rat FGF-16 construct had been produced in an
exemplification of the present invention.

ACCESSION NUMBER: AAZ55817 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates
proliferation and growth of hepatocytes is useful for
treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: pAMG21 vector PCR primer, SEQ ID NO:28.

L16 ANSWER 9 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates
proliferation and growth of hepatocytes is useful for treating hepatic
disorders -
AN AAZ55816 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16
(FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins.
FGF-16 has hepatocyte proliferation and growth activity, and increases
hepatic production of triglycerides and serum proteins (e.g.,
albumin). **FGF-16** nucleic acids and/or proteins may be
used for stimulating the proliferation and development of hepatocytes
both in vitro and in vivo. The isolated nucleic acid molecules may be
used directly in cell or gene therapy applications to treat or prevent
liver disorders, including hepatic cirrhosis, fulminant liver failure,
damage caused by acute viral hepatitis and toxic insults to the liver.
Sequences AAZ55815-Z55816 represent PCR primers used to clone rat FGF-16
cDNA (AAZ55790) into E. coli.

ACCESSION NUMBER: AAZ55816 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates
proliferation and growth of hepatocytes is useful for
treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat FGF-16 PCR primer, SEQ ID NO:28.

L16 ANSWER 10 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates
proliferation and growth of hepatocytes is useful for treating hepatic
disorders -
AN AAZ55815 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16
(FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins.
FGF-16 has hepatocyte proliferation and growth activity, and increases
hepatic production of triglycerides and serum proteins (e.g.,
albumin). **FGF-16** nucleic acids and/or proteins may be
used for stimulating the proliferation and development of hepatocytes
both in vitro and in vivo. The isolated nucleic acid molecules may be
used directly in cell or gene therapy applications to treat or prevent
liver disorders, including hepatic cirrhosis, fulminant liver failure,
damage caused by acute viral hepatitis and toxic insults to the liver.

Sequences AAZ55815-Z55816 represent PCR primers used to clone rat FGF-16 cDNA (AAZ55790) into E. coli.

ACCESSION NUMBER: AAZ55815 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat FGF-16 PCR primer, SEQ ID NO:27.

L16 ANSWER 11 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55814 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55813-Z55814 represent PCR primers used to detect human FGF-16 DNA in bacteria which had previously been transformed with a vector comprising human FGF-16 DNA.

ACCESSION NUMBER: AAZ55814 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat FGF-16 PCR primer, SEQ ID NO:26.

L16 ANSWER 12 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55813 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55813-Z55814 represent PCR primers used to detect human

FGF-16 DNA in bacteria which had previously been transformed with a vector comprising human FGF-16 DNA.

ACCESSION NUMBER: AAZ55813 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 PCR primer, SEQ ID NO:25.

L16 ANSWER 13 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55812 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55810-Z55812 represent PCR primers used in a PCR technique similar to 5' RACE (rapid amplification of cDNA ends) for extension and amplification of human genomic FGF-16 DNA sequences.

ACCESSION NUMBER: AAZ55812 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat FGF-16 genomic PCR primer, SEQ ID NO:24.

L16 ANSWER 14 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55811 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55810-Z55812 represent PCR primers used in a PCR technique

similar to 5' RACE (rapid amplification of cDNA ends) for extension and amplification of human genomic FGF-16 DNA sequences.

ACCESSION NUMBER: AAZ55811 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 genomic PCR primer, SEQ ID NO:23.

L16 ANSWER 15 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55810 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55810-Z55812 represent PCR primers used in a PCR technique similar to 5' RACE (rapid amplification of cDNA ends) for extension and amplification of human genomic FGF-16 DNA sequences.

ACCESSION NUMBER: AAZ55810 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 partially random genomic PCR primer, SEQ ID NO:22.

L16 ANSWER 16 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55809 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.

Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55809 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 PCR primer, SEQ ID NO:21.

L16 ANSWER 17 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55808 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55808 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 5' RACE PCR primer, SEQ ID NO:20.

L16 ANSWER 18 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55807 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55807 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 5' RACE PCR primer, SEQ ID NO:19.

L16 ANSWER 19 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55806 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55806 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 partially random 5' RACE PCR primer, SEQ ID NO:18 (E).

L16 ANSWER 20 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55805 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55805 DNA DGENE

TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 partially random 5' RACE PCR primer, SEQ ID NO:18 (D).

L16 ANSWER 21 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55804 DNA DGENE

AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55804 DNA DGENE

TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H

PATENT ASSIGNEE: (AMGE-N)AMGEN INC.

PATENT INFO: US 5998170 A 19991207 33p

APPLICATION INFO: US 1997-943915 19971003

PRIORITY INFO: US 1997-943915 19971003

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-085497 [07]

DESCRIPTION: Human FGF-16 partially random 5' RACE PCR primer, SEQ ID NO:18 (C).

L16 ANSWER 22 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55803 DNA DGENE

AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55803 DNA DGENE

TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 partially random 5' RACE PCR primer, SEQ ID NO:18 (B).

L16 ANSWER 23 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55802 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55802 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 partially random 5' RACE PCR primer, SEQ ID NO:18 (A).

L16 ANSWER 24 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55801 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.
ACCESSION NUMBER: AAZ55801 DNA DGENE

TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 5' RACE PCR primer, SEQ ID NO:16.

L16 ANSWER 25 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55800 DNA DGENE

AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. This sequence represents a PCR primer used with primer AAZ55799 in 3' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55800 DNA DGENE

TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H

PATENT ASSIGNEE: (AMGE-N)AMGEN INC.

PATENT INFO: US 5998170 A 19991207 33p

APPLICATION INFO: US 1997-943915 19971003

PRIORITY INFO: US 1997-943915 19971003

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-085497 [07]

DESCRIPTION: Human FGF-16 3' RACE PCR primer, SEQ ID NO:15.

L16 ANSWER 26 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55799 DNA DGENE

AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. This sequence represents a primer used to synthesise first strand cDNA from human heart polyA+ RNA, and also used as a PCR primer in 3' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55799 DNA DGENE

TITLE: Fibroblast growth factor family polypeptide which stimulates

proliferation and growth of hepatocytes is useful for
treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Reverse transcription/human FGF-16 3' RACE PCR primer, SEQ ID
NO:14:

L16 ANSWER 27 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates
proliferation and growth of hepatocytes is useful for treating hepatic
disorders -

AN AAZ55798 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16
(FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins.
FGF-16 has hepatocyte proliferation and growth activity, and increases
hepatic production of triglycerides and serum proteins (e.g.,
albumin). FGF-16 nucleic acids and/or proteins may be
used for stimulating the proliferation and development of hepatocytes
both in vitro and in vivo. The isolated nucleic acid molecules may be
used directly in cell or gene therapy applications to treat or prevent
liver disorders, including hepatic cirrhosis, fulminant liver failure,
damage caused by acute viral hepatitis and toxic insults to the liver.
Sequences AAZ55793-Z55798 represent primers used to isolate and clone a
human FGF-16 cDNA fragment in an exemplification of the present
invention.

ACCESSION NUMBER: AAZ55798 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates
proliferation and growth of hepatocytes is useful for
treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human fibroblast growth factor FGF-16 PCR primer, SEQ ID
NO:132.

L16 ANSWER 28 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates
proliferation and growth of hepatocytes is useful for treating hepatic
disorders -

AN AAZ55797 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16
(FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins.
FGF-16 has hepatocyte proliferation and growth activity, and increases
hepatic production of triglycerides and serum proteins (e.g.,
albumin). FGF-16 nucleic acids and/or proteins may be
used for stimulating the proliferation and development of hepatocytes
both in vitro and in vivo. The isolated nucleic acid molecules may be
used directly in cell or gene therapy applications to treat or prevent
liver disorders, including hepatic cirrhosis, fulminant liver failure,
damage caused by acute viral hepatitis and toxic insults to the liver.
Sequences AAZ55793-Z55798 represent primers used to isolate and clone a
human FGF-16 cDNA fragment in an exemplification of the present
invention.

ACCESSION NUMBER: AAZ55797 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat fibroblast growth factor FGF-16 PCR primer, SEQ ID NO:12.

L16 ANSWER 29 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55796 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55793-Z55798 represent primers used to isolate and clone a human FGF-16 cDNA fragment in an exemplification of the present invention.

ACCESSION NUMBER: AAZ55796 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human heart polyA+ RNA reverse transcription primer, SEQ ID NO:11.

L16 ANSWER 30 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55795 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55793-Z55798 represent primers used to isolate and clone a human FGF-16 cDNA fragment in an exemplification of the present

invention.

ACCESSION NUMBER: AAZ55795 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat fibroblast growth factor FGF-16 PCR primer, SEQ ID NO:10.

L16 ANSWER 31 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55794 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF-16** nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55793-Z55798 represent primers used to isolate and clone a human FGF-16 cDNA fragment in an exemplification of the present invention.

ACCESSION NUMBER: AAZ55794 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat fibroblast growth factor FGF-16 PCR primer, SEQ ID NO:9.

L16 ANSWER 32 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55793 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF-16** nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55793-Z55798 represent primers used to isolate and clone a human FGF-16 cDNA fragment in an exemplification of the present

invention.

ACCESSION NUMBER: AAZ55793 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat fibroblast growth factor FGF-16 PCR primer, SEQ ID NO:8.

L16 ANSWER 33 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55792 cDNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. This sequence represents a rat fibroblast growth factor-16 partial cDNA, used to design PCR primers to isolate CDNA encoding human FGF-16 in an exemplification of the present invention.

ACCESSION NUMBER: AAZ55792 cDNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat fibroblast growth factor FGF-16 partial cDNA.

L16 ANSWER 34 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55791 cDNA DGENE
AB This sequence represents cDNA encoding human fibroblast growth factor-16 (FGF-16). FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.

ACCESSION NUMBER: AAZ55791 cDNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for

treating hepatic disorders --
 INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
 PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
 PATENT INFO: US 5998170 A 19991207 33p
 APPLICATION INFO: US 1997-943915 19971003
 PRIORITY INFO: US 1997-943915 19971003
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 OTHER SOURCE: 2000-085497 [07]
 CROSS REFERENCES: P-PSDB: AAY58429
 DESCRIPTION: cDNA encoding human fibroblast growth factor FGF-16.

L16 ANSWER 35 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 TI Fibroblast growth factor family polypeptide which stimulates
 proliferation and growth of hepatocytes is useful for treating hepatic
 disorders -
 AN AAZ55790 cDNA DGENE
 AB This sequence represents cDNA encoding rat fibroblast growth factor-16
 (FGF-16). FGF-16 has hepatocyte proliferation and growth activity, and
 increases hepatic production of triglycerides and serum proteins (e.g.,
 albumin). FGF-16 nucleic acids and/or proteins may be
 used for stimulating the proliferation and development of hepatocytes
 both in vitro and in vivo. The isolated nucleic acid molecules may be
 used directly in cell or gene therapy applications to treat or prevent
 liver disorders, including hepatic cirrhosis, fulminant liver failure,
 damage caused by acute viral hepatitis and toxic insults to the liver.
 ACCESSION NUMBER: AAZ55790 cDNA DGENE
 TITLE: Fibroblast growth factor family polypeptide which stimulates
 proliferation and growth of hepatocytes is useful for
 treating hepatic disorders -
 INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
 PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
 PATENT INFO: US 5998170 A 19991207 33p
 APPLICATION INFO: US 1997-943915 19971003
 PRIORITY INFO: US 1997-943915 19971003
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 OTHER SOURCE: 2000-085497 [07]
 CROSS REFERENCES: P-PSDB: AAY58428
 DESCRIPTION: cDNA encoding rat fibroblast growth factor FGF-16.

=> d his

(FILE 'HOME' ENTERED AT 12:38:37 ON 16 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS,
 BIOSIS' ENTERED AT 12:39:04 ON 16 JAN 2004

L1 13014 S RANTES
 L2 2849 S ALBUMIN FUSION PROTEIN
 L3 8 S L1 AND L2
 L4 1364 S FGF-8
 L5 509 S L4 AND ALBUMIN
 L6 491 S L5 AND FUSION
 L7 207 S L6 AND L1
 L8 0 S L7 AND STABILIZER
 L9 6424 S FUSION PARTNER
 L10 2467 S L9 AND ALBUMIN
 L11 176 S L9 AND BMP
 L12 141 S L11 AND L10
 L13 101 S L12 AND L1
 L14 2849 S ALBUMIN () FUSION PROTEIN
 L15 0 S ALBUMIN () BMP
 L16 35 S ALBUMIN () FGF

Hit List

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Search Results - Record(s) 1 through 1 of 1 returned.

☐ 1. Document ID: US 4563489 A

L2: Entry 1 of 1

File: USPT

Jan 7, 1986

US-PAT-NO: 4563489

DOCUMENT-IDENTIFIER: US 4563489 A

TITLE: Biodegradable organic polymer delivery system for bone morphogenetic protein

DATE-ISSUED: January 7, 1986

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Urist; Marshall R.	Pacific Palisades	CA		

US-CL-CURRENT: 514/21; 424/426, 523/115, 524/17, 524/21, 604/891.1, 623/915

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KINC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Terms	Documents
albumin adj2 BMP	1

Display Format:

CIT

Change Format

[Previous Page](#) [Next Page](#) [Go to Doc#](#)

Hit List

Search Results - Record(s) 1 through 2 of 2 returned.

☐ 1. Document ID: US 6025194 A

L8: Entry 1 of 2

File: USPT

Feb 15, 2000

US-PAT-NO: 6025194

DOCUMENT-IDENTIFIER: US 6025194 A

TITLE: Nucleic acid sequence of senescence associated gene

DATE-ISSUED: February 15, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Funk; Walter	Hayward	CA		

US-CL-CURRENT: 435/320.1; 435/325, 536/23.1, 536/23.5, 536/24.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequence	Attachments	Claims	KIMC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	----------	-------------	--------	------	----------

☐ 2. Document ID: US 5733541 A

L8: Entry 2 of 2

File: USPT

Mar 31, 1998

US-PAT-NO: 5733541

DOCUMENT-IDENTIFIER: US 5733541 A

**** See image for Certificate of Correction ****

TITLE: Hematopoietic cells: compositions and methods

DATE-ISSUED: March 31, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Taichman; Russell S.	Ann Arbor	MI		
Emerson; Stephen G.	Wayne	PA		

US-CL-CURRENT: 424/93.1; 424/93.7, 435/325, 435/347, 435/373, 435/375, 435/377

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequence	Attachments	Claims	KIMC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	----------	-------------	--------	------	----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
BMP-2 and L7	2

Display Format:

[Previous Page](#) [Next Page](#) [Go to Doc#](#)

Freeform Search

Database:

US Pre-Grant Publication Full-Text Database

US Patents Full-Text Database

US OCR Full-Text Database

EPO Abstracts Database

JPO Abstracts Database

Derwent World Patents Index

IBM Technical Disclosure Bulletins

Term:

albumin and fusion protein

Display:

10

Documents in

Display Format:

CIT

Starting with Number

1

Generate:

☐ Hit List

☒ Hit Count

☐ Side by Side

☐ Image

Search

Clear

Interrupt

Search History

DATE: Friday, January 16, 2004 [Printable Copy](#) [Create Case](#)

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side		result set	
<i>DB=USPT; PLUR=YES; OP=OR</i>			
<u>L10</u>	19 adj BMP	980	<u>L10</u>
<u>L9</u>	albumin fusion protein	198014	<u>L9</u>
<u>L8</u>	BMP-2 and L7	2	<u>L8</u>
<u>L7</u>	L6 and IL-6	284	<u>L7</u>
<u>L6</u>	L5 and Rantes	838	<u>L6</u>
<u>L5</u>	human chemokine and albumin	314787	<u>L5</u>
<u>L4</u>	albumin adj2 CXC3	0	<u>L4</u>
<u>L3</u>	albumin fused to BMP	159316	<u>L3</u>
<u>L2</u>	albumin adj2 BMP	1	<u>L2</u>
<u>L1</u>	albumin and fusion protein	144237	<u>L1</u>

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	CA/Caplus records now contain indexing from 1907 to the present
NEWS	4	DEC 08	INPADOC: Legal Status data reloaded
NEWS	5	SEP 29	DISSABS now available on STN
NEWS	6	OCT 10	PCTFULL: Two new display fields added
NEWS	7	OCT 21	BIOSIS file reloaded and enhanced
NEWS	8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS	9	NOV 24	MSDS-CCOHS file reloaded
NEWS	10	DEC 08	CABA reloaded with left truncation
NEWS	11	DEC 08	IMS file names changed
NEWS	12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS	13	DEC 09	STN Entry Date available for display in REGISTRY and CA/Caplus
NEWS	14	DEC 17	DGENE: Two new display fields added
NEWS	15	DEC 18	BIOTECHNO no longer updated
NEWS	16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS	17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS	18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS	19	DEC 22	ABI-INFORM now available on STN
NEWS EXPRESS			DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:22:40 ON 16 JAN 2004

=> file medline, uspatful, biosis, fsta, wpids, japio, jicst, embase, dgene, biobusiness

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 12:23:20 ON 16 JAN 2004

FILE 'USPATFULL' ENTERED AT 12:23:20 ON 16 JAN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'FSTA' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'WPIDS' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'JAPIO' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 Japanese Patent Office (JPO)- JAPIO

FILE 'JICST-EPLUS' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'EMBASE' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'DGENE' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'BIOBUSINESS' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 Biological Abstracts, Inc. (BIOSIS)

=> s albumin fusion protein
L1 2849 ALBUMIN FUSION PROTEIN

=> s BMP-1 and albumin
9 FILES SEARCHED...
L2 193 BMP-1 AND ALBUMIN

=> s l2 and l1
L3 0 L2 AND L1

=> d l2 ti abs ibib 1-10

L2 ANSWER 1 OF 193 USPATFULL on STN
TI Novel proteins and nucleic acids encoding same
AB Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

ACCESSION NUMBER: 2004:13595 USPATFULL
TITLE: Novel proteins and nucleic acids encoding same
INVENTOR(S): Zerhusen, Bryan D., Branford, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Spytek, Kimberly, New Haven, CT, UNITED STATES
Spaderna, Steven, Berlin, CT, UNITED STATES
Gangolli, Esha A., Branford, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES

Burgess, Catherine E., Wethersfield, CT, UNITED STATES
 Majumder, Kumud, Stamford, CT, UNITED STATES
 Shimkets, Richard, West Haven, CT, UNITED STATES
 Mishra, Vishnu, Branford, CT, UNITED STATES
 Vernet, Corine, North Branford, CT, UNITED STATES
 Szekeres, Edward S., Branford, CT, UNITED STATES
 Grosse, William M., Branford, CT, UNITED STATES
 Alsobrook, John P., II, Madison, CT, UNITED STATES
 Liu, Xiaohong, Branford, CT, UNITED STATES
 Gerlach, Valerie L., Branford, CT, UNITED STATES
 Ellerman, Karen, Branford, CT, UNITED STATES
 Smithson, Glennda, Branford, CT, UNITED STATES
 Peyman, John, New Haven, CT, UNITED STATES
 Stone, David, Guilford, CT, UNITED STATES
 MacDougall, John, Hamden, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010118	A1	20040115
APPLICATION INFO.:	US 2001-930512	A1	20010815 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-225692P	20000816 (60)
	US 2000-225693P	20000816 (60)
	US 2000-225837P	20000816 (60)
	US 2000-226236P	20000818 (60)
	US 2000-226353P	20000818 (60)
	US 2000-227085P	20000822 (60)
	US 2000-227395P	20000823 (60)
	US 2000-227492P	20000824 (60)
	US 2000-227600P	20000824 (60)
	US 2001-275952P	20010314 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C.,
 ONE FINANCIAL CENTER, BOSTON, MA, 02111
 NUMBER OF CLAIMS: 49
 EXEMPLARY CLAIM: 1
 LINE COUNT: 9358

L2 ANSWER 2 OF 193 USPATFULL on STN
 TI Methods of treatment of periodontal disease
 AB Purified BMP-2 and BMP-4 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.

ACCESSION NUMBER: 2004:13394 USPATFULL
 TITLE: Methods of treatment of periodontal disease
 INVENTOR(S): Wang, Elizabeth, Carlisle, MA, UNITED STATES
 Wozney, John M., Hudson, MA, UNITED STATES
 Rosen, Vicki A., Brookline, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009916	A1	20040115
APPLICATION INFO.:	US 2003-397214	A1	20030327 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-804625, filed on 9 Mar 2001, PENDING Continuation of Ser. No. US 1997-925779, filed on 9 Sep 1997, GRANTED, Pat. No. US 6245889		
	Continuation of Ser. No. US 1991-721847, filed on 14 Jun 1991, GRANTED, Pat. No. US 6150328		
	Continuation-in-part of Ser. No. US 1990-493272, filed on 14 Mar 1990, ABANDONED Continuation-in-part of Ser.		

No. US 1989-406217, filed on 12 Sep 1989, ABANDONED
Continuation-in-part of Ser. No. US 1989-378537, filed
on 11 Jul 1989, GRANTED, Pat. No. US 5166058

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow,, Garrett & Dunner,
L.L.P., 1300 I Street, N.W., Washington, DC, 20005-3315
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 1876

L2 ANSWER 3 OF 193 USPATFULL on STN
TI Chondrogenic and osteogenic inducing molecule
AB The present invention is directed to methods of using and compositions
comprising amelogenin peptides capable of inducing chondrogenesis and
osteogenesis when implanted in vivo, a chondrogenesis in cultures in
vitro. Compositions and methods of enhancing bone and cartilage growth
using these peptides are described.

ACCESSION NUMBER: 2004:9593 USPATFULL
TITLE: Chondrogenic and osteogenic inducing molecule
INVENTOR(S): Veis, Arthur, Skokie, IL, United States
Nebgen, Denise R., Houston, TX, United States
PATENT ASSIGNEE(S): Northwestern University, Evanston, IL, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6677306	B1	20040113
	WO 2000006734		20000210
APPLICATION INFO.:	US 2001-744128		20010516 (9)
	WO 1999-US17342		19990729

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-94489P	19980729 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Mertz, Prema	
LEGAL REPRESENTATIVE:	Marshall, Gerstein & Borun LLP	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	16 Drawing Figure(s); 16 Drawing Page(s)	
LINE COUNT:	1877	

L2 ANSWER 4 OF 193 USPATFULL on STN
TI Treatment of inflammatory bowel disease using growth factors
AB The present invention is based upon methods of treating inflammatory
conditions in the intestinal tract of mammals using growth factor
related polypeptides. The invention includes methods of reducing the
mortality rate or delaying mortality in a subject suffering from an
inflammatory pathology. Methods of using fibroblast growth factor-CX
(FGF-CX) polynucleotides sequences and the FGF-CX polypeptides encoded
by such nucleic acid sequence, or variants, fragments and homologs
thereof, are claimed in the invention. Similarly, methods of using FCTR
polynucleotide sequences and the FCTR polypeptides encoded by such
nucleic acid sequences, or variants, fragments and homologs thereof,
alone or in combination, are also claimed in the invention. FCTR
collectively refers to any of six variant FCTR sequences, variously
designated FCTR1, FCTR2, FCTR3, FCTR4, FCTR5 and FCTR6.

ACCESSION NUMBER: 2004:7775 USPATFULL
TITLE: Treatment of inflammatory bowel disease using growth

INVENTOR(S) : factors
 Boldog, Ferenc L., North Haven, CT, UNITED STATES
 Burgess, Catherine E., Wethersfield, CT, UNITED STATES
 Fernandes, Elma R., Branford, CT, UNITED STATES
 Jeffers, Michael E., Branford, CT, UNITED STATES
 LaRochelle, William J., Madison, CT, UNITED STATES
 Lichenstein, Henri S., Guilford, CT, UNITED STATES
 Peterson, Jeffrey, Brookfield, CT, UNITED STATES
 Prayaga, Sudhirdas K., O'Fallon, MO, UNITED STATES
 Rittman, Beth, Colchester, CT, UNITED STATES
 Shimkets, Juliette B., Guilford, CT, UNITED STATES
 Shimkets, Richard A., Guilford, CT, UNITED STATES
 Yang, Meijia, East Lyme, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004006015	A1	20040108
APPLICATION INFO.:	US 2002-321962	A1	20021216 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-11364, filed on 16 Nov 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-386545P	20020606 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C., ONE FINANCIAL CENTER, BOSTON, MA, 02111	
NUMBER OF CLAIMS:	67	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	73 Drawing Page(s)	
LINE COUNT:	7115	

L2 ANSWER 5 OF 193 USPATFULL on STN
 TI Proteins and nucleic acids encoding same
 AB Disclosed are polypeptides and nucleic acids encoding same. Also disclosed are vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using same.

ACCESSION NUMBER: 2004:7342 USPATFULL
 TITLE: Proteins and nucleic acids encoding same
 INVENTOR(S) : Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES
 Li, Li, Branford, CT, UNITED STATES
 Patturajan, Meera, Branford, CT, UNITED STATES
 Shimkets, Richard A., Guilford, CT, UNITED STATES
 Casman, Stacie J., North Haven, CT, UNITED STATES
 Malyankar, Uriel M., Branford, CT, UNITED STATES
 Tchernev, Velizar T., Branford, CT, UNITED STATES
 Vernet, Corine A., North Branford, CT, UNITED STATES
 Spytek, Kimberly A., New Haven, CT, UNITED STATES
 Shenoy, Suresh G., Branford, CT, UNITED STATES
 Alsobrook, John P., II, Madison, CT, UNITED STATES
 Edinger, Schlomit, New Haven, CT, UNITED STATES
 Peyman, John A., New Haven, CT, UNITED STATES
 Stone, David J., Guilford, CT, UNITED STATES
 Ellerman, Karen, Branford, CT, UNITED STATES
 Gangolli, Esha A., Madison, CT, UNITED STATES
 Boldog, Ferenc L., North Haven, CT, UNITED STATES
 Colman, Steven D., Guilford, CT, UNITED STATES
 Eisen, Andrew, Rockville, MD, UNITED STATES
 Liu, Xiaohong, Lexington, MA, UNITED STATES
 Padigaru, Muralidhara, Branford, CT, UNITED STATES
 Spaderna, Steven K., Berlin, CT, UNITED STATES

Zerhusen, Bryan D., Branford, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005576	A1	20040108
APPLICATION INFO.:	US 2002-231913	A1	20020830 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-10680, filed on 6 Dec 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-251660P	20001206 (60)
	US 2001-260326P	20010108 (60)
	US 2001-318712P	20010912 (60)
	US 2000-255029P	20001212 (60)
	US 2001-263800P	20010124 (60)
	US 2001-286183P	20010424 (60)
	US 2001-269942P	20010220 (60)
	US 2001-313627P	20010820 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C., ONE FINANCIAL CENTER, BOSTON, MA, 02111	
NUMBER OF CLAIMS:	41	
EXEMPLARY CLAIM:	1	
LINE COUNT:	17887	

L2 ANSWER 6 OF 193 USPATFULL on STN
TI Growth factor homolog ZVEGF4
AB Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 70% identical to residues 52-179 of SEQ ID NO:2 or residues 258-370 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents.

ACCESSION NUMBER: 2004:2119 USPATFULL
TITLE: Growth factor homolog ZVEGF4
INVENTOR(S): Gilbert, Teresa, Seattle, WA, UNITED STATES
Hart, Charles E., Woodinville, WA, UNITED STATES
Sheppard, Paul O., Granite Falls, WA, UNITED STATES
Gilbertson, Debra G., Seattle, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002140	A1	20040101
APPLICATION INFO.:	US 2001-876813	A1	20010606 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-564595, filed on 3 May 2000, GRANTED, Pat. No. US 6495668		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-132250P	19990503 (60)
	US 1999-164463P	19991110 (60)
	US 2000-180169P	20000204 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Gary E. Parker, ZymoGenetics, Inc., Patent Department, 1201 Eastlake Avenue East, Seattle, WA, 98102	
NUMBER OF CLAIMS:	54	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	

LINE COUNT: 5092

L2 ANSWER 7 OF 193 USPATFULL on STN

TI Bone morphogenic protein polynucleotides, polypeptides, and antibodies
AB The present invention relates to novel human BMP polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human BMP polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human BMP polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:318756 USPATFULL

TITLE: Bone morphogenic protein polynucleotides, polypeptides, and antibodies

INVENTOR(S): Young, Paul E., Gaithersburg, MD, UNITED STATES
Ruben, Steven M., Brookeville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003224501	A1	20031204
APPLICATION INFO.:	US 2003-366345	A1	20030214 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-345236, filed on 16 Jan 2003, PENDING Continuation-in-part of Ser. No. US 2001-809269, filed on 16 Mar 2001, ABANDONED Continuation-in-part of Ser. No. WO 2001-US9229, filed on 23 Mar 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-356749P	20020215 (60)
	US 2000-190067P	20000317 (60)
	US 2002-348621P	20020117 (60)
	US 2002-349356P	20020122 (60)
	US 2002-351520P	20020128 (60)
	US 2002-354265P	20020206 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 42

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 23 Drawing Page(s)

LINE COUNT: 16963

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 8 OF 193 USPATFULL on STN

TI Sulfonamide compounds

AB This invention relates to certain sulfonamide derivatives that are inhibitors of procollagen C-proteinase, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:306969 USPATFULL

TITLE: Sulfonamide compounds

INVENTOR(S): Billledeau, Roland Joseph, Santa Clara, CA, UNITED STATES
Broka, Chris Allen, Foster City, CA, UNITED STATES
Campbell, Jeffrey Allen, Middletown, CT, UNITED STATES
Chen, Jian Jeffrey, Santa Clara, CA, UNITED STATES
Dankwardt, Sharon Marie, Foster City, CA, UNITED STATES
Delaet, Nancy, San Diego, CA, UNITED STATES

Robinson, Leslie Ann, San Diego, CA, UNITED STATES
Walker, Keith Adrian Murray, Los Altos, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003216405	A1	20031120
APPLICATION INFO.:	US 2002-267727	A1	20021009 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-469660, filed on 22 Dec 1999, GRANTED, Pat. No. US 6492394		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-113311P	19981222 (60)
	US 1999-147053P	19990803 (60)
	US 1999-164138P	19991108 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ROCHE PALO ALTO LLC, 3431 HILLVIEW AVENUE, PATENT DEPT., M/S A2-250, PALO ALTO, CA, 94304	
NUMBER OF CLAIMS:	52	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3904	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 9 OF 193 USPATFULL on STN
TI Composition and method for modulating vasculogenesis or angiogenesis
AB A method for modulating vasculogenesis or angiogenesis using the core domain protein of PDGF-C, a new member of the PDGF/VEGF family of growth factors, or a homodimer or a heterodimer comprising the core domain. Also disclosed are pharmaceutical compositions comprising the core protein, nucleotide sequences encoding the protein, and uses thereof in medical and diagnostic applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:300768 USPATFULL
TITLE: Composition and method for modulating vasculogenesis or angiogenesis
INVENTOR(S): Li, Xuri, Stockholm, SWEDEN
Eriksson, Ulf, Stockholm, SWEDEN
Carmeliet, Peter, Leuven, BELGIUM
Collen, Desire, Leuven, BELGIUM
PATENT ASSIGNEE(S): Ludwig Institute for Cancer Research (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003211994	A1	20031113
APPLICATION INFO.:	US 2002-303997	A1	20021126 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-410349, filed on 30 Sep 1999, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-102461P	19980930 (60)
	US 1998-108109P	19981112 (60)
	US 1998-110749P	19981203 (60)
	US 1998-113002P	19981218 (60)
	US 1999-135426P	19990521 (60)
	US 1999-144022P	19990715 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	CROWELL & MORING LLP, INTELLECTUAL PROPERTY GROUP, P.O. BOX 14300, WASHINGTON, DC, 20044-4300	

NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 42 Drawing Page(s)
LINE COUNT: 2790
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 10 OF 193 USPATFULL on STN

TI OSTEOPROTEGERIN

AB The present invention discloses a novel secreted polypeptide, termed osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind OPG, and pharmaceutical compositions. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:294810 USPATFULL

TITLE: OSTEOPROTEGERIN

INVENTOR(S): BOYLE, WILLIAM J., MOORPARK, CA, UNITED STATES
LACEY, DAVID L., THOUSAND OAKS, CA, UNITED STATES
CALZONE, FRANK J., WEST LAKE VILLAGE, CA, UNITED STATES
CHANG, MING-SHI, NEWBURY PARK, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003207827	A1	20031106
APPLICATION INFO.:	US 1999-405032	A1	19990924 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-132985, filed on 12 Aug 1998, PENDING Continuation of Ser. No. US 1996-771777, filed on 20 Dec 1996, ABANDONED Continuation-in-part of Ser. No. US 1996-706945, filed on 3 Sep 1996, GRANTED, Pat. No. US 6369027 Continuation-in-part of Ser. No. US 1995-577788, filed on 22 Dec 1995, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	AMGEN INCORPORATED, MAIL STOP 27-4-A, ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320-1799		
NUMBER OF CLAIMS:	60		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	46 Drawing Page(s)		
LINE COUNT:	5457		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:22:40 ON 16 JAN 2004)

FILE 'MEDLINE, USPATFULL, BIOSIS, FSTA, WPIDS, JAPIO, JICST-EPLUS, EMBASE, DGENE, BIOBUSINESS' ENTERED AT 12:23:20 ON 16 JAN 2004

L1 2849 S ALBUMIN FUSION PROTEIN

L2 193 S BMP-1 AND ALBUMIN

L3 0 S L2 AND L1

=> s l1 and FGF-16

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	CA/CAPLUS records now contain indexing from 1907 to the present
NEWS	4	DEC 08	INPADOC: Legal Status data reloaded
NEWS	5	SEP 29	DISSABS now available on STN
NEWS	6	OCT 10	PCTFULL: Two new display fields added
NEWS	7	OCT 21	BIOSIS file reloaded and enhanced
NEWS	8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS	9	NOV 24	MSDS-CCOHS file reloaded
NEWS	10	DEC 08	CABA reloaded with left truncation
NEWS	11	DEC 08	IMS file names changed
NEWS	12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS	13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAPLUS
NEWS	14	DEC 17	DGENE: Two new display fields added
NEWS	15	DEC 18	BIOTECHNO no longer updated
NEWS	16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS	17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS	18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS	19	DEC 22	ABI-INFORM now available on STN
NEWS EXPRESS			DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:38:37 ON 16 JAN 2004

=> file medline, uspatful, dgene, embase, wpids, fsta, jicst, biosis		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 12:39:04 ON 16 JAN 2004

FILE 'USPATFULL' ENTERED AT 12:39:04 ON 16 JAN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'JICST-EPLUS' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'BIOSIS' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

=> s Rantes
L1 13014 RANTES

=> s albumin fusion protein
L2 2849 ALBUMIN FUSION PROTEIN

=> s l1 and l2
L3 8 L1 AND L2

=> d l3 ti abs ibib tot

L3 ANSWER 1 OF 8 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

ACCESSION NUMBER: 2004:13611 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)

US 2000-229358P 20000412 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 25066

L3 ANSWER 2 OF 8 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:312278 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219875	A1	20031127
APPLICATION INFO.:	US 2001-833118	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 15415

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 3 OF 8 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:282700 USPATFULL

TITLE: Albumin fusion proteins
INVENTOR(S): Ballance, David J., Berwyn, PA, UNITED STATES
Sleep, Darrell, West Bridgford, UNITED KINGDOM
Prior, Christopher P., Rosemont, PA, UNITED STATES
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199043	A1	20031023
APPLICATION INFO.:	US 2001-832501	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 14339
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 8 USPATFULL on STN

TI Neutrokin- α and neutrokin- α splice variant
AB The present invention relates to nucleic acid molecules encoding Neutrokin- α and/or Neutrokin- α SV polypeptides, including soluble forms of the extracellular domain. Neutrokin- α and/or Neutrokin- α SV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokin- α and/or Neutrokin- α SV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:250423 USPATFULL
TITLE: Neutrokin- α and neutrokin- α splice variant
INVENTOR(S): Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Rosen, Craig A., Laytonville, MD, UNITED STATES
Ullrich, Stephen, Rockville, MD, UNITED STATES
Laird, Michael, Germantown, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003175208	A1	20030918
APPLICATION INFO.:	US 2002-270487	A1	20021016 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-929493, filed on 15 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2000-588947, filed on 8 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-589285, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589286, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589287, filed		

on 8 Jun 2000, GRANTED, Pat. No. US 6403770
 Continuation-in-part of Ser. No. US 2000-589288, filed
 on 8 Jun 2000, PENDING Continuation-in-part of Ser. No.
 US 2000-507968, filed on 22 Feb 2000, PENDING
 Continuation-in-part of Ser. No. US 1999-255794, filed
 on 23 Feb 1999, PENDING Continuation-in-part of Ser.
 No. US 2000-588947, filed on 8 Jun 2000, ABANDONED
 Continuation-in-part of Ser. No. US 2000-589285, filed
 on 8 Jun 2000, PENDING Continuation-in-part of Ser. No.
 US 2000-589286, filed on 8 Jun 2000, PENDING
 Continuation-in-part of Ser. No. US 2000-589288, filed
 on 8 Jun 2000, PENDING Continuation-in-part of Ser. No.
 US 2000-507968, filed on 22 Feb 2000, PENDING
 Continuation-in-part of Ser. No. US 1999-255794, filed
 on 23 Feb 1999, PENDING Continuation-in-part of Ser.
 No. US 1998-5874, filed on 12 Jan 1998, PENDING
 Continuation-in-part of Ser. No. WO 1996-US17957, filed
 on 25 Oct 1996, PENDING Continuation-in-part of Ser.
 No. US 1999-255794, filed on 23 Feb 1999, PENDING
 Continuation-in-part of Ser. No. US 1998-5874, filed on
 12 Jan 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-329508P	20011017 (60)
	US 2001-329747P	20011018 (60)
	US 2001-330835P	20011031 (60)
	US 2001-331478P	20011116 (60)
	US 2001-336726P	20011207 (60)
	US 2002-368548P	20020401 (60)
	US 2000-225628P	20000815 (60)
	US 2000-227008P	20000823 (60)
	US 2000-234338P	20000922 (60)
	US 2000-240806P	20001017 (60)
	US 2000-250020P	20001130 (60)
	US 2001-276248P	20010316 (60)
	US 2001-293499P	20010525 (60)
	US 2001-296122P	20010607 (60)
	US 2001-304809P	20010713 (60)
	US 1999-122388P	19990302 (60)
	US 1999-124097P	19990312 (60)
	US 1999-126599P	19990326 (60)
	US 1999-127598P	19990402 (60)
	US 1999-130412P	19990416 (60)
	US 1999-130696P	19990423 (60)
	US 1999-131278P	19990427 (60)
	US 1999-131673P	19990429 (60)
	US 1999-136784P	19990528 (60)
	US 1999-142659P	19990706 (60)
	US 1999-145824P	19990727 (60)
	US 1999-167239P	19991124 (60)
	US 1999-168624P	19991203 (60)
	US 1999-171108P	19991216 (60)
	US 1999-171626P	19991223 (60)
	US 2000-176015P	20000114 (60)
	US 1999-122388P	19990302 (60)
	US 1999-124097P	19990312 (60)
	US 1999-126599P	19990326 (60)
	US 1999-127598P	19990402 (60)
	US 1999-130412P	19990416 (60)
	US 1999-130696P	19990423 (60)
	US 1999-131278P	19990427 (60)
	US 1999-131673P	19990429 (60)
	US 1999-136784P	19990528 (60)

US 1999-142659P	19990706 (60)
US 1999-145824P	19990727 (60)
US 1999-167239P	19991124 (60)
US 1999-168624P	19991203 (60)
US 1999-171108P	19991216 (60)
US 1999-171626P	19991223 (60)
US 2000-176015P	20000114 (60)
US 1997-36100P	19970114 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
 ROCKVILLE, MD, 20850
 NUMBER OF CLAIMS: 44
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 27 Drawing Page(s)
 LINE COUNT: 18884
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 8 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:244853 USPATFULL
 TITLE: Albumin fusion proteins
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
 Prior, Christopher P., Rosemont, PA, UNITED STATES
 Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003171267	A1	20030911
APPLICATION INFO.:	US 2001-833117	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
 ROCKVILLE, MD, 20850
 NUMBER OF CLAIMS: 59
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 20 Drawing Page(s)
 LINE COUNT: 13208
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 8 USPATFULL on STN

TI Chemokine beta-1 fusion proteins

AB The present invention relates to novel chemokine polypeptides and encoding nucleic acids. More specifically, therapeutic compositions and methods are provided using isolated nucleic acid molecules encoding a

human chemokine beta-1 (Ck.beta.-1 or Ckb1) polypeptide (previously termed monocyte-colony inhibitory factor (M-CIF), MIP1-.gamma., and Hemofiltrate CC chemokine-1 (HCC-1)), and Ckb1 polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same. Also provided are methods of treating, preventing, ameliorating diseases using such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:206834 USPATFULL
TITLE: Chemokine beta-1 fusion proteins
INVENTOR(S): Bell, Adam, Germantown, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003143191	A1	20030731
APPLICATION INFO.:	US 2002-153604	A1	20020524 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-293212P	20010525 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	21 Drawing Page(s)	
LINE COUNT:	15446	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 8 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:181414 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003125247	A1	20030703
APPLICATION INFO.:	US 2001-833041	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	

NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 15235
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 8 USPATFULL on STN

TI Binding polypeptides and methods based thereon

AB Binding polypeptides that specifically bind BLYS protein or BLYS-like polypeptides can be used in methods of the invention for detecting, diagnosing, or prognosing a disease or disorder associated with aberrant BLYS or BLYS receptor expression or inappropriate function of BLYS or BLYS receptor, comprising BLYS binding polypeptides or fragments or variants thereof, that specifically bind to BLYS. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant BLYS or BLYS receptor expression or inappropriate BLYS function or BLYS receptor function, comprising administering to an animal, preferably a human, an effective amount of one or more BLYS binding polypeptides or fragments or variants thereof, that specifically bind to BLYS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:133480 USPATFULL
TITLE: Binding polypeptides and methods based thereon
INVENTOR(S): Beltzer, James P., Carlisle, MA, UNITED STATES
Potter, M. Daniel, UNITED STATES
Potter, Marilou, Acton, MA, UNITED STATES LR
Fleming, Tony J., Waltham, MA, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003091565	A1	20030515
APPLICATION INFO.:	US 2001-932613	A1	20010817 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-226700P	20000818 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Leon R. Yankwich, Esq., Yankwich & Associates, 130 Bishop Allen Drive, Cambridge, MA, 02139	
NUMBER OF CLAIMS:	71	
EXEMPLARY CLAIM:	1	
LINE COUNT:	11834	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:38:37 ON 16 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS, BIOSIS' ENTERED AT 12:39:04 ON 16 JAN 2004

L1 13014 S RANTES
L2 2849 S ALBUMIN FUSION PROTEIN
L3 8 S L1 AND L2

=> s FGF-8

L4 1364 FGF-8

=> s l4 and albumin

L5 509 L4 AND ALBUMIN

=> s 15 and fusion
L6 491 L5 AND FUSION

=> d 16 and 11
L1 IS NOT VALID HERE
For an explanation, enter "HELP DISPLAY".

=> s 16 and 11
L7 207 L6 AND L1

=> s 17 and stabilizer
L8 0 L7 AND STABILIZER

=> d 17 ti abs ibib 1-10

L7 ANSWER 1 OF 207 USPATFULL on STN

TI **Albumin fusion** proteins

AB The present invention encompasses **albumin fusion** proteins. Nucleic acid molecules encoding the **albumin fusion** proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin fusion** proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin fusion** proteins of the invention.

ACCESSION NUMBER: 2004:13611 USPATFULL
TITLE: **Albumin fusion** proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 25066

L7 ANSWER 2 OF 207 USPATFULL on STN

TI 53 human secreted proteins

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

ACCESSION NUMBER: 2004:13609 USPATFULL

TITLE: 53 human secreted proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
Duan, Roxanne D., Bethesda, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Florence, Kimberly A., Rockville, MD, UNITED STATES
Greene, John M., Gaithersburg, MD, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Ferrie, Ann M., Painted Post, NY, UNITED STATES
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Florence, Charles, Rockville, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Olsen, Henrik, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010132	A1	20040115
APPLICATION INFO.:	US 2001-984429	A1	20011030 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-288143, filed on 8 Apr 1999, GRANTED, Pat. No. US 6433139 Continuation-in-part of Ser. No. WO 1998-US21142, filed on 8 Oct 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-244591P	20001101 (60)
	US 1997-61463P	19971009 (60)
	US 1997-61529P	19971009 (60)
	US 1997-71498P	19971009 (60)
	US 1997-61527P	19971009 (60)
	US 1997-61536P	19971009 (60)
	US 1997-61532P	19971009 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 27480

L7 ANSWER 3 OF 207 USPATFULL on STN

TI 7 Human ovarian and ovarian cancer associated proteins
AB This invention relates to newly identified ovarian or ovarian cancer
related polynucleotides and the polypeptides encoded by these
polynucleotides herein collectively known as "ovarian cancer antigens",
and the use of such ovarian antigens for detecting disorders of the
reproductive system, particularly the presence of ovarian cancer and
ovarian cancer metastases. This invention relates to ovarian cancer
antigens as well as vectors, host cells, antibodies directed to ovarian
cancer antigens and the recombinant methods and synthetic methods for
producing the same. Also provided are diagnostic methods for detecting,
treating, preventing and/or prognosing disorders related to the ovary,
including ovarian cancer, and therapeutic methods for treating such
disorders. The invention further relates to screening methods for
identifying agonists and antagonists of ovarian cancer antigens of the
invention. The present invention further relates to inhibiting the
production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:13598 USPATFULL
TITLE: 7 Human ovarian and ovarian cancer associated proteins
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010121	A1	20040115
APPLICATION INFO.:	US 2003-333900	A1	20030124 (10)
	WO 2001-US8585		20010316
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
LINE COUNT:	16023		

L7 ANSWER 4 OF 207 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel polynucleotides associated with the plasma membrane, the polypeptides encoded by these polynucleotides herein collectively referred to as "plasma membrane associated antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such plasma membrane associated polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders related to these novel polypeptides. More specifically, isolated nucleic acid molecules are provided encoding novel plasma membrane associated polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing these plasma membrane associated polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the novel polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:12971 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009491	A1	20040115
APPLICATION INFO.:	US 2002-264237	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US16450, filed on 18 May 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	18144	

L7 ANSWER 5 OF 207 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel musculoskeletal system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "musculoskeletal system antigens," and the

use of such musculoskeletal system antigens for detecting disorders of the musculoskeletal system, particularly the presence of cancer and cancer metastases. More specifically, isolated musculoskeletal system associated nucleic acid molecules are provided encoding novel musculoskeletal system associated polypeptides. Novel musculoskeletal system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human musculoskeletal system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the musculoskeletal system, including cancer of musculoskeletal tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:12968 USPATFULL
 TITLE: Nucleic acids, proteins, and antibodies
 INVENTOR(S) : Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Ruben, Steven M., Olney, MD, UNITED STATES
 Barash, Steven C., Rockville, MD, UNITED STATES
 PATENT ASSIGNEE(S) : Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009488	A1	20040115
APPLICATION INFO.:	US 2002-242515	A1	20020913 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764877, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)

US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)

US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 32038

L7 ANSWER 6 OF 207 USPATFULL on STN

TI Apoptosis inducing molecule II and methods of use

AB The present invention relates to a novel member of the TNF-Ligand superfamily. More specifically, isolated nucleic acid molecules are provided encoding a human Apoptosis Inducing Molecule II (AIM II). AIM II polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of AIM II activity. Also provided are therapeutic methods for treating lymphadenopathy, aberrant bone development, autoimmune and other immune system diseases, graft versus host disease, rheumatoid arthritis, osteoarthritis and to inhibit neoplasia, such as tumor cell growth.

ACCESSION NUMBER: 2004:12629 USPATFULL
 TITLE: Apoptosis inducing molecule II and methods of use
 INVENTOR(S): Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
 Yu, Guo-Liang, Berkeley, CA, UNITED STATES
 Ruben, Steven M., Brookeville, MD, UNITED STATES
 Zhai, Yifan, Rockville, MD, UNITED STATES
 Ullrich, Stephen, Rockville, MD, UNITED STATES
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009147	A1	20040115
APPLICATION INFO.:	US 2003-375680	A1	20030228 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-523323, filed on 10 Mar 2000, GRANTED, Pat. No. US 6635743		
	Continuation-in-part of Ser. No. US 1999-252656, filed on 19 Feb 1999, GRANTED, Pat. No. US 6495520		
	Continuation-in-part of Ser. No. US 1998-27287, filed on 20 Feb 1998, GRANTED, Pat. No. US 6479254		
	Continuation-in-part of Ser. No. US 1998-3886, filed on 7 Jan 1998, ABANDONED		
	Continuation-in-part of Ser. No. US 1997-822953, filed on 21 Mar 1997, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-360234P	20020301 (60)
	US 1999-168380P	19991202 (60)
	US 1999-148326P	19990811 (60)
	US 1999-142657P	19990706 (60)
	US 1999-137457P	19990604 (60)
	US 1999-124041P	19990311 (60)
	US 1998-75409P	19980220 (60)
	US 1996-13923P	19960322 (60)
	US 1996-30157P	19961031 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W., WASHINGTON, DC, 20005
 NUMBER OF CLAIMS: 45
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 48 Drawing Page(s)
 LINE COUNT: 13322

L7 ANSWER 7 OF 207 USPATFULL on STN
 TI Nucleic acids, proteins, and antibodies
 AB The present invention relates to novel ovarian related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "ovarian antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such ovarian polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the reproductive system, particularly disorders of the ovaries and/or breast, including, but not limited to, the presence of ovarian and/or breast cancer and ovarian and/or breast cancer metastases. More specifically, isolated ovarian nucleic acid molecules are provided encoding novel ovarian polypeptides. Novel ovarian polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human ovarian polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the ovaries and/or breast, including ovarian and/or breast cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of

polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:7345 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005579	A1	20040108
APPLICATION INFO.:	US 2002-264049	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US18569, filed on 7 Jun 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-209467P	20000607 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	18130	

L7 ANSWER 8 OF 207 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:7343 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005577	A1	20040108
APPLICATION INFO.:	US 2002-242747	A1	20020913 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764881, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)

US 2000-225758P	20000814 (60)
US 2000-220963P	20000726 (60)
US 2000-217496P	20000711 (60)
US 2000-225447P	20000814 (60)
US 2000-218290P	20000714 (60)
US 2000-225757P	20000814 (60)
US 2000-226868P	20000822 (60)
US 2000-216647P	20000707 (60)
US 2000-225267P	20000814 (60)
US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)

US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)

US 2000-190076P 20000317 (60)
US 2000-209467P 20000607 (60)
US 2000-205515P 20000519 (60)
US 2001-259678P 20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 27694

L7 ANSWER 9 OF 207 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel cardiovascular system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cardiovascular system antigens," and the use of such cardiovascular system antigens for detecting disorders of the cardiovascular system, particularly the presence of cancer of cardiovascular system tissues and cancer metastases. More specifically, isolated cardiovascular system associated nucleic acid molecules are provided encoding novel cardiovascular system associated polypeptides. Novel cardiovascular system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human cardiovascular system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the cardiovascular system, including cancer of cardiovascular system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:7341 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005575	A1	20040108
APPLICATION INFO.:	US 2002-227577	A1	20020826 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-91504, filed on 7 Mar 2002, PENDING Continuation of Ser. No. US 2001-764869, filed on 17 Jan 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)

US 2000-226868P	20000822 (60)
US 2000-216647P	20000707 (60)
US 2000-225267P	20000814 (60)
US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)

US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE:
FILE SEGMENT:

Utility
APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 28742

L7 ANSWER 10 OF 207 USPATFULL on STN

TI 50 human secreted proteins

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:2568 USPATFULL

TITLE: 50 human secreted proteins

INVENTOR(S): Moore, Paul A., Germantown, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
LaFleur, David W., Washington, DC, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES

PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002591	A1	20040101
APPLICATION INFO.:	US 2002-47021	A1	20020117 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-722329, filed on 28 Nov 2000, PENDING Continuation of Ser. No. US 1999-262109, filed on 4 Mar 1999, ABANDONED Continuation-in-part of Ser. No. WO 1998-US18360, filed on 3 Sep 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-262066P	20010118 (60)
	US 1997-57626P	19970905 (60)
	US 1997-57663P	19970905 (60)
	US 1997-57669P	19970905 (60)
	US 1997-58666P	19970912 (60)
	US 1997-58667P	19970912 (60)
	US 1997-58973P	19970912 (60)
	US 1997-58974P	19970912 (60)
	US 1998-90112P	19980622 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 23

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 2 Drawing Page(s)

LINE COUNT: 33379

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:38:37 ON 16 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS, BIOSIS' ENTERED AT 12:39:04 ON 16 JAN 2004

L1 13014 S RANTES
L2 2849 S ALBUMIN FUSION PROTEIN
L3 8 S L1 AND L2
L4 1364 S FGF-8
L5 509 S L4 AND ALBUMIN
L6 491 S L5 AND FUSION
L7 207 S L6 AND L1
L8 0 S L7 AND STABILIZER

=> s fusion partner

L9 6424 FUSION PARTNER

=> s l9 and albumin

L10 2467 L9 AND ALBUMIN

=> s l9 and BMP

L11 176 L9 AND BMP

=> s l11 and l10

L12 141 L11 AND L10

=> s l12 and l1

L13 101 L12 AND L1

=> d l13 ti abs ibib 1-10

L13 ANSWER 1 OF 101 USPATFULL on STN

TI **Albumin** fusion proteins

AB The present invention encompasses **albumin** fusion proteins. Nucleic acid molecules encoding the **albumin** fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin** fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin** fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin** fusion proteins of the invention.

ACCESSION NUMBER: 2004:13611 USPATFULL

TITLE: **Albumin** fusion proteins

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 29

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 25066

L13 ANSWER 2 OF 101 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel polynucleotides associated with the plasma membrane, the polypeptides encoded by these polynucleotides herein collectively referred to as "plasma membrane associated antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such plasma membrane associated polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders related to these novel polypeptides. More specifically, isolated nucleic acid molecules are provided encoding novel plasma membrane associated polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing these plasma membrane associated polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the novel polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:12971 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009491	A1	20040115
APPLICATION INFO.:	US 2002-264237	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US16450, filed on 18 May 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	18144	

L13 ANSWER 3 OF 101 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel musculoskeletal system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "musculoskeletal system antigens," and the use of such musculoskeletal system antigens for detecting disorders of the musculoskeletal system, particularly the presence of cancer and cancer metastases. More specifically, isolated musculoskeletal system associated nucleic acid molecules are provided encoding novel musculoskeletal system associated polypeptides. Novel musculoskeletal system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human musculoskeletal system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating,

preventing and/or prognosing disorders related to the musculoskeletal system, including cancer of musculoskeletal tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:12968 USPATFULL
 TITLE: Nucleic acids, proteins, and antibodies
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Ruben, Steven M., Olney, MD, UNITED STATES
 Barash, Steven C., Rockville, MD, UNITED STATES
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009488	A1	20040115
APPLICATION INFO.:	US 2002-242515	A1	20020913 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764877, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-229345P	20000901 (60)
	US 2000-229287P	20000901 (60)
	US 2000-229513P	20000905 (60)

US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)

US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 32038

L13 ANSWER 4 OF 101 USPTATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel ovarian related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "ovarian antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such ovarian polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the reproductive system, particularly disorders of the ovaries and/or breast, including, but not limited to, the presence of ovarian and/or breast cancer and ovarian and/or breast cancer metastases. More specifically, isolated ovarian nucleic acid molecules are provided encoding novel ovarian polypeptides. Novel ovarian polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human ovarian polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the ovaries and/or breast, including ovarian and/or breast cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the

production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:7345 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005579	A1	20040108
APPLICATION INFO.:	US 2002-264049	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US18569, filed on 7 Jun 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-209467P	20000607 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	18130	

L13 ANSWER 5 OF 101 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:7343 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005577	A1	20040108
APPLICATION INFO.:	US 2002-242747	A1	20020913 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764881, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)

US 2000-217496P	20000711 (60)
US 2000-225447P	20000814 (60)
US 2000-218290P	20000714 (60)
US 2000-225757P	20000814 (60)
US 2000-226868P	20000822 (60)
US 2000-216647P	20000707 (60)
US 2000-225267P	20000814 (60)
US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)

US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)

US 2000-205515P 20000519 (60)
 US 2001-259678P 20010105 (60)
 DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
 ROCKVILLE, MD, 20850
 NUMBER OF CLAIMS: 24
 EXEMPLARY CLAIM: 1
 LINE COUNT: 27694

L13 ANSWER 6 OF 101 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel cardiovascular system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cardiovascular system antigens," and the use of such cardiovascular system antigens for detecting disorders of the cardiovascular system, particularly the presence of cancer of cardiovascular system tissues and cancer metastases. More specifically, isolated cardiovascular system associated nucleic acid molecules are provided encoding novel cardiovascular system associated polypeptides. Novel cardiovascular system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human cardiovascular system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the cardiovascular system, including cancer of cardiovascular system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:7341 USPATFULL
 TITLE: Nucleic acids, proteins, and antibodies
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Ruben, Steven M., Olney, MD, UNITED STATES
 Barash, Steven C., Rockville, MD, UNITED STATES
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005575	A1	20040108
APPLICATION INFO.:	US 2002-227577	A1	20020826 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-91504, filed on 7 Mar 2002, PENDING Continuation of Ser. No. US 2001-764869, filed on 17 Jan 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)

US 2000-225267P	20000814 (60)
US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)

US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE:

FILE SEGMENT:

LEGAL REPRESENTATIVE:

Utility

APPLICATION

HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 28742

L13 ANSWER 7 OF 101 USPATFULL on STN

TI 50 human secreted proteins

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:2568 USPATFULL

TITLE: 50 human secreted proteins

INVENTOR(S): Moore, Paul A., Germantown, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
LaFleur, David W., Washington, DC, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)

	NUMBER	KIND	DATE ^o
PATENT INFORMATION:	US 2004002591	A1	20040101
APPLICATION INFO.:	US 2002-47021	A1	20020117 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-722329, filed on 28 Nov 2000, PENDING Continuation of Ser. No. US 1999-262109, filed on 4 Mar 1999, ABANDONED Continuation-in-part of Ser. No. WO 1998-US18360, filed on 3 Sep 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-262066P	20010118 (60)
	US 1997-57626P	19970905 (60)
	US 1997-57663P	19970905 (60)
	US 1997-57669P	19970905 (60)
	US 1997-58666P	19970912 (60)
	US 1997-58667P	19970912 (60)
	US 1997-58973P	19970912 (60)
	US 1997-58974P	19970912 (60)
	US 1998-90112P	19980622 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 23

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 2 Drawing Page(s)

LINE COUNT: 33379

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 8 OF 101 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel excretory system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "excretory system antigens," and the use of

such excretory system antigens for detecting disorders of the excretory system, particularly the presence of cancer of excretory system tissues and cancer metastases. More specifically, isolated excretory system associated nucleic acid molecules are provided encoding novel excretory system associated polypeptides. Novel excretory system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human excretory system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the excretory system, including cancer of excretory system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:334955 USPATFULL
 TITLE: Nucleic acids, proteins, and antibodies
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Ruben, Steven M., Olney, MD, UNITED STATES
 Barash, Steven C., Rockville, MD, UNITED STATES
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235831	A1	20031225
APPLICATION INFO.:	US 2002-242355	A1	20020913 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764897, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)

US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)

US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 22457
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 9 OF 101 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for

identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:334953 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Birse, Charles E., North Potomac, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235829	A1	20031225
APPLICATION INFO.:	US 2002-227646	A1	20020826 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-860670, filed on 21 May 2001, PENDING Continuation-in-part of Ser. No. WO 2001-US1346, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)
	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-216880P	20000707 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-236367P	20000929 (60)
	US 2000-239937P	20001013 (60)
	US 2000-249210P	20001117 (60)
	US 2000-249211P	20001117 (60)
	US 2000-249214P	20001117 (60)
	US 2000-231243P	20000908 (60)
	US 2000-246477P	20001108 (60)
	US 2000-246528P	20001108 (60)
	US 2000-246525P	20001108 (60)
	US 2000-246476P	20001108 (60)
	US 2000-246526P	20001108 (60)
	US 2000-249265P	20001117 (60)
	US 2000-230437P	20000906 (60)
	US 2000-251990P	20001208 (60)
	US 2000-251988P	20001205 (60)
	US 2000-251030P	20001205 (60)
	US 2000-251479P	20001206 (60)
	US 2000-256719P	20001205 (60)
	US 2000-250160P	20001201 (60)
	US 2000-251989P	20001208 (60)
	US 2000-250391P	20001201 (60)
	US 2000-254097P	20001211 (60)
	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)

damage caused by acute viral hepatitis and toxic insults to the liver.
This sequence represents a pAMG21 vector PCR primer used to ascertain
that a pAMG21/rat FGF-16 construct had been produced in an
exemplification of the present invention.

ACCESSION NUMBER: AAZ55817 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates
proliferation and growth of hepatocytes is useful for
treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: pAMG21 vector PCR primer, SEQ ID NO:28.

L16 ANSWER 9 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates
proliferation and growth of hepatocytes is useful for treating hepatic
disorders -
AN AAZ55816 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16
(FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins.
FGF-16 has hepatocyte proliferation and growth activity, and increases
hepatic production of triglycerides and serum proteins (e.g.,
albumin). FGF-16 nucleic acids and/or proteins may be
used for stimulating the proliferation and development of hepatocytes
both in vitro and in vivo. The isolated nucleic acid molecules may be
used directly in cell or gene therapy applications to treat or prevent
liver disorders, including hepatic cirrhosis, fulminant liver failure,
damage caused by acute viral hepatitis and toxic insults to the liver.
Sequences AAZ55815-Z55816 represent PCR primers used to clone rat FGF-16
cDNA (AAZ55790) into E. coli.

ACCESSION NUMBER: AAZ55816 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates
proliferation and growth of hepatocytes is useful for
treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat FGF-16 PCR primer, SEQ ID NO:28.

L16 ANSWER 10 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates
proliferation and growth of hepatocytes is useful for treating hepatic
disorders -
AN AAZ55815 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16
(FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins.
FGF-16 has hepatocyte proliferation and growth activity, and increases
hepatic production of triglycerides and serum proteins (e.g.,
albumin). FGF-16 nucleic acids and/or proteins may be
used for stimulating the proliferation and development of hepatocytes
both in vitro and in vivo. The isolated nucleic acid molecules may be
used directly in cell or gene therapy applications to treat or prevent
liver disorders, including hepatic cirrhosis, fulminant liver failure,
damage caused by acute viral hepatitis and toxic insults to the liver.

Sequences AAZ55815-Z55816 represent PCR primers used to clone rat FGF-16 cDNA (AAZ55790) into E. coli.

ACCESSION NUMBER: AAZ55815 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat FGF-16 PCR primer, SEQ ID NO:27.

L16 ANSWER 11 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55814 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55813-Z55814 represent PCR primers used to detect human FGF-16 DNA in bacteria which had previously been transformed with a vector comprising human FGF-16 DNA.

ACCESSION NUMBER: AAZ55814 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat FGF-16 PCR primer, SEQ ID NO:26.

L16 ANSWER 12 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55813 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55813-Z55814 represent PCR primers used to detect human

FGF-16 DNA in bacteria which had previously been transformed with a vector comprising human FGF-16 DNA.

ACCESSION NUMBER: AAZ55813 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 PCR primer, SEQ ID NO:25.

L16 ANSWER 13 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55812 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55810-Z55812 represent PCR primers used in a PCR technique similar to 5' RACE (rapid amplification of cDNA ends) for extension and amplification of human genomic FGF-16 DNA sequences.

ACCESSION NUMBER: AAZ55812 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat FGF-16 genomic PCR primer, SEQ ID NO:24.

L16 ANSWER 14 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55811 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55810-Z55812 represent PCR primers used in a PCR technique

similar to 5' RACE (rapid amplification of cDNA ends) for extension and amplification of human genomic FGF-16 DNA sequences.

ACCESSION NUMBER: AAZ55811 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 genomic PCR primer, SEQ ID NO:23.

L16 ANSWER 15 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55810 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55810-Z55812 represent PCR primers used in a PCR technique similar to 5' RACE (rapid amplification of cDNA ends) for extension and amplification of human genomic FGF-16 DNA sequences.

ACCESSION NUMBER: AAZ55810 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 partially random genomic PCR primer, SEQ ID NO:22.

L16 ANSWER 16 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55809 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.

Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55809 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 PCR primer, SEQ ID NO:21.

L16 ANSWER 17 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55808 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55808 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 5' RACE PCR primer, SEQ ID NO:20.

L16 ANSWER 18 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55807 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55807 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 5' RACE PCR primer, SEQ ID NO:19.

L16 ANSWER 19 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55806 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55806 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 partially random 5' RACE PCR primer, SEQ ID NO:18 (E).

L16 ANSWER 20 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55805 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55805 DNA DGENE

TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 partially random 5' RACE PCR primer, SEQ ID NO:18 (D).

L16 ANSWER 21 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55804 DNA DGENE

AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55804 DNA DGENE

TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H

PATENT ASSIGNEE: (AMGE-N)AMGEN INC.

PATENT INFO: US 5998170 A 19991207 33p

APPLICATION INFO: US 1997-943915 19971003

PRIORITY INFO: US 1997-943915 19971003

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-085497 [07]

DESCRIPTION: Human FGF-16 partially random 5' RACE PCR primer, SEQ ID NO:18 (C).

L16 ANSWER 22 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55803 DNA DGENE

AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55803 DNA DGENE

TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 partially random 5' RACE PCR primer, SEQ ID NO:18 (B).

L16 ANSWER 23 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55802 DNA DGENE

AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55802 DNA DGENE

TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H

PATENT ASSIGNEE: (AMGE-N)AMGEN INC.

PATENT INFO: US 5998170 A 19991207 33p

APPLICATION INFO: US 1997-943915 19971003

PRIORITY INFO: US 1997-943915 19971003

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-085497 [07]

DESCRIPTION: Human FGF-16 partially random 5' RACE PCR primer, SEQ ID NO:18 (A).

L16 ANSWER 24 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55801 DNA DGENE

AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55801 DNA DGENE

TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 5' RACE PCR primer, SEQ ID NO:16.

L16 ANSWER 25 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55800 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. This sequence represents a PCR primer used with primer AAZ55799 in 3' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55800 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 3' RACE PCR primer, SEQ ID NO:15.

L16 ANSWER 26 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55799 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. This sequence represents a primer used to synthesise first strand cDNA from human heart polyA+ RNA, and also used as a PCR primer in 3' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55799 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates

proliferation and growth of hepatocytes is useful for treating hepatic disorders -

INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H

PATENT ASSIGNEE: (AMGE-N)AMGEN INC.

PATENT INFO: US 5998170 A 19991207 33p

APPLICATION INFO: US 1997-943915 19971003

PRIORITY INFO: US 1997-943915 19971003

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-085497 [07]

DESCRIPTION: Reverse transcription/human FGF-16 3' RACE PCR primer, SEQ ID NO:14.

L16 ANSWER 27 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55798 DNA DGENE

AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55793-Z55798 represent primers used to isolate and clone a human FGF-16 cDNA fragment in an exemplification of the present invention.

ACCESSION NUMBER: AAZ55798 DNA DGENE

TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H

PATENT ASSIGNEE: (AMGE-N)AMGEN INC.

PATENT INFO: US 5998170 A 19991207 33p

APPLICATION INFO: US 1997-943915 19971003

PRIORITY INFO: US 1997-943915 19971003

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-085497 [07]

DESCRIPTION: Human fibroblast growth factor FGF-16 PCR primer, SEQ ID NO:132.

L16 ANSWER 28 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55797 DNA DGENE

AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55793-Z55798 represent primers used to isolate and clone a human FGF-16 cDNA fragment in an exemplification of the present invention.

ACCESSION NUMBER: AAZ55797 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat fibroblast growth factor FGF-16 PCR primer, SEQ ID NO:12.

L16 ANSWER 29 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55796 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55793-Z55798 represent primers used to isolate and clone a human FGF-16 cDNA fragment in an exemplification of the present invention.

ACCESSION NUMBER: AAZ55796 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human heart polyA+ RNA reverse transcription primer, SEQ ID NO:11.

L16 ANSWER 30 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55795 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55793-Z55798 represent primers used to isolate and clone a human FGF-16 cDNA fragment in an exemplification of the present

invention.

ACCESSION NUMBER: AAZ55795 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat fibroblast growth factor FGF-16 PCR primer, SEQ ID NO:10.

L16 ANSWER 31 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55794 DNA DGENE

AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF-16** nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55793-Z55798 represent primers used to isolate and clone a human FGF-16 cDNA fragment in an exemplification of the present invention.

ACCESSION NUMBER: AAZ55794 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat fibroblast growth factor FGF-16 PCR primer, SEQ ID NO:9.

L16 ANSWER 32 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55793 DNA DGENE

AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF-16** nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55793-Z55798 represent primers used to isolate and clone a human FGF-16 cDNA fragment in an exemplification of the present

invention.

ACCESSION NUMBER: AAZ55793 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat fibroblast growth factor FGF-16 PCR primer, SEQ ID NO:8.

L16 ANSWER 33 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55792 cDNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF-16** nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. This sequence represents a rat fibroblast growth factor-16 partial cDNA, used to design PCR primers to isolate CDNA encoding human FGF-16 in an exemplification of the present invention.

ACCESSION NUMBER: AAZ55792 cDNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat fibroblast growth factor FGF-16 partial cDNA.

L16 ANSWER 34 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55791 cDNA DGENE
AB This sequence represents cDNA encoding human fibroblast growth factor-16 (FGF-16). FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF-16** nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.

ACCESSION NUMBER: AAZ55791 cDNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for

treating hepatic disorders -
 INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
 PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
 PATENT INFO: US 5998170 A 19991207 33p
 APPLICATION INFO: US 1997-943915 19971003
 PRIORITY INFO: US 1997-943915 19971003
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 OTHER SOURCE: 2000-085497 [07]
 CROSS REFERENCES: P-PSDB: AAY58429
 DESCRIPTION: cDNA encoding human fibroblast growth factor FGF-16.

L16 ANSWER 35 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 TI Fibroblast growth factor family polypeptide which stimulates
 proliferation and growth of hepatocytes is useful for treating hepatic
 disorders -
 AN AAZ55790 cDNA DGENE
 AB This sequence represents cDNA encoding rat fibroblast growth factor-16
 (FGF-16). FGF-16 has hepatocyte proliferation and growth activity, and
 increases hepatic production of triglycerides and serum proteins (e.g.,
 albumin). FGF-16 nucleic acids and/or proteins may be
 used for stimulating the proliferation and development of hepatocytes
 both in vitro and in vivo. The isolated nucleic acid molecules may be
 used directly in cell or gene therapy applications to treat or prevent
 liver disorders, including hepatic cirrhosis, fulminant liver failure,
 damage caused by acute viral hepatitis and toxic insults to the liver.
 ACCESSION NUMBER: AAZ55790 cDNA DGENE
 TITLE: Fibroblast growth factor family polypeptide which stimulates
 proliferation and growth of hepatocytes is useful for
 treating hepatic disorders -
 INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
 PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
 PATENT INFO: US 5998170 A 19991207 33p
 APPLICATION INFO: US 1997-943915 19971003
 PRIORITY INFO: US 1997-943915 19971003
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 OTHER SOURCE: 2000-085497 [07]
 CROSS REFERENCES: P-PSDB: AAY58428
 DESCRIPTION: cDNA encoding rat fibroblast growth factor FGF-16.

=> d his

(FILE 'HOME' ENTERED AT 12:38:37 ON 16 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS,
 BIOSIS' ENTERED AT 12:39:04 ON 16 JAN 2004

L1 13014 S RANTES
 L2 2849 S ALBUMIN FUSION PROTEIN
 L3 8 S L1 AND L2
 L4 1364 S FGF-8
 L5 509 S L4 AND ALBUMIN
 L6 491 S L5 AND FUSION
 L7 207 S L6 AND L1
 L8 0 S L7 AND STABILIZER
 L9 6424 S FUSION PARTNER
 L10 2467 S L9 AND ALBUMIN
 L11 176 S L9 AND BMP
 L12 141 S L11 AND L10
 L13 101 S L12 AND L1
 L14 2849 S ALBUMIN () FUSION PROTEIN
 L15 0 S ALBUMIN () BMP
 L16 35 S ALBUMIN () FGF

Hit List

Search Results - Record(s) 1 through 1 of 1 returned.

☐ 1. Document ID: US 4563489 A

L2: Entry 1 of 1

File: USPT

Jan 7, 1986

US-PAT-NO: 4563489

DOCUMENT-IDENTIFIER: US 4563489 A

TITLE: Biodegradable organic polymer delivery system for bone morphogenetic protein

DATE-ISSUED: January 7, 1986

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Urist; Marshall R.	Pacific Palisades	CA		

US-CL-CURRENT: 514/21; 424/426, 523/115, 524/17, 524/21, 604/891.1, 623/915

Full	Title	Citation	Front	Review	Classification	Date	Reference	References	Abstracts	Claims	KIMC	Draw De
------	-------	----------	-------	--------	----------------	------	-----------	------------	-----------	--------	------	---------

Terms	Documents
albumin adj2 BMP	1

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#)
[Generate OACS](#)

Search Results - Record(s) 1 through 2 of 2 returned.

☐ 1. Document ID: US 6025194 A

L8: Entry 1 of 2

File: USPT

Feb 15, 2000

US-PAT-NO: 6025194

DOCUMENT-IDENTIFIER: US 6025194 A

TITLE: Nucleic acid sequence of senescence associated gene

DATE-ISSUED: February 15, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Funk; Walter	Hayward	CA		

US-CL-CURRENT: [435/320.1](#); [435/325](#), [536/23.1](#), [536/23.5](#), [536/24.1](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw Dg
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	------------------------	----------------------	-------------------------

☐ 2. Document ID: US 5733541 A

L8: Entry 2 of 2

File: USPT

Mar 31, 1998

US-PAT-NO: 5733541

DOCUMENT-IDENTIFIER: US 5733541 A

**** See image for Certificate of Correction ****

TITLE: Hematopoietic cells: compositions and methods

DATE-ISSUED: March 31, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Taichman; Russell S.	Ann Arbor	MI		
Emerson; Stephen G.	Wayne	PA		

US-CL-CURRENT: [424/93.1](#); [424/93.7](#), [435/325](#), [435/347](#), [435/373](#), [435/375](#), [435/377](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw Dg
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	------------------------	----------------------	-------------------------

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Terms	Documents
BMP-2 and L7	2

Display Format:

CIT

Change Format

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Freeform Search

Database:

US Pre-Grant Publication Full-Text Database

US Patents Full-Text Database

US OCR Full-Text Database

EPO Abstracts Database

JPO Abstracts Database

Derwent World Patents Index

IBM Technical Disclosure Bulletins

Term:

albumin and fusion protein

Display:

10

Documents in Display Format:

CIT

Starting with Number

1

Generate:

☐ Hit List

☒ Hit Count

☐ Side by Side

☐ Image

Search

Clear

Interrupt

Search History

DATE: Friday, January 16, 2004 [Printable Copy](#) [Create Case](#)

<u>Set Name Query</u>		<u>Hit Count</u>	<u>Set Name</u>
side by side			result set
<i>DB=USPT; PLUR=YES; OP=OR</i>			
<u>L10</u>	19 adj BMP	980	<u>L10</u>
<u>L9</u>	albumin fusion protein	198014	<u>L9</u>
<u>L8</u>	BMP-2 and L7	2	<u>L8</u>
<u>L7</u>	L6 and IL-6	284	<u>L7</u>
<u>L6</u>	L5 and Rantes	838	<u>L6</u>
<u>L5</u>	human chemokine and albumin	314787	<u>L5</u>
<u>L4</u>	albumin adj2 CXC3	0	<u>L4</u>
<u>L3</u>	albumin fused to BMP	159316	<u>L3</u>
<u>L2</u>	albumin adj2 BMP	1	<u>L2</u>
<u>L1</u>	albumin and fusion protein	144237	<u>L1</u>

END OF SEARCH HISTORY

US 2000-225757P	20000814 (60)
US 2000-226868P	20000822 (60)
US 2000-216647P	20000707 (60)
US 2000-225267P	20000814 (60)
US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)

US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)
US 2000-179065P	20000131 (60)

US 2000-180628P	20000204 (60)
US 2000-214886P	20000628 (60)
US 2000-217487P	20000711 (60)
US 2000-225758P	20000814 (60)
US 2000-220963P	20000726 (60)
US 2000-217496P	20000711 (60)
US 2000-225447P	20000814 (60)
US 2000-218290P	20000714 (60)
US 2000-225757P	20000814 (60)
US 2000-226868P	20000822 (60)
US 2000-216647P	20000707 (60)
US 2000-225267P	20000814 (60)
US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)

US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)

US 2000-198123P 20000418 (60)
 US 2000-227009P 20000823 (60)
 US 2000-235484P 20000926 (60)
 US 2000-190076P 20000317 (60)
 US 2000-209467P 20000607 (60)
 US 2000-205515P 20000519 (60)
 US 2001-259678P 20010105 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
 ROCKVILLE, MD, 20850
 NUMBER OF CLAIMS: 24
 EXEMPLARY CLAIM: 1
 LINE COUNT: 20415
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 10 OF 101 USPATFULL on STN
 TI Novel methods of diagnosis of metastatic colorectal cancer, compositions
 and methods of screening for modulators of metastatic colorectal cancer
 AB Described herein are methods and compositions that can be used for
 diagnosis and treatment of metastatic colorectal cancer. Also described
 herein are methods that can be used to identify modulators of metastatic
 colorectal cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:334944 USPATFULL
 TITLE: Novel methods of diagnosis of metastatic colorectal
 cancer, compositions and methods of screening for
 modulators of metastatic colorectal cancer
 INVENTOR(S): Mack, David H., Menlo Park, CA, UNITED STATES
 Markowitz, Sanford David, Pepper Pike, OH, UNITED
 STATES
 PATENT ASSIGNEE(S): Eos Biotechnology, Inc., South San Francisco, CA (U.S.
 corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235820	A1	20031225
APPLICATION INFO.:	US 2002-87080	A1	20020227 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-284555P	20010417 (60)
	US 2001-281149P	20010402 (60)
	US 2001-272206P	20010227 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO
 CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
 NUMBER OF CLAIMS: 21
 EXEMPLARY CLAIM: 1
 LINE COUNT: 22670
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:38:37 ON 16 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS,
 BIOSIS' ENTERED AT 12:39:04 ON 16 JAN 2004

L1 13014 S RANTES
 L2 2849 S ALBUMIN FUSION PROTEIN
 L3 8 S L1 AND L2

L4 1364 S FGF-8
 L5 509 S L4 AND ALBUMIN
 L6 491 S L5 AND FUSION
 L7 207 S L6 AND L1
 L8 0 S L7 AND STABILIZER
 L9 6424 S FUSION PARTNER
 L10 2467 S L9 AND ALBUMIN
 L11 176 S L9 AND BMP
 L12 141 S L11 AND L10
 L13 101 S L12 AND L1

=> s albumin () fusion protein
 L14 2849 ALBUMIN (W) FUSION PROTEIN

=> s albumin () BMP
 L15 0 ALBUMIN (W) BMP

=> s albumin () FGF
 L16 35 ALBUMIN (W) FGF

=> d l16 ti abs ibib tot

L16 ANSWER 1 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
 AN AAY58432 Protein DGENE
 AB This sequence represents a truncated rat fibroblast growth factor-16 (FGF-16) des-N-9, where residues 1-9 of the full-length rat FGF-16 (AAY58428) have been removed by proteolytic cleavage. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF-16** nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.
 ACCESSION NUMBER: AAY58432 Protein DGENE
 TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
 INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
 PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
 PATENT INFO: US 5998170 A 19991207 33p
 APPLICATION INFO: US 1997-943915 19971003
 PRIORITY INFO: US 1997-943915 19971003
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 OTHER SOURCE: 2000-085497 [07]
 DESCRIPTION: Rat truncated fibroblast growth factor FGF-16, des-N-9.

L16 ANSWER 2 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
 AN AAY58431 Protein DGENE
 AB This sequence represents a truncated rat fibroblast growth factor-16 (FGF-16) des-N-34, where residues 1-34 of the full-length rat FGF-16 (AAY58428) have been removed by proteolytic cleavage. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF-16** nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	CA/CAPLUS records now contain indexing from 1907 to the present
NEWS	4	DEC 08	INPADOC: Legal Status data reloaded
NEWS	5	SEP 29	DISSABS now available on STN
NEWS	6	OCT 10	PCTFULL: Two new display fields added
NEWS	7	OCT 21	BIOSIS file reloaded and enhanced
NEWS	8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS	9	NOV 24	MSDS-CCOHS file reloaded
NEWS	10	DEC 08	CABA reloaded with left truncation
NEWS	11	DEC 08	IMS file names changed
NEWS	12	DEC 09	Experimental/property data collected by CAS now available in REGISTRY
NEWS	13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAPLUS
NEWS	14	DEC 17	DGENE: Two new display fields added
NEWS	15	DEC 18	BIOTECHNO no longer updated
NEWS	16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS	17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS	18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS	19	DEC 22	ABI-INFORM now available on STN
NEWS EXPRESS			DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:22:40 ON 16 JAN 2004

=> file medline, uspatful, biosis, fsta, wpids, japio, jicst, embase, dgene, biobusiness

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 12:23:20 ON 16 JAN 2004

FILE 'USPATFULL' ENTERED AT 12:23:20 ON 16 JAN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'FSTA' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'WPIDS' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'JAPIO' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 Japanese Patent Office (JPO) - JAPIO

FILE 'JICST-EPLUS' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'EMBASE' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'DGENE' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'BIOBUSINESS' ENTERED AT 12:23:20 ON 16 JAN 2004
COPYRIGHT (C) 2004 Biological Abstracts, Inc. (BIOSIS)

=> s albumin fusion protein
L1 2849 ALBUMIN FUSION PROTEIN

=> s BMP-1 and albumin
9 FILES SEARCHED...
L2 193 BMP-1 AND ALBUMIN

=> s l2 and l1
L3 0 L2 AND L1

=> d l2 ti abs ibib 1-10

L2 ANSWER 1 OF 193 USPATFULL on STN
TI Novel proteins and nucleic acids encoding same
AB Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

ACCESSION NUMBER: 2004:13595 USPATFULL
TITLE: Novel proteins and nucleic acids encoding same
INVENTOR(S): Zerhusen, Bryan D., Branford, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Spytek, Kimberly, New Haven, CT, UNITED STATES
Spaderna, Steven, Berlin, CT, UNITED STATES
Gangolli, Esha A., Branford, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES

Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Majumder, Kumud, Stamford, CT, UNITED STATES
Shimkets, Richard, West Haven, CT, UNITED STATES
Mishra, Vishnu, Branford, CT, UNITED STATES
Vernet, Corine, North Branford, CT, UNITED STATES
Szekeres, Edward S., Branford, CT, UNITED STATES
Grosse, William M., Branford, CT, UNITED STATES
Alsobrook, John P., II, Madison, CT, UNITED STATES
Liu, Xiaohong, Branford, CT, UNITED STATES
Gerlach, Valerie L., Branford, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Smithson, Glennda, Branford, CT, UNITED STATES
Peyman, John, New Haven, CT, UNITED STATES
Stone, David, Guilford, CT, UNITED STATES
MacDougall, John, Hamden, CT, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004010118	A1	20040115	
APPLICATION INFO.:	US 2001-930512	A1	20010815	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-225692P	20000816	(60)
	US 2000-225693P	20000816	(60)
	US 2000-225837P	20000816	(60)
	US 2000-226236P	20000818	(60)
	US 2000-226353P	20000818	(60)
	US 2000-227085P	20000822	(60)
	US 2000-227395P	20000823	(60)
	US 2000-227492P	20000824	(60)
	US 2000-227600P	20000824	(60)
	US 2001-275952P	20010314	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C.,
ONE FINANCIAL CENTER, BOSTON, MA, 02111
NUMBER OF CLAIMS: 49
EXEMPLARY CLAIM: 1
LINE COUNT: 9358

L2 ANSWER 2 OF 193 USPATFULL on STN
TI Methods of treatment of periodontal disease
AB Purified BMP-2 and BMP-4 proteins and processes for producing them are
disclosed. The proteins may be used in the treatment of bone and
cartilage defects and in wound healing and related tissue repair.

ACCESSION NUMBER: 2004:13394 USPATFULL
TITLE: Methods of treatment of periodontal disease
INVENTOR(S): Wang, Elizabeth, Carlisle, MA, UNITED STATES
Wozney, John M., Hudson, MA, UNITED STATES
Rosen, Vicki A., Brookline, MA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004009916	A1	20040115	
APPLICATION INFO.:	US 2003-397214	A1	20030327	(10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-804625, filed on 9 Mar 2001, PENDING Continuation of Ser. No. US 1997-925779, filed on 9 Sep 1997, GRANTED, Pat. No. US 6245889 Continuation of Ser. No. US 1991-721847, filed on 14 Jun 1991, GRANTED, Pat. No. US 6150328 Continuation-in-part of Ser. No. US 1990-493272, filed on 14 Mar 1990, ABANDONED Continuation-in-part of Ser.			

No. US 1989-406217, filed on 12 Sep 1989, ABANDONED
Continuation-in-part of Ser. No. US 1989-378537, filed
on 11 Jul 1989, GRANTED, Pat. No. US 5166058

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow,, Garrett & Dunner,
L.L.P., 1300 I Street, N.W., Washington, DC, 20005-3315
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 1876

L2 ANSWER 3 OF 193 USPATFULL on STN

TI Chondrogenic and osteogenic inducing molecule
AB The present invention is directed to methods of using and compositions
comprising amelogenin peptides capable of inducing chondrogenesis and
osteogenesis when implanted in vivo, a chondrogenesis in cultures in
vitro. Compositions and methods of enhancing bone and cartilage growth
using these peptides are described.

ACCESSION NUMBER: 2004:9593 USPATFULL
TITLE: Chondrogenic and osteogenic inducing molecule
INVENTOR(S): Veis, Arthur, Skokie, IL, United States
Nebgen, Denise R., Houston, TX, United States
PATENT ASSIGNEE(S): Northwestern University, Evanston, IL, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6677306	B1	20040113
	WO 2000006734		20000210
APPLICATION INFO.:	US 2001-744128		20010516 (9)
	WO 1999-US17342		19990729

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-94489P	19980729 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Mertz, Prema	
LEGAL REPRESENTATIVE:	Marshall, Gerstein & Borun LLP	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	16 Drawing Figure(s); 16 Drawing Page(s)	
LINE COUNT:	1877	

L2 ANSWER 4 OF 193 USPATFULL on STN

TI Treatment of inflammatory bowel disease using growth factors
AB The present invention is based upon methods of treating inflammatory
conditions in the intestinal tract of mammals using growth factor
related polypeptides. The invention includes methods of reducing the
mortality rate or delaying mortality in a subject suffering from an
inflammatory pathology. Methods of using fibroblast growth factor-CX
(FGF-CX) polynucleotides sequences and the FGF-CX polypeptides encoded
by such nucleic acid sequence, or variants, fragments and homologs
thereof, are claimed in the invention. Similarly, methods of using FCTR
polynucleotide sequences and the FCTR polypeptides encoded by such
nucleic acid sequences, or variants, fragments and homologs thereof,
alone or in combination, are also claimed in the invention. FCTR
collectively refers to any of six variant FCTR sequences, variously
designated FCTR1, FCTR2, FCTR3, FCTR4, FCTR5 and FCTR6.

ACCESSION NUMBER: 2004:7775 USPATFULL
TITLE: Treatment of inflammatory bowel disease using growth

INVENTOR(S) : factors
 Boldog, Ferenc L., North Haven, CT, UNITED STATES
 Burgess, Catherine E., Wethersfield, CT, UNITED STATES
 Fernandes, Elma R., Branford, CT, UNITED STATES
 Jeffers, Michael E., Branford, CT, UNITED STATES
 LaRochelle, William J., Madison, CT, UNITED STATES
 Lichenstein, Henri S., Guilford, CT, UNITED STATES
 Peterson, Jeffrey, Brookfield, CT, UNITED STATES
 Prayaga, Sudhirdas K., O'Fallon, MO, UNITED STATES
 Rittman, Beth, Colchester, CT, UNITED STATES
 Shimkets, Juliette B., Guilford, CT, UNITED STATES
 Shimkets, Richard A., Guilford, CT, UNITED STATES
 Yang, Meijia, East Lyme, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004006015	A1	20040108
APPLICATION INFO.:	US 2002-321962	A1	20021216 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-11364, filed on 16 Nov 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-386545P	20020606 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C., ONE FINANCIAL CENTER, BOSTON, MA, 02111	
NUMBER OF CLAIMS:	67	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	73 Drawing Page(s)	
LINE COUNT:	7115	

L2 ANSWER 5 OF 193 USPATFULL on STN
 TI Proteins and nucleic acids encoding same
 AB Disclosed are polypeptides and nucleic acids encoding same. Also disclosed are vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using same.

ACCESSION NUMBER: 2004:7342 USPATFULL
 TITLE: Proteins and nucleic acids encoding same
 INVENTOR(S) : Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES
 Li, Li, Branford, CT, UNITED STATES
 Patturajan, Meera, Branford, CT, UNITED STATES
 Shimkets, Richard A., Guilford, CT, UNITED STATES
 Casman, Stacie J., North Haven, CT, UNITED STATES
 Malyankar, Uriel M., Branford, CT, UNITED STATES
 Tchernev, Velizar T., Branford, CT, UNITED STATES
 Vernet, Corine A., North Branford, CT, UNITED STATES
 Spytek, Kimberly A., New Haven, CT, UNITED STATES
 Shenoy, Suresh G., Branford, CT, UNITED STATES
 Alsobrook, John P., II, Madison, CT, UNITED STATES
 Edinger, Schlomit, New Haven, CT, UNITED STATES
 Peyman, John A., New Haven, CT, UNITED STATES
 Stone, David J., Guilford, CT, UNITED STATES
 Ellerman, Karen, Branford, CT, UNITED STATES
 Gangolli, Esha A., Madison, CT, UNITED STATES
 Boldog, Ferenc L., North Haven, CT, UNITED STATES
 Colman, Steven D., Guilford, CT, UNITED STATES
 Eisen, Andrew, Rockville, MD, UNITED STATES
 Liu, Xiaohong, Lexington, MA, UNITED STATES
 Padigaru, Muralidhara, Branford, CT, UNITED STATES
 Spaderna, Steven K., Berlin, CT, UNITED STATES

Zerhusen, Bryan D., Branford, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005576	A1	20040108
APPLICATION INFO.:	US 2002-231913	A1	20020830 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-10680, filed on 6 Dec 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-251660P	20001206 (60)
	US 2001-260326P	20010108 (60)
	US 2001-318712P	20010912 (60)
	US 2000-255029P	20001212 (60)
	US 2001-263800P	20010124 (60)
	US 2001-286183P	20010424 (60)
	US 2001-269942P	20010220 (60)
	US 2001-313627P	20010620 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C., ONE FINANCIAL CENTER, BOSTON, MA, 02111	
NUMBER OF CLAIMS:	41	
EXEMPLARY CLAIM:	1	
LINE COUNT:	17887	

L2 ANSWER 6 OF 193 USPATFULL on STN
TI Growth factor homolog ZVEGF4
AB Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 70% identical to residues 52-179 of SEQ ID NO:2 or residues 258-370 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents.

ACCESSION NUMBER: 2004:2119 USPATFULL
TITLE: Growth factor homolog ZVEGF4
INVENTOR(S): Gilbert, Teresa, Seattle, WA, UNITED STATES
Hart, Charles E., Woodinville, WA, UNITED STATES
Sheppard, Paul O., Granite Falls, WA, UNITED STATES
Gilbertson, Debra G., Seattle, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002140	A1	20040101
APPLICATION INFO.:	US 2001-876813	A1	20010606 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-564595, filed on 3 May 2000, GRANTED, Pat. No. US 6495668		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-132250P	19990503 (60)
	US 1999-164463P	19991110 (60)
	US 2000-180169P	20000204 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Gary E. Parker, ZymoGenetics, Inc., Patent Department, 1201 Eastlake Avenue East, Seattle, WA, 98102	
NUMBER OF CLAIMS:	54	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	

LINE COUNT: 5092

L2 ANSWER 7 OF 193 USPATFULL on STN

TI Bone morphogenic protein polynucleotides, polypeptides, and antibodies
AB The present invention relates to novel human BMP polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human BMP polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human BMP polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:318756 USPATFULL
TITLE: Bone morphogenic protein polynucleotides, polypeptides, and antibodies
INVENTOR(S): Young, Paul E., Gaithersburg, MD, UNITED STATES
Ruben, Steven M., Brookeville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003224501	A1	20031204
APPLICATION INFO.:	US 2003-366345	A1	20030214 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-345236, filed on 16 Jan 2003, PENDING Continuation-in-part of Ser. No. US 2001-809269, filed on 16 Mar 2001, ABANDONED Continuation-in-part of Ser. No. WO 2001-US9229, filed on 23 Mar 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-356749P	20020215 (60)
	US 2000-190067P	20000317 (60)
	US 2002-348621P	20020117 (60)
	US 2002-349356P	20020122 (60)
	US 2002-351520P	20020128 (60)
	US 2002-354265P	20020206 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Page(s)
LINE COUNT: 16963
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 8 OF 193 USPATFULL on STN

TI Sulfonamide compounds
AB This invention relates to certain sulfonamide derivatives that are inhibitors of procollagen C-proteinase, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:306969 USPATFULL
TITLE: Sulfonamide compounds
INVENTOR(S): Billledeau, Roland Joseph, Santa Clara, CA, UNITED STATES
Broka, Chris Allen, Foster City, CA, UNITED STATES
Campbell, Jeffrey Allen, Middletown, CT, UNITED STATES
Chen, Jian Jeffrey, Santa Clara, CA, UNITED STATES
Dankwardt, Sharon Marie, Foster City, CA, UNITED STATES
Delaet, Nancy, San Diego, CA, UNITED STATES

Robinson, Leslie Ann, San Diego, CA, UNITED STATES
Walker, Keith Adrian Murray, Los Altos, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003216405	A1	20031120
APPLICATION INFO.:	US 2002-267727	A1	20021009 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-469660, filed on 22 Dec 1999, GRANTED, Pat. No. US 6492394		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-113311P	19981222 (60)
	US 1999-147053P	19990803 (60)
	US 1999-164138P	19991108 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ROCHE PALO ALTO LLC, 3431 HILLVIEW AVENUE, PATENT DEPT., M/S A2-250, PALO ALTO, CA, 94304	
NUMBER OF CLAIMS:	52	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3904	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 9 OF 193 USPATFULL on STN
TI Composition and method for modulating vasculogenesis or angiogenesis
AB A method for modulating vasculogenesis or angiogenesis using the core domain protein of PDGF-C, a new member of the PDGF/VEGF family of growth factors, or a homodimer or a heterodimer comprising the core domain. Also disclosed are pharmaceutical compositions comprising the core protein, nucleotide sequences encoding the protein, and uses thereof in medical and diagnostic applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:300768 USPATFULL
TITLE: Composition and method for modulating vasculogenesis or angiogenesis
INVENTOR(S): Li, Xuri, Stockholm, SWEDEN
Eriksson, Ulf, Stockholm, SWEDEN
Carmeliet, Peter, Leuven, BELGIUM
Collen, Desire, Leuven, BELGIUM
PATENT ASSIGNEE(S): Ludwig Institute for Cancer Research (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003211994	A1	20031113
APPLICATION INFO.:	US 2002-303997	A1	20021126 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-410349, filed on 30 Sep 1999, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-102461P	19980930 (60)
	US 1998-108109P	19981112 (60)
	US 1998-110749P	19981203 (60)
	US 1998-113002P	19981218 (60)
	US 1999-135426P	19990521 (60)
	US 1999-144022P	19990715 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	CROWELL & MORING LLP, INTELLECTUAL PROPERTY GROUP, P.O. BOX 14300, WASHINGTON, DC, 20044-4300	

NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 42 Drawing Page(s)
LINE COUNT: 2790
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 10 OF 193 USPATFULL on STN

TI OSTEOPROTEGERIN

AB The present invention discloses a novel secreted polypeptide, termed osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind OPG, and pharmaceutical compositions. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:294810 USPATFULL

TITLE: OSTEOPROTEGERIN

INVENTOR(S): BOYLE, WILLIAM J., MOORPARK, CA, UNITED STATES
LACEY, DAVID L., THOUSAND OAKS, CA, UNITED STATES
CALZONE, FRANK J., WEST LAKE VILLAGE, CA, UNITED STATES
CHANG, MING-SHI, NEWBURY PARK, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003207827	A1	20031106
APPLICATION INFO.:	US 1999-405032	A1	19990924 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-132985, filed on 12 Aug 1998, PENDING Continuation of Ser. No. US 1996-771777, filed on 20 Dec 1996, ABANDONED Continuation-in-part of Ser. No. US 1996-706945, filed on 3 Sep 1996, GRANTED, Pat. No. US 6369027 Continuation-in-part of Ser. No. US 1995-577788, filed on 22 Dec 1995, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	AMGEN INCORPORATED, MAIL STOP 27-4-A, ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320-1799		
NUMBER OF CLAIMS:	60		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	46 Drawing Page(s)		
LINE COUNT:	5457		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:22:40 ON 16 JAN 2004)

FILE 'MEDLINE, USPATFULL, BIOSIS, FSTA, WPIDS, JAPIO, JICST-EPLUS, EMBASE, DGENE, BIOBUSINESS' ENTERED AT 12:23:20 ON 16 JAN 2004

L1 2849 S ALBUMIN FUSION PROTEIN
L2 193 S BMP-1 AND ALBUMIN
L3 0 S L2 AND L1

=> s l1 and FGF-16

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: sssptal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?): 2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	CA/CAPLUS records now contain indexing from 1907 to the present
NEWS	4	DEC 08	INPADOC: Legal Status data reloaded
NEWS	5	SEP 29	DISSABS now available on STN
NEWS	6	OCT 10	PCTFULL: Two new display fields added
NEWS	7	OCT 21	BIOSIS file reloaded and enhanced
NEWS	8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS	9	NOV 24	MSDS-CCOHS file reloaded
NEWS	10	DEC 08	CABA reloaded with left truncation
NEWS	11	DEC 08	IMS file names changed
NEWS	12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS	13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAPLUS
NEWS	14	DEC 17	DGENE: Two new display fields added
NEWS	15	DEC 18	BIOTECHNO no longer updated
NEWS	16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS	17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS	18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS	19	DEC 22	ABI-INFORM now available on STN
NEWS EXPRESS			DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:38:37 ON 16 JAN 2004

=> file medline, uspatful, dgene, embase, wpids, fsta, jicst, biosis		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 12:39:04 ON 16 JAN 2004

FILE 'USPATFULL' ENTERED AT 12:39:04 ON 16 JAN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'JICST-EPLUS' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'BIOSIS' ENTERED AT 12:39:04 ON 16 JAN 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

=> s Rantes
L1 13014 RANTES

=> s albumin fusion protein
L2 2849 ALBUMIN FUSION PROTEIN

=> s l1 and l2
L3 8 L1 AND L2

=> d l3 ti abs ibib tot

L3 ANSWER 1 OF 8 USPATFULL on STN
TI Albumin fusion proteins
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

ACCESSION NUMBER: 2004:13611 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)

US 2000-229358P 20000412 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 25066

L3 ANSWER 2 OF 8 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:312278 USPATFULL

TITLE: Albumin fusion proteins

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219875	A1	20031127
APPLICATION INFO.:	US 2001-833118	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 15415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 3 OF 8 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:282700 USPATFULL

TITLE: Albumin fusion proteins
INVENTOR(S): Ballance, David J., Berwyn, PA, UNITED STATES
Sleep, Darrell, West Bridgford, UNITED KINGDOM
Prior, Christopher P., Rosemont, PA, UNITED STATES
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199043	A1	20031023
APPLICATION INFO.:	US 2001-832501	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 14339
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 8 USPATFULL on STN
TI Neutrokin-alpha and neutrokin-alpha splice variant
AB The present invention relates to nucleic acid molecules encoding Neutrokin-alpha and/or Neutrokin-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokin-alpha and/or Neutrokin-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokin-alpha and/or Neutrokin-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:250423 USPATFULL
TITLE: Neutrokin-alpha and neutrokin-alpha splice variant
INVENTOR(S): Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ullrich, Stephen, Rockville, MD, UNITED STATES
Laird, Michael, Germantown, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003175208	A1	20030918
APPLICATION INFO.:	US 2002-270487	A1	20021016 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-929493, filed on 15 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2000-588947, filed on 8 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-589285, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589286, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589287, filed		

on 8 Jun 2000, GRANTED, Pat. No. US 6403770
 Continuation-in-part of Ser. No. US 2000-589288, filed
 on 8 Jun 2000, PENDING Continuation-in-part of Ser. No.
 US 2000-507968, filed on 22 Feb 2000, PENDING
 Continuation-in-part of Ser. No. US 1999-255794, filed
 on 23 Feb 1999, PENDING Continuation-in-part of Ser.
 No. US 2000-588947, filed on 8 Jun 2000, ABANDONED
 Continuation-in-part of Ser. No. US 2000-589285, filed
 on 8 Jun 2000, PENDING Continuation-in-part of Ser. No.
 US 2000-589286, filed on 8 Jun 2000, PENDING
 Continuation-in-part of Ser. No. US 2000-589288, filed
 on 8 Jun 2000, PENDING Continuation-in-part of Ser. No.
 US 2000-507968, filed on 22 Feb 2000, PENDING
 Continuation-in-part of Ser. No. US 1999-255794, filed
 on 23 Feb 1999, PENDING Continuation-in-part of Ser.
 No. US 1998-5874, filed on 12 Jan 1998, PENDING
 Continuation-in-part of Ser. No. WO 1996-US17957, filed
 on 25 Oct 1996, PENDING Continuation-in-part of Ser.
 No. US 1999-255794, filed on 23 Feb 1999, PENDING
 Continuation-in-part of Ser. No. US 1998-5874, filed on
 12 Jan 1998, PENDING

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-329508P	20011017	(60)
	US 2001-329747P	20011018	(60)
	US 2001-330835P	20011031	(60)
	US 2001-331478P	20011116	(60)
	US 2001-336726P	20011207	(60)
	US 2002-368548P	20020401	(60)
	US 2000-225628P	20000815	(60)
	US 2000-227008P	20000823	(60)
	US 2000-234338P	20000922	(60)
	US 2000-240806P	20001017	(60)
	US 2000-250020P	20001130	(60)
	US 2001-276248P	20010316	(60)
	US 2001-293499P	20010525	(60)
	US 2001-296122P	20010607	(60)
	US 2001-304809P	20010713	(60)
	US 1999-122388P	19990302	(60)
	US 1999-124097P	19990312	(60)
	US 1999-126599P	19990326	(60)
	US 1999-127598P	19990402	(60)
	US 1999-130412P	19990416	(60)
	US 1999-130696P	19990423	(60)
	US 1999-131278P	19990427	(60)
	US 1999-131673P	19990429	(60)
	US 1999-136784P	19990528	(60)
	US 1999-142659P	19990706	(60)
	US 1999-145824P	19990727	(60)
	US 1999-167239P	19991124	(60)
	US 1999-168624P	19991203	(60)
	US 1999-171108P	19991216	(60)
	US 1999-171626P	19991223	(60)
	US 2000-176015P	20000114	(60)
	US 1999-122388P	19990302	(60)
	US 1999-124097P	19990312	(60)
	US 1999-126599P	19990326	(60)
	US 1999-127598P	19990402	(60)
	US 1999-130412P	19990416	(60)
	US 1999-130696P	19990423	(60)
	US 1999-131278P	19990427	(60)
	US 1999-131673P	19990429	(60)
	US 1999-136784P	19990528	(60)

US 1999-142659P 19990706 (60)
US 1999-145824P 19990727 (60)
US 1999-167239P 19991124 (60)
US 1999-168624P 19991203 (60)
US 1999-171108P 19991216 (60)
US 1999-171626P 19991223 (60)
US 2000-176015P 20000114 (60)
US 1997-36100P 19970114 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 27 Drawing Page(s)
LINE COUNT: 18884
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 8 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:244853 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
Prior, Christopher P., Rosemont, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003171267	A1	20030911
APPLICATION INFO.:	US 2001-833117	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 59
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 13208
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 8 USPATFULL on STN

TI Chemokine beta-1 fusion proteins

AB The present invention relates to novel chemokine polypeptides and encoding nucleic acids. More specifically, therapeutic compositions and methods are provided using isolated nucleic acid molecules encoding a

human chemokine beta-1 (Ck.beta.-1 or Ckb1) polypeptide (previously termed monocyte-colony inhibitory factor (M-CIF), MIP1-.gamma., and Hemofiltrate CC chemokine-1 (HCC-1)), and Ckb1 polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same. Also provided are methods of treating, preventing, ameliorating diseases using such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:206834 USPATFULL
TITLE: Chemokine beta-1 fusion proteins
INVENTOR(S): Bell, Adam, Germantown, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003143191	A1	20030731
APPLICATION INFO.:	US 2002-153604	A1	20020524 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-293212P	20010525 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	21 Drawing Page(s)	
LINE COUNT:	15446	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 8 USPATFULL on STN

TI Albumin fusion proteins

AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:181414 USPATFULL
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003125247	A1	20030703
APPLICATION INFO.:	US 2001-833041	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	

NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 15235
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 8 USPATFULL on STN
TI Binding polypeptides and methods based thereon
AB Binding polypeptides that specifically bind BLyS protein or BLyS-like polypeptides can be used in methods of the invention for detecting, diagnosing, or prognosing a disease or disorder associated with aberrant BLyS or BLyS receptor expression or inappropriate function of BLyS or BLyS receptor, comprising BLyS binding polypeptides or fragments or variants thereof, that specifically bind to BLyS. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant BLyS or BLyS receptor expression or inappropriate BLyS function or BLyS receptor function, comprising administering to an animal, preferably a human, an effective amount of one or more BLyS binding polypeptides or fragments or variants thereof, that specifically bind to BLyS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:133480 USPATFULL
TITLE: Binding polypeptides and methods based thereon
INVENTOR(S): Beltzer, James P., Carlisle, MA, UNITED STATES
Potter, M. Daniel, UNITED STATES
Potter, Marilou, Acton, MA, UNITED STATES LR
Fleming, Tony J., Waltham, MA, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003091565	A1	20030515
APPLICATION INFO.:	US 2001-932613	A1	20010817 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-226700P	20000818 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Leon R. Yankwich, Esq., Yankwich & Associates, 130 Bishop Allen Drive, Cambridge, MA, 02139	
NUMBER OF CLAIMS:	71	
EXEMPLARY CLAIM:	1	
LINE COUNT:	11834	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:38:37 ON 16 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS, BIOSIS' ENTERED AT 12:39:04 ON 16 JAN 2004

L1 13014 S RANTES
L2 2849 S ALBUMIN FUSION PROTEIN
L3 8 S L1 AND L2

=> s FGF-8
L4 1364 FGF-8

=> s l4 and albumin
L5 509 L4 AND ALBUMIN

=> s 15 and fusion
L6 491 L5 AND FUSION

=> d 16 and l1
L1 IS NOT VALID HERE
For an explanation, enter "HELP DISPLAY".

=> s 16 and l1
L7 207 L6 AND L1

=> s 17 and stabilizer
L8 0 L7 AND STABILIZER

=> d 17 ti abs ibib 1-10

L7 ANSWER 1 OF 207 USPATFULL on STN

TI **Albumin fusion** proteins

AB The present invention encompasses **albumin fusion** proteins. Nucleic acid molecules encoding the **albumin fusion** proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the **albumin fusion** proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising **albumin fusion** proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using **albumin fusion** proteins of the invention.

ACCESSION NUMBER: 2004:13611 USPATFULL
TITLE: **Albumin fusion** proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 25066

L7 ANSWER 2 OF 207 USPATFULL on STN

TI 53 human secreted proteins

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

ACCESSION NUMBER: 2004:13609 USPATFULL

TITLE: 53 human secreted proteins
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Brewer, Laurie A., St. Paul, MN, UNITED STATES
 Duan, Roxanne D., Bethesda, MD, UNITED STATES
 Ruben, Steven M., Olney, MD, UNITED STATES
 Florence, Kimberly A., Rockville, MD, UNITED STATES
 Greene, John M., Gaithersburg, MD, UNITED STATES
 Young, Paul E., Gaithersburg, MD, UNITED STATES
 Ferrie, Ann M., Painted Post, NY, UNITED STATES
 Yu, Guo-Liang, Berkeley, CA, UNITED STATES
 Florence, Charles, Rockville, MD, UNITED STATES
 Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
 Olsen, Henrik, Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010132	A1	20040115
APPLICATION INFO.:	US 2001-984429	A1	20011030 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-288143, filed on 8 Apr 1999, GRANTED, Pat. No. US 6433139		
	Continuation-in-part of Ser. No. WO 1998-US21142, filed on 8 Oct 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-244591P	20001101 (60)
	US 1997-61463P	19971009 (60)
	US 1997-61529P	19971009 (60)
	US 1997-71498P	19971009 (60)
	US 1997-61527P	19971009 (60)
	US 1997-61536P	19971009 (60)
	US 1997-61532P	19971009 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
 NUMBER OF CLAIMS: 24
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 4 Drawing Page(s)
 LINE COUNT: 27480

L7 ANSWER 3 OF 207 USPATFULL on STN

TI 7 Human ovarian and ovarian cancer associated proteins
 AB This invention relates to newly identified ovarian or ovarian cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "ovarian cancer antigens", and the use of such ovarian antigens for detecting disorders of the reproductive system, particularly the presence of ovarian cancer and ovarian cancer metastases. This invention relates to ovarian cancer antigens as well as vectors, host cells, antibodies directed to ovarian cancer antigens and the recombinant methods and synthetic methods for producing the same. Also provided are diagnostic methods for detecting, treating, preventing and/or prognosing disorders related to the ovary, including ovarian cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of ovarian cancer antigens of the invention. The present invention further relates to inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:13598 USPATFULL
 TITLE: 7 Human ovarian and ovarian cancer associated proteins
 INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
 Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010121	A1	20040115
APPLICATION INFO.:	US 2003-333900	A1	20030124 (10)
	WO 2001-US8585		20010316
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
LINE COUNT:	16023		

L7 ANSWER 4 OF 207 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel polynucleotides associated with the plasma membrane, the polypeptides encoded by these polynucleotides herein collectively referred to as "plasma membrane associated antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such plasma membrane associated polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders related to these novel polypeptides. More specifically, isolated nucleic acid molecules are provided encoding novel plasma membrane associated polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing these plasma membrane associated polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the novel polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:12971 USPATFULL
 TITLE: Nucleic acids, proteins, and antibodies
 INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
 Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009491	A1	20040115
APPLICATION INFO.:	US 2002-264237	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US16450, filed on 18 May 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	18144	

L7 ANSWER 5 OF 207 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel musculoskeletal system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "musculoskeletal system antigens," and the

use of such musculoskeletal system antigens for detecting disorders of the musculoskeletal system, particularly the presence of cancer and cancer metastases. More specifically, isolated musculoskeletal system associated nucleic acid molecules are provided encoding novel musculoskeletal system associated polypeptides. Novel musculoskeletal system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human musculoskeletal system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the musculoskeletal system, including cancer of musculoskeletal tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:12966 USPATFULL
 TITLE: Nucleic acids, proteins, and antibodies
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Ruben, Steven M., Olney, MD, UNITED STATES
 Barash, Steven C., Rockville, MD, UNITED STATES
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009488	A1	20040115
APPLICATION INFO.:	US 2002-242515	A1	20020913 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764877, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)

US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)

US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 32038

L7 ANSWER 6 OF 207 USPATFULL on STN

TI Apoptosis inducing molecule II and methods of use
AB The present invention relates to a novel member of the TNF-Ligand superfamily. More specifically, isolated nucleic acid molecules are provided encoding a human Apoptosis Inducing Molecule II (AIM II). AIM II polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of AIM II activity. Also provided are therapeutic methods for treating lymphadenopathy, aberrant bone development, autoimmune and other immune system diseases, graft versus host disease, rheumatoid arthritis, osteoarthritis and to inhibit neoplasia, such as tumor cell growth.

ACCESSION NUMBER: 2004:12629 USPATFULL
 TITLE: Apoptosis inducing molecule II and methods of use
 INVENTOR(S): Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
 Yu, Guo-Liang, Berkeley, CA, UNITED STATES
 Ruben, Steven M., Brookeville, MD, UNITED STATES
 Zhai, Yifan, Rockville, MD, UNITED STATES
 Ullrich, Stephen, Rockville, MD, UNITED STATES
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009147	A1	20040115
APPLICATION INFO.:	US 2003-375680	A1	20030228 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-523323, filed on 10 Mar 2000, GRANTED, Pat. No. US 6635743		
	Continuation-in-part of Ser. No. US 1999-252656, filed on 19 Feb 1999, GRANTED, Pat. No. US 6495520		
	Continuation-in-part of Ser. No. US 1998-27287, filed on 20 Feb 1998, GRANTED, Pat. No. US 6479254		
	Continuation-in-part of Ser. No. US 1998-3886, filed on 7 Jan 1998, ABANDONED		
	Continuation-in-part of Ser. No. US 1997-822953, filed on 21 Mar 1997, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-360234P	20020301 (60)
	US 1999-168380P	19991202 (60)
	US 1999-148326P	19990811 (60)
	US 1999-142657P	19990706 (60)
	US 1999-137457P	19990604 (60)
	US 1999-124041P	19990311 (60)
	US 1998-75409P	19980220 (60)
	US 1996-13923P	19960322 (60)
	US 1996-30157P	19961031 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W., WASHINGTON, DC, 20005
 NUMBER OF CLAIMS: 45
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 48 Drawing Page(s)
 LINE COUNT: 13322

L7 ANSWER 7 OF 207 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel ovarian related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "ovarian antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such ovarian polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the reproductive system, particularly disorders of the ovaries and/or breast, including, but not limited to, the presence of ovarian and/or breast cancer and ovarian and/or breast cancer metastases. More specifically, isolated ovarian nucleic acid molecules are provided encoding novel ovarian polypeptides. Novel ovarian polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human ovarian polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the ovaries and/or breast, including ovarian and/or breast cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of

polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:7345 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005579	A1	20040108
APPLICATION INFO.:	US 2002-264049	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US18569, filed on 7 Jun 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-209467P	20000607 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	18130	

L7 ANSWER 8 OF 207 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:7343 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005577	A1	20040108
APPLICATION INFO.:	US 2002-242747	A1	20020913 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764881, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)

US 2000-225758P	20000814 (60)
US 2000-220963P	20000726 (60)
US 2000-217496P	20000711 (60)
US 2000-225447P	20000814 (60)
US 2000-218290P	20000714 (60)
US 2000-225757P	20000814 (60)
US 2000-226868P	20000822 (60)
US 2000-216647P	20000707 (60)
US 2000-225267P	20000814 (60)
US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)

US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)

US 2000-190076P 20000317 (60)
US 2000-209467P 20000607 (60)
US 2000-205515P 20000519 (60)
US 2001-259678P 20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 27694

L7 ANSWER 9 OF 207 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel cardiovascular system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cardiovascular system antigens," and the use of such cardiovascular system antigens for detecting disorders of the cardiovascular system, particularly the presence of cancer of cardiovascular system tissues and cancer metastases. More specifically, isolated cardiovascular system associated nucleic acid molecules are provided encoding novel cardiovascular system associated polypeptides. Novel cardiovascular system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human cardiovascular system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the cardiovascular system, including cancer of cardiovascular system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:7341 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005575	A1	20040108
APPLICATION INFO.:	US 2002-227577	A1	20020826 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-91504, filed on 7 Mar 2002, PENDING Continuation of Ser. No. US 2001-764869, filed on 17 Jan 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)

US 2000-226868P	20000822 (60)
US 2000-216647P	20000707 (60)
US 2000-225267P	20000814 (60)
US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)

US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE:
FILE SEGMENT:

Utility
APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 28742

L7 ANSWER 10 OF 207 USPATFULL on STN
TI 50 human secreted proteins
AB The present invention relates to novel human secreted proteins and
isolated nucleic acids containing the coding regions of the genes
encoding such proteins. Also provided are vectors, host cells,
antibodies, and recombinant methods for producing human secreted
proteins. The invention further relates to diagnostic and therapeutic
methods useful for diagnosing and treating diseases, disorders, and/or
conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:2568 USPATFULL
TITLE: 50 human secreted proteins
INVENTOR(S): Moore, Paul A., Germantown, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
LaFleur, David W., Washington, DC, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002591	A1	20040101
APPLICATION INFO.:	US 2002-47021	A1	20020117 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-722329, filed on 28 Nov 2000, PENDING Continuation of Ser. No. US 1999-262109, filed on 4 Mar 1999, ABANDONED Continuation-in-part of Ser. No. WO 1998-US18360, filed on 3 Sep 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-262066P	20010118 (60)
	US 1997-57626P	19970905 (60)
	US 1997-57663P	19970905 (60)
	US 1997-57669P	19970905 (60)
	US 1997-58666P	19970912 (60)
	US 1997-58667P	19970912 (60)
	US 1997-58973P	19970912 (60)
	US 1997-58974P	19970912 (60)
	US 1998-90112P	19980622 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 33379
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:38:37 ON 16 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS,
BIOSIS' ENTERED AT 12:39:04 ON 16 JAN 2004

L1 13014 S RANTES
L2 2849 S ALBUMIN FUSION PROTEIN
L3 8 S L1 AND L2
L4 1364 S FGF-8
L5 509 S L4 AND ALBUMIN
L6 491 S L5 AND FUSION
L7 207 S L6 AND L1
L8 0 S L7 AND STABILIZER

=> s fusion partner

L9 6424 FUSION PARTNER

=> s l9 and albumin

L10 2467 L9 AND ALBUMIN

=> s l9 and BMP

L11 176 L9 AND BMP

=> s l11 and l10

L12 141 L11 AND L10

=> s l12 and l1

L13 101 L12 AND L1

=> d l13 ti abs ibib 1-10

L13 ANSWER 1 OF 101 USPATFULL on STN

TI **Albumin** fusion proteins

AB The present invention encompasses **albumin** fusion proteins.
Nucleic acid molecules encoding the **albumin** fusion proteins of
the invention are also encompassed by the invention, as are vectors
containing these nucleic acids, host cells transformed with these
nucleic acids vectors, and methods of making the **albumin**
fusion proteins of the invention and using these nucleic acids, vectors,
and/or host cells. Additionally the present invention encompasses
pharmaceutical compositions comprising **albumin** fusion proteins
and methods of treating, preventing, or ameliorating diseases, disorders
or conditions using **albumin** fusion proteins of the invention.

ACCESSION NUMBER: 2004:13611 USPATFULL
TITLE: **Albumin** fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004010134	A1	20040115
APPLICATION INFO.:	US 2001-833245	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 25066

L13 ANSWER 2 OF 101 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel polynucleotides associated with the plasma membrane, the polypeptides encoded by these polynucleotides herein collectively referred to as "plasma membrane associated antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such plasma membrane associated polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders related to these novel polypeptides. More specifically, isolated nucleic acid molecules are provided encoding novel plasma membrane associated polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing these plasma membrane associated polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the novel polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:12971 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009491	A1	20040115
APPLICATION INFO.:	US 2002-264237	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US16450, filed on 18 May 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	18144	

L13 ANSWER 3 OF 101 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel musculoskeletal system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "musculoskeletal system antigens," and the use of such musculoskeletal system antigens for detecting disorders of the musculoskeletal system, particularly the presence of cancer and cancer metastases. More specifically, isolated musculoskeletal system associated nucleic acid molecules are provided encoding novel musculoskeletal system associated polypeptides. Novel musculoskeletal system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human musculoskeletal system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating,

preventing and/or prognosing disorders related to the musculoskeletal system, including cancer of musculoskeletal tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:12968 USPATFULL
 TITLE: Nucleic acids, proteins, and antibodies
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Ruben, Steven M., Olney, MD, UNITED STATES
 Barash, Steven C., Rockville, MD, UNITED STATES
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009488	A1	20040115
APPLICATION INFO.:	US 2002-242515	A1	20020913 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764877, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)
	US 2000-244617P	20001101 (60)
	US 2000-225268P	20000814 (60)
	US 2000-236368P	20000929 (60)
	US 2000-251856P	20001208 (60)
	US 2000-251868P	20001208 (60)
	US 2000-229344P	20000901 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-229345P	20000901 (60)
	US 2000-229287P	20000901 (60)
	US 2000-229513P	20000905 (60)

US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)

US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 32038

L13 ANSWER 4 OF 101 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel ovarian related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "ovarian antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such ovarian polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the reproductive system, particularly disorders of the ovaries and/or breast, including, but not limited to, the presence of ovarian and/or breast cancer and ovarian and/or breast cancer metastases. More specifically, isolated ovarian nucleic acid molecules are provided encoding novel ovarian polypeptides. Novel ovarian polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human ovarian polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the ovaries and/or breast, including ovarian and/or breast cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compositions for inhibiting or promoting the

production and/or function of the polypeptides of the invention.

ACCESSION NUMBER: 2004:7345 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Birse, Charles E., North Potomac, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005579	A1	20040108
APPLICATION INFO.:	US 2002-264049	A1	20021004 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US18569, filed on 7 Jun 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-209467P	20000607 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
LINE COUNT:	18130	

L13 ANSWER 5 OF 101 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:7343 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005577	A1	20040108
APPLICATION INFO.:	US 2002-242747	A1	20020913 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764881, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)

US 2000-217496P	20000711 (60)
US 2000-225447P	20000814 (60)
US 2000-218290P	20000714 (60)
US 2000-225757P	20000814 (60)
US 2000-226868P	20000822 (60)
US 2000-216647P	20000707 (60)
US 2000-225267P	20000814 (60)
US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)

US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)

US 2000-205515P 20000519 (60)
US 2001-259678P 20010105 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 27694

L13 ANSWER 6 OF 101 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel cardiovascular system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cardiovascular system antigens," and the use of such cardiovascular system antigens for detecting disorders of the cardiovascular system, particularly the presence of cancer of cardiovascular system tissues and cancer metastases. More specifically, isolated cardiovascular system associated nucleic acid molecules are provided encoding novel cardiovascular system associated polypeptides. Novel cardiovascular system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human cardiovascular system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the cardiovascular system, including cancer of cardiovascular system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

ACCESSION NUMBER: 2004:7341 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004005575	A1	20040108
APPLICATION INFO.:	US 2002-227577	A1	20020826 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-91504, filed on 7 Mar 2002, PENDING Continuation of Ser. No. US 2001-764869, filed on 17 Jan 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)

US 2000-225267P	20000814 (60)
US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)

US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE:

FILE SEGMENT:

LEGAL REPRESENTATIVE:

Utility

APPLICATION

HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 28742

L13 ANSWER 7 OF 101 USPATFULL on STN

TI 50 human secreted proteins

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:2568 USPATFULL

TITLE: 50 human secreted proteins

INVENTOR(S): Moore, Paul A., Germantown, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
LaFleur, David W., Washington, DC, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)

	NUMBER	KIND	DATE°
PATENT INFORMATION:	US 2004002591	A1	20040101
APPLICATION INFO.:	US 2002-47021	A1	20020117 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-722329, filed on 28 Nov 2000, PENDING Continuation of Ser. No. US 1999-262109, filed on 4 Mar 1999, ABANDONED Continuation-in-part of Ser. No. WO 1998-US18360, filed on 3 Sep 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-262066P	20010118 (60)
	US 1997-57626P	19970905 (60)
	US 1997-57663P	19970905 (60)
	US 1997-57669P	19970905 (60)
	US 1997-58666P	19970912 (60)
	US 1997-58667P	19970912 (60)
	US 1997-58973P	19970912 (60)
	US 1997-58974P	19970912 (60)
	US 1998-90112P	19980622 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 23

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 2 Drawing Page(s)

LINE COUNT: 33379

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 8 OF 101 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel excretory system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "excretory system antigens," and the use of

such excretory system antigens for detecting disorders of the excretory system, particularly the presence of cancer of excretory system tissues and cancer metastases. More specifically, isolated excretory system associated nucleic acid molecules are provided encoding novel excretory system associated polypeptides. Novel excretory system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human excretory system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the excretory system, including cancer of excretory system tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:334955 USPATFULL
 TITLE: Nucleic acids, proteins, and antibodies
 INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Ruben, Steven M., Olney, MD, UNITED STATES
 Barash, Steven C., Rockville, MD, UNITED STATES
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235831	A1	20031225
APPLICATION INFO.:	US 2002-242355	A1	20020913 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-764897, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)
	US 2000-241785P	20001020 (60)

US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)

US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)
US 2000-198123P	20000418 (60)
US 2000-227009P	20000823 (60)
US 2000-235484P	20000926 (60)
US 2000-190076P	20000317 (60)
US 2000-209467P	20000607 (60)
US 2000-205515P	20000519 (60)
US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 22457
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 9 OF 101 USPATFULL on STN

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for

identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:334953 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Birse, Charles E., North Potomac, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235829	A1	20031225
APPLICATION INFO.:	US 2002-227646	A1	20020826 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-860670, filed on 21 May 2001, PENDING Continuation-in-part of Ser. No. WO 2001-US1346, filed on 17 Jan 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205515P	20000519 (60)
	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-216880P	20000707 (60)
	US 2000-234997P	20000925 (60)
	US 2000-229343P	20000901 (60)
	US 2000-236367P	20000929 (60)
	US 2000-239937P	20001013 (60)
	US 2000-249210P	20001117 (60)
	US 2000-249211P	20001117 (60)
	US 2000-249214P	20001117 (60)
	US 2000-231243P	20000908 (60)
	US 2000-246477P	20001108 (60)
	US 2000-246528P	20001108 (60)
	US 2000-246525P	20001108 (60)
	US 2000-246476P	20001108 (60)
	US 2000-246526P	20001108 (60)
	US 2000-249265P	20001117 (60)
	US 2000-230437P	20000906 (60)
	US 2000-251990P	20001208 (60)
	US 2000-251988P	20001205 (60)
	US 2000-251030P	20001205 (60)
	US 2000-251479P	20001206 (60)
	US 2000-256719P	20001205 (60)
	US 2000-250160P	20001201 (60)
	US 2000-251989P	20001208 (60)
	US 2000-250391P	20001201 (60)
	US 2000-254097P	20001211 (60)
	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)

US 2000-225757P	20000814 (60)
US 2000-226868P	20000822 (60)
US 2000-216647P	20000707 (60)
US 2000-225267P	20000814 (60)
US 2000-216880P	20000707 (60)
US 2000-225270P	20000814 (60)
US 2000-251869P	20001208 (60)
US 2000-235834P	20000927 (60)
US 2000-234274P	20000921 (60)
US 2000-234223P	20000921 (60)
US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)
US 2000-239937P	20001013 (60)
US 2000-241787P	20001020 (60)
US 2000-246474P	20001108 (60)
US 2000-246532P	20001108 (60)
US 2000-249216P	20001117 (60)
US 2000-249210P	20001117 (60)
US 2000-226681P	20000822 (60)
US 2000-225759P	20000814 (60)
US 2000-225213P	20000814 (60)
US 2000-227182P	20000822 (60)
US 2000-225214P	20000814 (60)
US 2000-235836P	20000927 (60)
US 2000-230438P	20000906 (60)
US 2000-215135P	20000630 (60)
US 2000-225266P	20000814 (60)
US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)

US 2000-249211P	20001117	(60)
US 2000-249215P	20001117	(60)
US 2000-249264P	20001117	(60)
US 2000-249214P	20001117	(60)
US 2000-249297P	20001117	(60)
US 2000-232400P	20000914	(60)
US 2000-231242P	20000908	(60)
US 2000-232081P	20000908	(60)
US 2000-232080P	20000908	(60)
US 2000-231414P	20000908	(60)
US 2000-231244P	20000908	(60)
US 2000-233064P	20000914	(60)
US 2000-233063P	20000914	(60)
US 2000-232397P	20000914	(60)
US 2000-232399P	20000914	(60)
US 2000-232401P	20000914	(60)
US 2000-241808P	20001020	(60)
US 2000-241826P	20001020	(60)
US 2000-241786P	20001020	(60)
US 2000-241221P	20001020	(60)
US 2000-246475P	20001108	(60)
US 2000-231243P	20000908	(60)
US 2000-233065P	20000914	(60)
US 2000-232398P	20000914	(60)
US 2000-234998P	20000925	(60)
US 2000-246477P	20001108	(60)
US 2000-246528P	20001108	(60)
US 2000-246525P	20001108	(60)
US 2000-246476P	20001108	(60)
US 2000-246526P	20001108	(60)
US 2000-249209P	20001117	(60)
US 2000-246527P	20001108	(60)
US 2000-246523P	20001108	(60)
US 2000-246524P	20001108	(60)
US 2000-246478P	20001108	(60)
US 2000-246609P	20001108	(60)
US 2000-246613P	20001108	(60)
US 2000-249300P	20001117	(60)
US 2000-249265P	20001117	(60)
US 2000-246610P	20001108	(60)
US 2000-246611P	20001108	(60)
US 2000-230437P	20000906	(60)
US 2000-251990P	20001208	(60)
US 2000-251988P	20001205	(60)
US 2000-251030P	20001205	(60)
US 2000-251479P	20001206	(60)
US 2000-256719P	20001205	(60)
US 2000-250160P	20001201	(60)
US 2000-251989P	20001208	(60)
US 2000-250391P	20001201	(60)
US 2000-254097P	20001211	(60)
US 2000-231968P	20000912	(60)
US 2000-226279P	20000818	(60)
US 2000-186350P	20000302	(60)
US 2000-184664P	20000224	(60)
US 2000-189874P	20000316	(60)
US 2000-198123P	20000418	(60)
US 2000-227009P	20000823	(60)
US 2000-235484P	20000926	(60)
US 2000-190076P	20000317	(60)
US 2000-209467P	20000607	(60)
US 2000-205515P	20000519	(60)
US 2001-259678P	20010105	(60)
US 2000-179065P	20000131	(60)

US 2000-180628P	20000204	(60)
US 2000-214886P	20000628	(60)
US 2000-217487P	20000711	(60)
US 2000-225758P	20000814	(60)
US 2000-220963P	20000726	(60)
US 2000-217496P	20000711	(60)
US 2000-225447P	20000814	(60)
US 2000-218290P	20000714	(60)
US 2000-225757P	20000814	(60)
US 2000-226868P	20000822	(60)
US 2000-216647P	20000707	(60)
US 2000-225267P	20000814	(60)
US 2000-216880P	20000707	(60)
US 2000-225270P	20000814	(60)
US 2000-251869P	20001208	(60)
US 2000-235834P	20000927	(60)
US 2000-234274P	20000921	(60)
US 2000-234223P	20000921	(60)
US 2000-228924P	20000830	(60)
US 2000-224518P	20000814	(60)
US 2000-236369P	20000929	(60)
US 2000-224519P	20000814	(60)
US 2000-220964P	20000726	(60)
US 2000-241809P	20001020	(60)
US 2000-249299P	20001117	(60)
US 2000-236327P	20000929	(60)
US 2000-241785P	20001020	(60)
US 2000-244617P	20001101	(60)
US 2000-225268P	20000814	(60)
US 2000-236368P	20000929	(60)
US 2000-251856P	20001208	(60)
US 2000-251868P	20001208	(60)
US 2000-229344P	20000901	(60)
US 2000-234997P	20000925	(60)
US 2000-229343P	20000901	(60)
US 2000-229345P	20000901	(60)
US 2000-229287P	20000901	(60)
US 2000-229513P	20000905	(60)
US 2000-231413P	20000908	(60)
US 2000-229509P	20000905	(60)
US 2000-236367P	20000929	(60)
US 2000-237039P	20001002	(60)
US 2000-237038P	20001002	(60)
US 2000-236370P	20000929	(60)
US 2000-236802P	20001002	(60)
US 2000-237037P	20001002	(60)
US 2000-237040P	20001002	(60)
US 2000-240960P	20001020	(60)
US 2000-239935P	20001013	(60)
US 2000-239937P	20001013	(60)
US 2000-241787P	20001020	(60)
US 2000-246474P	20001108	(60)
US 2000-246532P	20001108	(60)
US 2000-249216P	20001117	(60)
US 2000-249210P	20001117	(60)
US 2000-226681P	20000822	(60)
US 2000-225759P	20000814	(60)
US 2000-225213P	20000814	(60)
US 2000-227182P	20000822	(60)
US 2000-225214P	20000814	(60)
US 2000-235836P	20000927	(60)
US 2000-230438P	20000906	(60)
US 2000-215135P	20000630	(60)
US 2000-225266P	20000814	(60)

US 2000-249218P	20001117 (60)
US 2000-249208P	20001117 (60)
US 2000-249213P	20001117 (60)
US 2000-249212P	20001117 (60)
US 2000-249207P	20001117 (60)
US 2000-249245P	20001117 (60)
US 2000-249244P	20001117 (60)
US 2000-249217P	20001117 (60)
US 2000-249211P	20001117 (60)
US 2000-249215P	20001117 (60)
US 2000-249264P	20001117 (60)
US 2000-249214P	20001117 (60)
US 2000-249297P	20001117 (60)
US 2000-232400P	20000914 (60)
US 2000-231242P	20000908 (60)
US 2000-232081P	20000908 (60)
US 2000-232080P	20000908 (60)
US 2000-231414P	20000908 (60)
US 2000-231244P	20000908 (60)
US 2000-233064P	20000914 (60)
US 2000-233063P	20000914 (60)
US 2000-232397P	20000914 (60)
US 2000-232399P	20000914 (60)
US 2000-232401P	20000914 (60)
US 2000-241808P	20001020 (60)
US 2000-241826P	20001020 (60)
US 2000-241786P	20001020 (60)
US 2000-241221P	20001020 (60)
US 2000-246475P	20001108 (60)
US 2000-231243P	20000908 (60)
US 2000-233065P	20000914 (60)
US 2000-232398P	20000914 (60)
US 2000-234998P	20000925 (60)
US 2000-246477P	20001108 (60)
US 2000-246528P	20001108 (60)
US 2000-246525P	20001108 (60)
US 2000-246476P	20001108 (60)
US 2000-246526P	20001108 (60)
US 2000-249209P	20001117 (60)
US 2000-246527P	20001108 (60)
US 2000-246523P	20001108 (60)
US 2000-246524P	20001108 (60)
US 2000-246478P	20001108 (60)
US 2000-246609P	20001108 (60)
US 2000-246613P	20001108 (60)
US 2000-249300P	20001117 (60)
US 2000-249265P	20001117 (60)
US 2000-246610P	20001108 (60)
US 2000-246611P	20001108 (60)
US 2000-230437P	20000906 (60)
US 2000-251990P	20001208 (60)
US 2000-251988P	20001205 (60)
US 2000-251030P	20001205 (60)
US 2000-251479P	20001206 (60)
US 2000-256719P	20001205 (60)
US 2000-250160P	20001201 (60)
US 2000-251989P	20001208 (60)
US 2000-250391P	20001201 (60)
US 2000-254097P	20001211 (60)
US 2000-231968P	20000912 (60)
US 2000-226279P	20000818 (60)
US 2000-186350P	20000302 (60)
US 2000-184664P	20000224 (60)
US 2000-189874P	20000316 (60)

US 2000-198123P 20000418 (60)
US 2000-227009P 20000823 (60)
US 2000-235484P 20000926 (60)
US 2000-190076P 20000317 (60)
US 2000-209467P 20000607 (60)
US 2000-205515P 20000519 (60)
US 2001-259678P 20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 20415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 10 OF 101 USPATFULL on STN

TI Novel methods of diagnosis of metastatic colorectal cancer, compositions
and methods of screening for modulators of metastatic colorectal cancer
AB Described herein are methods and compositions that can be used for
diagnosis and treatment of metastatic colorectal cancer. Also described
herein are methods that can be used to identify modulators of metastatic
colorectal cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:334944 USPATFULL
TITLE: Novel methods of diagnosis of metastatic colorectal
cancer, compositions and methods of screening for
modulators of metastatic colorectal cancer
INVENTOR(S): Mack, David H., Menlo Park, CA, UNITED STATES
Markowitz, Sanford David, Pepper Pike, OH, UNITED
STATES
PATENT ASSIGNEE(S): Eos Biotechnology, Inc., South San Francisco, CA (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235820	A1	20031225
APPLICATION INFO.:	US 2002-87080	A1	20020227 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-284555P	20010417 (60)
	US 2001-281149P	20010402 (60)
	US 2001-272206P	20010227 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO
CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 22670
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 12:38:37 ON 16 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS,
BIOSIS' ENTERED AT 12:39:04 ON 16 JAN 2004

L1 13014 S RANTES
L2 2849 S ALBUMIN FUSION PROTEIN
L3 8 S L1 AND L2

L4 1364 S FGF-8
 L5 509 S L4 AND ALBUMIN
 L6 491 S L5 AND FUSION
 L7 207 S L6 AND L1
 L8 0 S L7 AND STABILIZER
 L9 6424 S FUSION PARTNER
 L10 2467 S L9 AND ALBUMIN
 L11 176 S L9 AND BMP
 L12 141 S L11 AND L10
 L13 101 S L12 AND L1

=> s albumin () fusion protein
 L14 2849 ALBUMIN (W) FUSION PROTEIN

=> s albumin () BMP
 L15 0 ALBUMIN (W) BMP

=> s albumin () FGF
 L16 35 ALBUMIN (W) FGF

=> d l16 ti abs ibib tot

L16 ANSWER 1 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
 AN AAY58432 Protein DGENE
 AB This sequence represents a truncated rat fibroblast growth factor-16 (FGF-16) des-N-9, where residues 1-9 of the full-length rat FGF-16 (AAY58428) have been removed by proteolytic cleavage. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF-16** nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.
 ACCESSION NUMBER: AAY58432 Protein DGENE
 TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
 INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
 PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
 PATENT INFO: US 5998170 A 19991207 33p
 APPLICATION INFO: US 1997-943915 19971003
 PRIORITY INFO: US 1997-943915 19971003
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 OTHER SOURCE: 2000-085497 [07]
 DESCRIPTION: Rat truncated fibroblast growth factor FGF-16, des-N-9.

L16 ANSWER 2 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
 AN AAY58431 Protein DGENE
 AB This sequence represents a truncated rat fibroblast growth factor-16 (FGF-16) des-N-34, where residues 1-34 of the full-length rat FGF-16 (AAY58428) have been removed by proteolytic cleavage. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF-16** nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in

vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.

ACCESSION NUMBER: AAY58431 Protein DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat truncated fibroblast growth factor FGF-16, des-N-34.

L16 ANSWER 3 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAY58430 peptide DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF-16** nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. This sequence represents an E tag, DNA encoding which was fused to the 3' end of the rat FGF-16 coding region, along with DNA encoding a hexahistidine tag. The tagged rat FGF-16 cDNA was cloned into a baculovirus expression system in an exemplification of the present invention.

ACCESSION NUMBER: AAY58430 peptide DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: E tag peptide, SEQ ID NO:6.

L16 ANSWER 4 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAY58429 Protein DGENE
AB This sequence represents human fibroblast growth factor-16 (FGF-16). FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF-16** nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent

liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.

ACCESSION NUMBER: AAY58429 Protein DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
CROSS REFERENCES: N-PSDB: AAZ55791
DESCRIPTION: Human fibroblast growth factor FGF-16.

L16 ANSWER 5 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAY58428 Protein DGENE
AB This sequence represents rat fibroblast growth factor-16 (FGF-16). FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF-16** nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.

ACCESSION NUMBER: AAY58428 Protein DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
CROSS REFERENCES: N-PSDB: AAZ55790
DESCRIPTION: Rat fibroblast growth factor FGF-16.

L16 ANSWER 6 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55819 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF-16** nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55818-Z55819 represent oligonucleotides used in the preparation of the construct pAMG21-delta-N34-rFGF-16, comprising a fragment of the rat FGF-16 cDNA sequence, in an exemplification of the

present invention.

ACCESSION NUMBER: AAZ55819 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Oligonucleotide SEQ ID NO:32, used to construct pAMG21-delta-N34-rFGF-16.

L16 ANSWER 7 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55818 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF-16** nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55818-Z55819 represent oligonucleotides used in the preparation of the construct pAMG21-delta-N34-rFGF-16, comprising a fragment of the rat FGF-16 cDNA sequence, in an exemplification of the present invention.

ACCESSION NUMBER: AAZ55818 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Oligonucleotide SEQ ID NO:31, used to construct pAMG21-delta-N34-rFGF-16.

L16 ANSWER 8 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55817 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF-16** nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure,

damage caused by acute viral hepatitis and toxic insults to the liver. This sequence represents a pAMG21 vector PCR primer used to ascertain that a pAMG21/rat FGF-16 construct had been produced in an exemplification of the present invention.

ACCESSION NUMBER: AAZ55817 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: pAMG21 vector PCR primer, SEQ ID NO:28.

L16 ANSWER 9 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55816 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF-16** nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55815-Z55816 represent PCR primers used to clone rat FGF-16 cDNA (AAZ55790) into E. coli.

ACCESSION NUMBER: AAZ55816 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat FGF-16 PCR primer, SEQ ID NO:28.

L16 ANSWER 10 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
AN AAZ55815 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF-16** nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.

Sequences AAZ55815-Z55816 represent PCR primers used to clone rat FGF-16 cDNA (AAZ55790) into E. coli.

ACCESSION NUMBER: AAZ55815 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat FGF-16 PCR primer, SEQ ID NO:27.

L16 ANSWER 11 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55814 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF-16** nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55813-Z55814 represent PCR primers used to detect human FGF-16 DNA in bacteria which had previously been transformed with a vector comprising human FGF-16 DNA.

ACCESSION NUMBER: AAZ55814 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat FGF-16 PCR primer, SEQ ID NO:26.

L16 ANSWER 12 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55813 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF-16** nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55813-Z55814 represent PCR primers used to detect human

FGF-16 DNA in bacteria which had previously been transformed with a vector comprising human FGF-16 DNA.

ACCESSION NUMBER: AAZ55813 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 PCR primer, SEQ ID NO:25.

L16 ANSWER 13 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55812 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55810-Z55812 represent PCR primers used in a PCR technique similar to 5' RACE (rapid amplification of cDNA ends) for extension and amplification of human genomic FGF-16 DNA sequences.

ACCESSION NUMBER: AAZ55812 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat FGF-16 genomic PCR primer, SEQ ID NO:24.

L16 ANSWER 14 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55811 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55810-Z55812 represent PCR primers used in a PCR technique

similar to 5' RACE (rapid amplification of cDNA ends) for extension and amplification of human genomic FGF-16 DNA sequences.

ACCESSION NUMBER: AAZ55811 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 genomic PCR primer, SEQ ID NO:23.

L16 ANSWER 15 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55810 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55810-Z55812 represent PCR primers used in a PCR technique similar to 5' RACE (rapid amplification of cDNA ends) for extension and amplification of human genomic FGF-16 DNA sequences.

ACCESSION NUMBER: AAZ55810 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 partially random genomic PCR primer, SEQ ID NO:22.

L16 ANSWER 16 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55809 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.

Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55809 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 PCR primer, SEQ ID NO:21.

L16 ANSWER 17 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55808 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55808 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 5' RACE PCR primer, SEQ ID NO:20.

L16 ANSWER 18 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55807 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., albumin). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55807 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 5' RACE PCR primer, SEQ ID NO:19.

L16 ANSWER 19 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55806 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55806 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 partially random 5' RACE PCR primer, SEQ ID NO:18 (E).

L16 ANSWER 20 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55805 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55805 DNA DGENE

TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 partially random 5' RACE PCR primer, SEQ ID NO:18 (D).

L16 ANSWER 21 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55804 DNA DGENE

AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55804 DNA DGENE

TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H

PATENT ASSIGNEE: (AMGE-N)AMGEN INC.

PATENT INFO: US 5998170 A 19991207 33p

APPLICATION INFO: US 1997-943915 19971003

PRIORITY INFO: US 1997-943915 19971003

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-085497 [07]

DESCRIPTION: Human FGF-16 partially random 5' RACE PCR primer, SEQ ID NO:18 (C).

L16 ANSWER 22 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55803 DNA DGENE

AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55803 DNA DGENE

TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 partially random 5' RACE PCR primer, SEQ ID NO:18 (B).

L16 ANSWER 23 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55802 DNA DGENE

AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55802 DNA DGENE

TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H

PATENT ASSIGNEE: (AMGE-N)AMGEN INC.

PATENT INFO: US 5998170 A 19991207 33p

APPLICATION INFO: US 1997-943915 19971003

PRIORITY INFO: US 1997-943915 19971003

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-085497 [07]

DESCRIPTION: Human FGF-16 partially random 5' RACE PCR primer, SEQ ID NO:18 (A).

L16 ANSWER 24 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55801 DNA DGENE

AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55801-Z55809 represent PCR primers used in 5' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55801 DNA DGENE

TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human FGF-16 5' RACE PCR primer, SEQ ID NO:16.

L16 ANSWER 25 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55800 DNA DGENE

AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF-16** nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. This sequence represents a PCR primer used with primer AAZ55799 in 3' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55800 DNA DGENE

TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H

PATENT ASSIGNEE: (AMGE-N)AMGEN INC.

PATENT INFO: US 5998170 A 19991207 33p

APPLICATION INFO: US 1997-943915 19971003

PRIORITY INFO: US 1997-943915 19971003

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-085497 [07]

DESCRIPTION: Human FGF-16 3' RACE PCR primer, SEQ ID NO:15.

L16 ANSWER 26 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55799 DNA DGENE

AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF-16** nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. This sequence represents a primer used to synthesise first strand cDNA from human heart polyA+ RNA, and also used as a PCR primer in 3' RACE (rapid amplification of cDNA ends) of human FGF-16 cDNA.

ACCESSION NUMBER: AAZ55799 DNA DGENE

TITLE: Fibroblast growth factor family polypeptide which stimulates

proliferation and growth of hepatocytes is useful for
treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Reverse transcription/human FGF-16 3' RACE PCR primer, SEQ ID
NO:14.

L16 ANSWER 27 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates
proliferation and growth of hepatocytes is useful for treating hepatic
disorders -

AN AAZ55798 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16
(FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins.
FGF-16 has hepatocyte proliferation and growth activity, and increases
hepatic production of triglycerides and serum proteins (e.g.,
albumin). FGF-16 nucleic acids and/or proteins may be
used for stimulating the proliferation and development of hepatocytes
both in vitro and in vivo. The isolated nucleic acid molecules may be
used directly in cell or gene therapy applications to treat or prevent
liver disorders, including hepatic cirrhosis, fulminant liver failure,
damage caused by acute viral hepatitis and toxic insults to the liver.
Sequences AAZ55793-Z55798 represent primers used to isolate and clone a
human FGF-16 cDNA fragment in an exemplification of the present
invention.

ACCESSION NUMBER: AAZ55798 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates
proliferation and growth of hepatocytes is useful for
treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human fibroblast growth factor FGF-16 PCR primer, SEQ ID
NO:132.

L16 ANSWER 28 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates
proliferation and growth of hepatocytes is useful for treating hepatic
disorders -

AN AAZ55797 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16
(FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins.
FGF-16 has hepatocyte proliferation and growth activity, and increases
hepatic production of triglycerides and serum proteins (e.g.,
albumin). FGF-16 nucleic acids and/or proteins may be
used for stimulating the proliferation and development of hepatocytes
both in vitro and in vivo. The isolated nucleic acid molecules may be
used directly in cell or gene therapy applications to treat or prevent
liver disorders, including hepatic cirrhosis, fulminant liver failure,
damage caused by acute viral hepatitis and toxic insults to the liver.
Sequences AAZ55793-Z55798 represent primers used to isolate and clone a
human FGF-16 cDNA fragment in an exemplification of the present
invention.

ACCESSION NUMBER: AAZ55797 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat fibroblast growth factor FGF-16 PCR primer, SEQ ID NO:12.

L16 ANSWER 29 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55796 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF-16** nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55793-Z55798 represent primers used to isolate and clone a human FGF-16 cDNA fragment in an exemplification of the present invention.

ACCESSION NUMBER: AAZ55796 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Human heart polyA+ RNA reverse transcription primer, SEQ ID NO:11.

L16 ANSWER 30 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55795 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF-16** nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55793-Z55798 represent primers used to isolate and clone a human FGF-16 cDNA fragment in an exemplification of the present

invention.

ACCESSION NUMBER: AAZ55795 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat fibroblast growth factor FGF-16 PCR primer, SEQ ID NO:10.

L16 ANSWER 31 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55794 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF-16** nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55793-Z55798 represent primers used to isolate and clone a human FGF-16 cDNA fragment in an exemplification of the present invention.

ACCESSION NUMBER: AAZ55794 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat fibroblast growth factor FGF-16 PCR primer, SEQ ID NO:9.

L16 ANSWER 32 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55793 DNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). **FGF-16** nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. Sequences AAZ55793-Z55798 represent primers used to isolate and clone a human FGF-16 cDNA fragment in an exemplification of the present

invention.

ACCESSION NUMBER: AAZ55793 DNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat fibroblast growth factor FGF-16 PCR primer, SEQ ID NO:8.

L16 ANSWER 33 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55792 cDNA DGENE
AB The invention relates to rat and human fibroblast growth factor-16 (FGF-16, AAY58428-Y58429), and nucleotides which encode these proteins. FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver. This sequence represents a rat fibroblast growth factor-16 partial cDNA, used to design PCR primers to isolate CDNA encoding human FGF-16 in an exemplification of the present invention.

ACCESSION NUMBER: AAZ55792 cDNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -
INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
PATENT INFO: US 5998170 A 19991207 33p
APPLICATION INFO: US 1997-943915 19971003
PRIORITY INFO: US 1997-943915 19971003
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-085497 [07]
DESCRIPTION: Rat fibroblast growth factor FGF-16 partial cDNA.

L16 ANSWER 34 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
TI Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for treating hepatic disorders -

AN AAZ55791 cDNA DGENE
AB This sequence represents cDNA encoding human fibroblast growth factor-16 (FGF-16). FGF-16 has hepatocyte proliferation and growth activity, and increases hepatic production of triglycerides and serum proteins (e.g., **albumin**). FGF-16 nucleic acids and/or proteins may be used for stimulating the proliferation and development of hepatocytes both in vitro and in vivo. The isolated nucleic acid molecules may be used directly in cell or gene therapy applications to treat or prevent liver disorders, including hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and toxic insults to the liver.

ACCESSION NUMBER: AAZ55791 cDNA DGENE
TITLE: Fibroblast growth factor family polypeptide which stimulates proliferation and growth of hepatocytes is useful for

treating hepatic disorders -
 INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
 PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
 PATENT INFO: US 5998170 A 19991207 33p
 APPLICATION INFO: US 1997-943915 19971003
 PRIORITY INFO: US 1997-943915 19971003
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 OTHER SOURCE: 2000-085497 [07]
 CROSS REFERENCES: P-PSDB: AAY58429
 DESCRIPTION: cDNA encoding human fibroblast growth factor FGF-16.

L16 ANSWER 35 OF 35 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 TI Fibroblast growth factor family polypeptide which stimulates
 proliferation and growth of hepatocytes is useful for treating hepatic
 disorders -

AN AAZ55790 cDNA DGENE
 AB This sequence represents cDNA encoding rat fibroblast growth factor-16
 (FGF-16). FGF-16 has hepatocyte proliferation and growth activity, and
 increases hepatic production of triglycerides and serum proteins (e.g.,
albumin). FGF-16 nucleic acids and/or proteins may be
 used for stimulating the proliferation and development of hepatocytes
 both in vitro and in vivo. The isolated nucleic acid molecules may be
 used directly in cell or gene therapy applications to treat or prevent
 liver disorders, including hepatic cirrhosis, fulminant liver failure,
 damage caused by acute viral hepatitis and toxic insults to the liver.

ACCESSION NUMBER: AAZ55790 cDNA DGENE
 TITLE: Fibroblast growth factor family polypeptide which stimulates
 proliferation and growth of hepatocytes is useful for
 treating hepatic disorders -

INVENTOR: Arakawa T; Itoh N; Danilenko D M; Martin F H
 PATENT ASSIGNEE: (AMGE-N)AMGEN INC.
 PATENT INFO: US 5998170 A 19991207 33p
 APPLICATION INFO: US 1997-943915 19971003
 PRIORITY INFO: US 1997-943915 19971003
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 OTHER SOURCE: 2000-085497 [07]
 CROSS REFERENCES: P-PSDB: AAY58428
 DESCRIPTION: cDNA encoding rat fibroblast growth factor FGF-16.

=> d his

(FILE 'HOME' ENTERED AT 12:38:37 ON 16 JAN 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JICST-EPLUS,
 BIOSIS' ENTERED AT 12:39:04 ON 16 JAN 2004

L1 13014 S RANTES
 L2 2849 S ALBUMIN FUSION PROTEIN
 L3 8 S L1 AND L2
 L4 1364 S FGF-8
 L5 509 S L4 AND ALBUMIN
 L6 491 S L5 AND FUSION
 L7 207 S L6 AND L1
 L8 0 S L7 AND STABILIZER
 L9 6424 S FUSION PARTNER
 L10 2467 S L9 AND ALBUMIN
 L11 176 S L9 AND BMP
 L12 141 S L11 AND L10
 L13 101 S L12 AND L1
 L14 2849 S ALBUMIN () FUSION PROTEIN
 L15 0 S ALBUMIN () BMP
 L16 35 S ALBUMIN () FGF

Hit List

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Search Results - Record(s) 1 through 1 of 1 returned.

☐ 1. Document ID: US 4563489 A

L2: Entry 1 of 1

File: USPTJan 7, 1986

US-PAT-NO: 4563489

DOCUMENT-IDENTIFIER: US 4563489 A

TITLE: Biodegradable organic polymer delivery system for bone morphogenetic protein

DATE-ISSUED: January 7, 1986

INVENTOR-INFORMATION:

NAMECITYSTATEZIP CODECOUNTRY

Urist; Marshall R.Pacific PalisadesCA

US-CL-CURRENT: 514/21; 424/426, 523/115, 524/17, 524/21, 604/891.1, 623/915

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Alignments	Claims	KMC	Draw De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	------------	--------	-----	---------

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Terms	Documents
albumin adj2 BMP	1

Display Format:

CIT

Change Format

[Previous Page](#) [Next Page](#) [Go to Doc#](#)

Hit List

[Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#)
[Generate ACS](#)

Search Results - Record(s) 1 through 2 of 2 returned.

☐ 1. Document ID: US 6025194 A

L8: Entry 1 of 2

File: USPT

Feb 15, 2000

US-PAT-NO: 6025194

DOCUMENT-IDENTIFIER: US 6025194 A

TITLE: Nucleic acid sequence of senescence associated gene

DATE-ISSUED: February 15, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Funk; Walter	Hayward	CA		

US-CL-CURRENT: [435/320.1](#); [435/325](#), [536/23.1](#), [536/23.5](#), [536/24.1](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw Data
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	------------------------	----------------------	---------------------------

☐ 2. Document ID: US 5733541 A

L8: Entry 2 of 2

File: USPT

Mar 31, 1998

US-PAT-NO: 5733541

DOCUMENT-IDENTIFIER: US 5733541 A

**** See image for [Certificate of Correction](#) ****

TITLE: Hematopoietic cells: compositions and methods

DATE-ISSUED: March 31, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Taichman; Russell S.	Ann Arbor	MI		
Emerson; Stephen G.	Wayne	PA		

US-CL-CURRENT: [424/93.1](#); [424/93.7](#), [435/325](#), [435/347](#), [435/373](#), [435/375](#), [435/377](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw Data
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	------------------------	----------------------	---------------------------

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Terms	Documents
BMP-2 and L7	2

Display Format:

CIT

Change Format

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Freeform Search

Database:

US Pre-Grant Publication Full-Text Database

US Patents Full-Text Database

US OCR Full-Text Database

EPO Abstracts Database

JPO Abstracts Database

Derwent World Patents Index

IBM Technical Disclosure Bulletins

Term:

albumin and fusion protein

Display:

10

Documents in Display Format:

CIT

Starting with Number

1

Generate:

☐ Hit List

☒ Hit Count

☐ Side by Side

☐ Image

Search

Clear

Interrupt

Search History

DATE: Friday, January 16, 2004

[Printable Copy](#)

[Create Case](#)

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side		result set	
<i>DB=USPT; PLUR=YES; OP=OR</i>			
<u>L10</u>	19 adj BMP	980	<u>L10</u>
<u>L9</u>	albumin fusion protein	198014	<u>L9</u>
<u>L8</u>	BMP-2 and L7	2	<u>L8</u>
<u>L7</u>	L6 and IL-6	284	<u>L7</u>
<u>L6</u>	L5 and Rantes	838	<u>L6</u>
<u>L5</u>	human chemokine and albumin	314787	<u>L5</u>
<u>L4</u>	albumin adj2 CXC3	0	<u>L4</u>
<u>L3</u>	albumin fused to BMP	159316	<u>L3</u>
<u>L2</u>	albumin adj2 BMP	1	<u>L2</u>
<u>L1</u>	albumin and fusion protein	144237	<u>L1</u>

END OF SEARCH HISTORY